


L1

STR



G1 A, Q, Ak

G2 Ak, C, O, S, N, CH2, CH, A, Q

G3 N, CH

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:14:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2045 TO ITERATE

97.8% PROCESSED 2000 ITERATIONS

33 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 38188 TO 43612

PROJECTED ANSWERS: 326 TO 1022

L2

33 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:14:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 40428 TO ITERATE

100.0% PROCESSED 40428 ITERATIONS

829 ANSWERS

SEARCH TIME: 00.00.02

L3

829 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 10:14:40 ON 28 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2006 VOL 144 ISS 19

FILE LAST UPDATED: 27 Apr 2006 (20060427/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 52 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006.123845 CAPLUS
 DOCUMENT NUMBER: 144:198906
 TITLE: Pharmaceutical formulations comprising pleconaril and a pharmaceutically active agent for treating respiratory tract diseases
 INVENTOR(S): Lithgow, Theodore L.; Medeiros, Paul T.; Ellway, Keith
 PATENT ASSIGNEE(S): Anthony; Higgins, Thomas J.; Lorber, Richard R.; Malcolm, Bruce A.; Radwanski, Elaine; Staudinger, Heribert W.
 SOURCE: U.S. Pat. Appl. Publ., 12 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006030550	A1	20060209	US 2005-196745	20050803
WO 2006017505	A2	20060216	WO 2005-US27428	20050803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPL. INFO.: US 2004-598618P P 20040804

AB The present invention is directed to formulations containing pleconaril either alone or in combination with one or more other pharmaceutically active ingredients in novel dosage forms and methods of using the same in treating upper or lower respiratory, viral, inflammatory, or obstructive airway disease. Specifically, the medicaments contain sep. or together (A) Pleconaril or a pharmaceutically acceptable salt thereof and (B) a pharmaceutically active agent including a corticosteroid, an antihistamine, an expectorant, an NSAID, a decongestant, an anticholinergic, an antibiotic, etc., for simultaneous, sequential or sep. administration in the treatment of a viral infection and/or other disease states and the symptoms associated therewith.

IT 110588-56-2, Noberastine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical formulations comprising pleconaril and pharmaceutically active agent for treating respiratory tract diseases)

RN 110588-56-2, CAPLUS

L4 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006.100738 CAPLUS
 DOCUMENT NUMBER: 144:198849
 TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
 INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024365	A1	20060202	US 2005-134633	20050519
US 2004096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPL. INFO.: IN 2002-MU697 A 20020805				
IN 2002-MU699 A 20020805				
IN 2003-MU80 A 20030122				
IN 2003-MU82 A 20030122				
US 2003-630446 A2 20030729				

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.


IT 99156-66-8, Barmastine 110588-56-2, Noberastine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (novel dosage form comprising modified-release and immediate-release active ingredients)

RN 99156-66-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-{4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl}-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 110588-56-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:1080533 CAPLUS
 DOCUMENT NUMBER: 142:43824
 TITLE: Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihistamines
 INVENTOR(S): Berlin, Roger; Ramsey, Peter; Usayapant, Arunya; Pubara, Josephine; Poxon, Scott; Bubnis, Bill; Giamalva, David; Strode, John; Bachert, John; Williams, Michael
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 740,386.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004253311	A1	20041216	US 2004-859256	20040602
US 2004186184	A1	20040923	US 2003-740386	20031217
WO 2005120465	A2	20051222	WO 2005-US19200	20050601

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-434342P P 20021218
 US 2003-740386 A2 20031217
 US 2004-859256 A 20040602

AB The present invention is directed to a pharmaceutical composition and method for treatment of rhinitis and cold like symptoms, the composition includes a non-steroidal anti-inflammatory drug (NSAID), a decongestant and an antihistamine preferably in a multi-layer tablet comprising an immediate release layer and an extended release layer to optimize the delivery profile and match the duration of biol. action of the multiple active agents. For example, a bilayer tablet was formulated for twice daily oral administration, comprising an immediate release layer containing 5 mg loratadine and 220 mg naproxen sodium, and an extended-release layer containing 120 mg pseudoephedrine-HCl.

IT 110588-56-2, Noverastine

L4 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (multi-layer tablet comprising NSAID, decongestant and non-sedating antihistamine for treatment of rhinitis and cold-like symptoms)
 RN 110588-56-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:675663 CAPLUS
 DOCUMENT NUMBER: 141:185095
 TITLE: Use of combinations of H1 and H3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
 INVENTOR(S): Hey, John A.; Kreutner, William; McLeod, Robbie L.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069338	A1	20040819	WO 2004-US2170	20040129

W: AE, AG, AL, AM, AN, AP, AR, AT, AU, AZ, BA, BB, BG, BO, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, GR, GR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, ME, NZ, NA, NI


RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004198743 A1 20041007 US 2004-767164 20040129
 US 2003-443948P P 20030131

AB The invention provides methods for treating allergic skin and ocular conditions and disorders by combined administration of an histamine H1 receptor antagonist and a histamine H3 receptor antagonist.

IT 110588-56-2, Noverastine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combinations of H1 and H3 histamine receptor antagonists for treatment of allergic skin and allergic ocular conditions)

RN 110588-56-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:648353 CAPLUS

DOCUMENT NUMBER: 141:167797

TITLE: Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis

INVENTOR(S): Anthes, John C.; West, Robert E.; Hey, John A.; Aslanian, Robert G.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004066960	A2	20040812	WO 2004-US3565	20040126
WO 2004066960	A3	20041021		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BO, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MX, MY, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD

US 2005090527 A1 20050428 US 2004-764780 20040126

PRIORITY APPL. INFO.: US 2003-443207P P 20030128

AB The invention includes methods for treating allergic conditions involving the airway by administering histamine receptor antagonists.

IT 110588-56-2, Noberastine


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis)

RN 110588-56-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

viral transmission, reduce viral load or otherwise treat viral infections.

The invention also encompasses the use of hetero-substituted benzimidazole

compds. as inhibitors of membrane fusion assocd. events, such as viral transmission. The invention provides methods for treating, preventing or ameliorating symptoms assocd. with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compds. of the invention. For instance, imidazopyridine deriv. II [PRA(IC50) = 0.001 µg/mL; XTT(CC50) = 100 µg/mL] was prepd. via heterocyclization of the prepd. benzimidazole deriv. III with ClCH2C(=NH)OEt and subsequent amination of the obtained imidazopyridine IV by morpholine.

IT 692772-79-5P 692772-80-6P 692772-93-3P

692772-94-4P 692772-95-5P 692772-96-6P

692772-97-7P 692772-98-8P 692772-99-9P

692773-00-0P 692773-01-6P 692773-02-7P

692773-05-0P 692773-06-1P 692773-07-2P


692773-08-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hetero-substituted benzimidazole derivs. useful as antiviral agents)

RN 692772-79-5 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine, 3-[(1H-benzimidazol-2-ylmethyl)-2-(1-piperazinylmethyl)]- (9CI) (CA INDEX NAME)



RN 692772-80-8 CAPLUS

CN Piperazine,

1-[[3-(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-4-(phenylacetyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:428901 CAPLUS

DOCUMENT NUMBER: 140:423675

TITLE: A preparation of hetero-substituted benzimidazole derivatives useful as antiviral agents

INVENTOR(S): Lackey, John William

PATENT ASSIGNEE(S): Trimeris, Inc., USA

SOURCE: PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043913	A2	20040527	WO 2003-US35542	20031106
WO 2004043913	A3	20040923		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD

TG AU 2003294249 A1 20040603 AU 2003-294249 20031106

US 2004166137 A1 20040826 US 2003-704224 20031106

PRIORITY APPL. INFO.: US 2002-424940P P 20021108

WO 2003-US35542 W 20031106

OTHER SOURCE(S): MARPAT 140:423675

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to novel hetero-substituted benzimidazole derivs.

of

formula I [wherein: Z1, Z2, Z3, Z4 are each independently N or C, and at least one of Z1, Z2, Z3, Z4 is C; R1 and R2 are each independently H, (un)saturated (un)substituted alkyl, (un)substituted (hetero)cycloalkyl, (hetero)aryl, etc.; R3 is H, halide, OH, (un)substituted aryl, arylalkyl, etc.; R4, R5, R6, R7 are each independently H, halide, alkyl, OH, alkoxy, etc.; X is a bond, (un)substituted alkyl, -alkyl-N-, -alkyl-O-, -C=N-, C(O), etc.; Y is N, P, O, S; if Y is O or S, R2 is not present], useful


as antiviral agents. The invention encompasses hetero-substituted benzimidazole compds. that inhibit membrane fusion associated events such as

L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692772-93-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 3-[(1H-benzimidazol-2-ylmethyl)-2-[(4-(trifluoromethyl)phenyl)-1-piperazinylmethyl]]- (9CI) (CA INDEX NAME)



RN 692772-94-4 CAPLUS


CN 6,7-Isoquinolinediol, 2-[[3-(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 692772-95-5 CAPLUS

CN Piperazine, 1-acetyl-4-[[3-(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692772-96-6 CAPLUS
 CN Piperazine,
 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-(9CI) (CA INDEX NAME)




RN 692772-97-7 CAPLUS
 CN 1-Piperazinecarboxamide,
 4-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-(9CI) (CA INDEX NAME)




RN 692772-98-8 CAPLUS
 CN Piperazine,
 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-(9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 692773-01-6 CAPLUS
 CN 4-Piperidineethanol, 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-(9CI) (CA INDEX NAME)




RN 692773-02-7 CAPLUS
 CN Pyridinium,
 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-(9CI) (CA INDEX NAME)




RN 692773-05-0 CAPLUS
 CN Piperazine,
 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-4-[(2,5-dimethyl-3-thienyl)sulfonyl]-(9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692773-99-9 CAPLUS
 CN 2-Pyrrolidinemethanol, 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 692773-00-5 CAPLUS
 CN 2-Piperidineethanol, 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-(9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692773-06-1 CAPLUS
 CN Piperazine,
 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-4-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-(9CI) (CA INDEX NAME)



RN 692773-07-2 CAPLUS
 CN Piperazine,
 1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-4-[(2,4-difluorophenyl)sulfonyl]-(9CI) (CA INDEX NAME)


L4 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 692773-08-3 CAPLUS

CN Piperazine.

1-[[3-[(1H-benzimidazol-2-ylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-4-(3-thienylsulfonyl)-(9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



III

AB Title compds. I [wherein R1 = (un)substituted indolyl or an aza derivative

thereof; R2 = (un)substituted (hetero)aryl, quinolyl, heterocycloalkyl; R12, R13 = alkyl, hydroxyl, alkoxy, etc., or R13 = O; m = independently 0-3; n = 1-3; p = 1-3; q = 1-5; X = a bond or alkylene; Y = CO, CS, COCH2,

etc.; Z = a bond, alkylene, alkenylene, CO, etc.; M1 = CH or N; M2 = CR3 or N; and salts or solvates thereof] were prepared as histamine H3 antagonists in treatment of H3 receptor related diseases. For example, reaction of II with 3-(4-piperidinyl)-2-(2-pyridinyl)indole, followed by deprotection and substitution with 2-chloromethylpyridine gave III, which showed 1.50 nM binding constant with histamine H3. Thus, I and their pharmaceutical compds., as well as in combination with H1 receptor antagonists, are useful as histamine H3 antagonists for the treatment of inflammatory diseases, allergic conditions and central nervous system disorders (no data).


IT 110588-56-2, Noverastine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy agent; preparation of indole deriva. as

histamine H3 antagonists)

RN 110588-56-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

Habe

L4 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER:

2004:2876 CAPLUS

DOCUMENT NUMBER:

140:59522

TITLE:

Preparation of indole derivatives as histamine H3 antagonists

INVENTOR(S):

Aslanian, Robert G.; Berlin, Michael Y.;

Mangiaracina,

Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.;

Rosenblum, Stuart B.

Schering Corporation, USA

PCT Int. Appl., 62 pp.

PATENT ASSIGNEE(S):

CODEN: PIXXD2

SOURCE:

Patent

DOCUMENT TYPE:

English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000831	A1	20031231	WO 2003-US19619	20030620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2489337	AA	20031231	CA 2003-2489337	20030620
AU 2003243709	A1	20040106	AU 2003-243709	20030620
US 2004019099	A1	20040129	US 2003-600674	20030620
US 6951871	B2	20051004		
EP 1539742	A1	20050615	EP 2003-761216	20030620
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1662524	A	20050831	CN 2003-814717	20030620
JP 2005531615	T2	20051020	JP 2004-516072	20030620
ZA 2004010213	A	20051020	ZA 2004-10213	20041217
			US 2002-390987P	P 20020624
PRIORITY APPLN. INFO.:				
			WO 2003-US19619	W 20030620

OTHER SOURCE(S):

MARPAT 140:59522

GI

L4 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

04/28/2006

L4 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:991348 CAPLUS

DOCUMENT NUMBER: 140:27826

TITLE: Preparation of 1-(4-piperidinyl)benzimidazolones as histamine H3 antagonists

INVENTOR(S): Ting, Pauline C.; Aslanian, Robert G.; Berlin, Michael

Mangiaracina,

Daniel

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103669	A1	20031218	WO 2003-US11696	20030416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG				
CA 2482551	AA	20031218	CA 2003-2482551	20030416
AU 2003223631	A1	20031222	AU 2003-223631	20030416
US 2004048843	A1	20040311	US 2003-414943	20030416
US 2004097483	A1	20040520	US 2003-417391	20030416
EP 1494671	A1	20050112	EP 2003-719770	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1658875	A	20050824	CN 2003-813780	20030416
JP 2005529161	T2	20050929	JP 2004-510788	20030416
ZA 2004007985	A	20051019	ZA 2004-7985	20041004
PRIORITY APPLN. INFO.:			US 2002-373467P	P 20020418
			US 2002-373731P	P 20020418
			WO 2003-US11696	W 20030416

OTHER SOURCE(S):
GI

MARPAT 140:27826

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

L4 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:855801 CAPLUS

DOCUMENT NUMBER: 139:350734

TITLE: Preparation of 1-(4-piperidinyl)benzimidazolones as histamine H3 antagonists

INVENTOR(S): Zeng, Qingbei; Aslanian, Robert G.; Berlin, Michael; Y.; Boyce, Christopher W.; Cao, Jianhua; Kozlowski, Joseph A.; Mangiaracina, Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.; Shih, Neng-Yang; Solomon, Daniel M.; Tom, Wing C.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088967	A1	20031030	WO 2003-US11672	20030416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481940	AA	20031030	CA 2003-2481940	20030416
AU 2003223627	A1	20031103	AU 2003-223627	20030416
US 2004097483	A1	20040520	US 2003-417391	20030416
EP 1499316	A1	20050126	EP 2003-719766	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009348	A	20050301	BR 2003-9348	20030416
CN 1658874	A	20050824	CN 2003-813779	20030416
JP 2005529116	T2	20050929	JP 2003-585719	20030416
ZA 2004007984	A	20051018	ZA 2004-7984	20041004
NO 2004005002	A	20050118	NO 2004-5002	20041117
PRIORITY APPLN. INFO.:			US 2002-373731P	P 20020418
			US 2002-373467P	P 20020418
			WO 2003-US11672	W 20030416

OTHER SOURCE(S):
GI

MARPAT 139:350734

L4 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

AB Disclosed are histamine H3 antagonists I [a, b = 0-3; n = 1-3; p = 1-3 (with the proviso that when M2 = N, then p is not 1); r = 1-3 (with the proviso that when r = 2 or 3, then M2 = CR3 and p = 2 or 3); A = a bond, alkylene; M1 = CR3, N; M2 = CR3, N; Y = CO, CS, SO, SO2, etc.; Z = a bond,

alkylene, alkenylene, CO, CH(CN), etc.; R1 = (un)substituted benzimidazolone, quinazolone, etc.; R2 = (un)substituted aryl or heteroaryl; R3 = H, halo, alkyl, OH, alkoxy; R12, R13 = alkyl, OH, alkoxy,

etc.]. Synthesis of representative compds. I is described. Thus, amidation of the amine II with the acid III (preps. given) afforded 80% the compound IV. The compds. I showed a Ki within the range of about

0.1 to about 1000 nM in H3-receptor binding assay. Also disclosed are pharmaceutical compns. comprising the compds. I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. of I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I in combination with a H1 receptor antagonist.

IT 110588-56-2, Noverastine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(co-administration; preparation of 1-(4-piperidinyl)benzimidazolones


as histamine H3 antagonists for use in combination with an H1 receptor

antagonist)

RN 110588-56-2 CAPLUS

CN 3H-Imidazo(4,5-b)pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-



piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The title compds. I [R1 = (un)substituted benzimidazolyl or a derivative thereof; R2 = (un)substituted aryl or heteroaryl; M1, M2 = CR3, N; X = a bond, alkylene; Y = CO, CS, SO2, etc.; Z = a bond, alkylene, CO, etc.; R3 = H, halo, alkyl, etc.; R12 = alkyl, OH, alkoxy, etc.; R13 = alkyl, alkoxy, OH, etc.; a, b = 0-2; n, p = 1-3; r = 0-3; with the proviso] which are histamine H3 antagonists, were prepared. E.g., a multi-step synthesis of II which showed Ki of 1 nM in rHu H3 binding assay, was given. Also disclosed are pharmaceutical compns. comprising the compds. of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I. Also disclosed are methods of treating said diseases or conditions using the compds. of formula I in combination with an H1 receptor antagonist.

IT 110588-56-2, Noverastine

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(H1 receptor antagonist; preparation of 1-(4-piperidinyl)benzimidazolones as


histamine H3 antagonists for use in combination with an H1 receptor

antagonist)

RN 110588-56-2 CAPLUS

CN 3H-Imidazo(4,5-b)pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-

piperidinyl- (9CI) (CA INDEX NAME)





L4 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:716267 CAPLUS
 DOCUMENT NUMBER: 137:247716
 TITLE: Preparation and use of substituted piperazine/piperidine derivatives as H receptor antagonists
 INVENTOR(S): Rosenblum, Stuart B.; Zeng, Qingbei; Mutsaers, Mwangi Wa; Alesanian, Robert G.; Ting, Pauline C.; Shih, Neng-Yang; Solomon, Daniel M.; Cao, Jianhua; Vaccaro, Henry A.; McCormick, Kevin D.; Baldwin, John J.; Li, Ge
 PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacia, Inc.
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072570	A2	20020919	WO 2002-US7106	20020311
WO 2002072570	A3	20030306		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, ME, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440559	AA	20020919	CA 2002-2440559	20020311
US 2003109564	A1	20030612	US 2002-95134	20020311
US 6849621	B2	20050201		
EP 1373251	A2	20040102	EP 2002-709808	20020311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1496362	A	20040512	CN 2002-806561	20020311
JP 2004520435	T2	20040708	JP 2002-571486	20020311
US 2005113383	A1	20050526	US 2004-974329	20041027
PRIORITY APPLN. INFO.:			US 2001-275417P	P 20010313
			US 2002-95134	A3 20020311
			WO 2002-US7106	W 20020311

OTHER SOURCE(S): MARPAT 137:247716
 GI


L4 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [R = (hetero)aryl, heterocycloalkyl, alkyl, carboxamido, etc.; X = alkyl, S(O)2; Y = bond, CO, CS, alkyl, amido, etc.; M = C, N; Z = alkyl, SO2, CO, carboxamido; R = 5-6 membered heteroaryl, alkyl, aryl, etc.; R = alkyl, OH, alkoxy, F, etc.; n, p, q = 1-3; with some

provisions] were prepared. For instance, 2,5-dimethylpiperazine was alkylated with 2-bromobenzaldehyde (CH2Cl2, NaH(OAc)3) and subsequently acylated with N-Boc-isonipecotic acid (CH2Cl2, PyBOP, i-Pr2NET). The resulting intermediate was deprotected and reductively alkylated with pyridine-4-carboxaldehyde to afford. Selected example compds. had Ki within 0.2 and 600 nM for the H3 receptor. I, alone and in combination with a H1 receptor antagonist, are used for the treatment of various diseases or conditions, such as, allergy, allergy-induced airway responses and congestion (e.g., nasal congestion).

IT 110588-56-2, Noverastine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation and use of substituted piperazine/piperidine derivs. as H receptor antagonists)
 RN 110588-56-2 CAPLUS
 CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)





L4 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:314934 CAPLUS
 DOCUMENT NUMBER: 136:340592
 TITLE: Preparation of 4-[(4-(piperidin-1-ylcarbonyl)piperidin-1-yl)methyl]pyridin-2-ylamines as antagonists of histamine H3 receptors
 INVENTOR(S): Alesanian, Robert G.; Shih, Neng-Yang; Ting, Pauline C.; Berlin, Michael Y.; Rosenblum, Stuart B.; McCormick, Kevin D.; Tom, Wing C.; Boyce, Christopher W.; Mangiaracina, Pietro; Mutsaers, Mwangi Wa; Piwinski, John J.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032893	A2	20020425	WO 2001-US32151	20011015
WO 2002032893	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, ME, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2424664	AA	20020425	CA 2001-2424664	20011015
AU 2002015355	A5	20020429	AU 2002-15355	20011015
US 2003045519	A1	20030306	US 2001-978267	20011015
US 6720328	B2	20040413		
BR 2001014754	A	20030701	BR 2001-14754	20011015
EP 1326858	A2	20030716	EP 2001-983968	20011015
EP 1326858	B1	20051214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004511553	T2	20040415	JP 2002-536275	20011015
NZ 524857	A	20041224	NZ 2001-524857	20011015
EP 1571145	A1	20050907	EP 2005-9405	20011015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR				
AT 312833	E	20051215	AT 2001-983968	20011015
ZA 2003002521	A	20040630	ZA 2003-2521	20030331
NO 2003001744	A	20030614	NO 2003-1744	20030415
US 2004097513	A1	20040520	US 2003-699189	20031031
PRIORITY APPLN. INFO.:			US 2000-240901P	P 20001017
			EP 2001-983968	A3 20011015
			US 2001-978267	A3 20011015
			WO 2001-US32151	W 20011015

OTHER SOURCE(S): MARPAT 136:340592
 04/28/2006

L4 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

GI



AB The title compds. [I; R1 = (un)substituted aryl, heteroaryl, alkyl, etc.; X = CO, C(NOR3), C(NRR4R5), etc.; M1 = C; M2 = C, N; M3, M4 = C, N; Y = CH2, CO, C(NOH), etc.; Z = alkyl; R2 = (un)substituted 5-6 membered heteroaryl; R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; R5 = H, alkyl, COR4, etc.; R12, R13 = alkyl, OH, alkoxy, F; a, b = 0-2; n, p = 1-3, with the proviso that when M3 and M4 are both N atoms, then p = 2 or 3], useful in treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion), were prepared. E.g., a multi-step synthesis of II

which showed Ki of 0.83 nM in H3 receptor binding assay, was given. Also disclosed are methods of treating various diseases or conditions, such

as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I in combination with a H1 receptor antagonist.

IT 110588-56-2, Noverastine.


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(H1 receptor antagonist; preparation of 4-[(4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl)pyridin-2-ylamines as antagonists of histamine H3 receptors)

RN 110588-56-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

2001:560439 CAPLUS

DOCUMENT NUMBER:

135:338686

TITLE:

Similarity searching in large combinatorial chemistry spaces

AUTHOR(S):

Raney, Matthias; Stahl, Martin

CORPORATE SOURCE:

GMD-German National Research Center for Information Technology, Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, 53754, Germany

SOURCE:

Journal of Computer-Aided Molecular Design (2001), 15(6), 497-520

CODEN: JCADEQ; ISSN: 0920-654X

PUBLISHER:

Kluwer Academic Publishers

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB We present a novel algorithm, called Ftrees-FS, for similarity searching in large chemical spaces based on dynamic programming. Given a query compound, the algorithm generates sets of compds. from a given chemical space that are

similar to the query. The similarity search is based on the feature tree similarity measure representing mols. by tree structures. This descriptor

allows handling combinatorial chemical spaces as a whole instead of

looking at subsets of enumerated compds. Within few minutes of computing time, the algorithm is able to find the most similar compound in very large

spaces as well as sets of compds. at an arbitrary similarity level. In addition,

the diversity among the generated compds. can be controlled. A set of 17,000 fragments of known drugs, generated by the RECAP procedure from the

World Drug Index, was used as the search chemical space. These

fragments can be combined to more than 1018 compds. of reasonable size. For

validation,

known antagonists/inhibitors of several targets including dopamine D4, histamine H1, and COX2 are used as queries. Comparison of the compds. created by Ftrees-FS to other known actives demonstrates the ability of the method to jump between structurally unrelated mol. classes.

IT 110588-56-2

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); MSC (Miscellaneous); PRP (Properties); BIOL

(Biological study)

(search for histamine H1 antagonists; similarity searching in large


combinatorial chemical spaces)

RN 110588-56-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-

piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 35

THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE


L4 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:319725 CAPLUS
 DOCUMENT NUMBER: 134:320888
 TITLE: Use of substance P antagonists for influencing the circadian timing system
 Dugovic, Christine Jeanne; Janssens, Frans Eduard
 Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030348	A1	20010503	WO 2000-EP10201	20001016
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: EP 1999-203499 A 19991025

OTHER SOURCE(S): MARPAT 134:320888
 AB The invention concerns the use of N-containing heterocyclic deriva. (Markush included) in the manufacture of medicaments useful for beneficially influencing the circadian timing system or enhancing the sleep efficiency of a mammal, suitably a human being. The compds. of the invention are described in full in WO 97/16440, WO 97/14324, WO 97/24350, and WO 97/24356.
 IT 193201-95-5 193201-95-5D, N-oxides and stereoisomers
 193201-96-6 193201-96-6D, N-oxides and stereoisomers
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES
 (Uses)
 (substance P antagonists for influencing circadian timing system)
 RN 193201-95-5 CAPLUS
 CN [1,4'-Bipiperidin]-4-amine,
 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 193201-95-5 CAPLUS
 CN [1,4'-Bipiperidin]-4-amine,
 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 193201-96-6 CAPLUS
 CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-ylamino]-1-pyrrolidinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 193201-96-6 CAPLUS
 CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-ylamino]-1-pyrrolidinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:12448 CAPLUS
 DOCUMENT NUMBER: 134:86251
 TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.
 Janssens, Frans Eduard; Lacrampe, Jean Fernand
 INVENTOR(S): Guillemont, Jerome Emile Georges; Venet, Marc Gaston; Andries, Koenraad Jozef Lodewijk Marcel
 Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000615	A1	20010104	WO 2000-EP5677	20000620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2376785	AA	20010104	CA 2000-2376785	20000620
BR 2000011997	A	20000305	BR 2000-11997	20000620
EP 1196410	A1	20000417	EP 2000-936899	20000620
EP 1196410	B1	20000418		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200103805	T2	20020621	TR 2001-200103805	20000620
JP 2003503403	T2	20030128	JP 2001-507023	20000620
EE 200100694	A	20030217	EE 2001-694	20000620
EE 4592	B1	20060215		
AT 259796	E	20040315	AT 2000-936899	20000620
EP 1400519	A1	20040324	EP 2001-102464	20000620
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
NZ 515392	A	20040326	NZ 2000-515392	20000620
AU 774829	B2	20040708	AU 2000-52222	20000620
PT 1196410	T	20040730	PT 2000-936899	20000620
ES 2215670	T3	20041016	ES 2000-936899	20000620
TR 200500707	T2	20050421	TR 2005-200500707	20000620
HR 2001000934	A1	20030630	HR 2001-934	20011219
ZA 2001010473	A	20030320	ZA 2001-10473	20011220
NO 2001006370	A	20011227	NO 2001-6370	20011227
BG 106288	A	20021031	BG 2002-106288	20020108
HK 1045998	A1	20050603	HK 2002-107623	20021021
US 2006058309	A1	20060316	US 2005-247392	20051011
PRIORITY APPLN. INFO.:			EP 1999-202089	A 19990628
			EP 2000-936899	A3 20000620
			WO 2000-EP5677	W 20000620

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
US 2001-19376 A3 20011227

OTHER SOURCE(S): MARPAT 134:86251
GI



AB Title compds. [I; a1:a2a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:CHCH:CH, CH:CHCH:CH; Q = R2R4NAX1, R2R4NCOAX1, specified (substituted) heterocycles; A = (substituted) alkylene; X1 = imino, S, SO, SO2, O, CH2, CO, CH(OH), etc.; R1 = (substituted) bicyclic heterocycle; G = bond, (substituted) alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, etc.; R4 = H, alkyl, aralkyl], were prepared Thus,

1-[4-[(1-(2-quinolinylmethyl)-1H-benzimidazol-2-yl)amino]-1-piperidinyl]-3-methyl-2-butanone was hydrogenated with PhCH2NH2 in MeOH over Pd/C to give N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-(2-quinolinylmethyl)-1H-benzimidazol-2-amine and


N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-1-[(1,2,3,4-tetrahydro-2-quinolyl)methyl]-1H-benzimidazol-2-amine tetrahydrochloride. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.0004-1.5849 μM.

IT 317585-88-9P 317585-92-5P 317586-37-1P
317587-05-6P 317588-51-5P 317588-61-7P
317588-76-4P 317590-71-9P 317591-82-5P
317592-73-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)


RN 317585-88-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 4 HCl


RN 317585-92-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-7-methyl-3-(8-quinolinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

RN 317586-37-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(3-quinolinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 317587-05-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(8-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 317588-51-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-amino-3-methylbutyl)-4-piperidinyl]-3-(2-quinolinylmethyl)-, tetrahydrochloride (9CI) (CA INDEX NAME)




● 4 HCl

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 317588-61-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 317588-76-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-(8-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 317590-71-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(1-methyl-1H-benzimidazol-4-yl)methyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



● 4 HCl

RN 317591-82-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 7-methyl-N-4-piperidinyl-3-(8-quinolinylmethyl)- (9C1) (CA INDEX NAME)



RN 317592-73-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(8-quinolinylmethyl)- (9C1) (CA INDEX NAME)

own work


L4 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2001:12445 CAPLUS
 DOCUMENT NUMBER: 134:86249
 TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.
 INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus Marie-Jose; Sommen, Francois Maria; Andries, Koenraad Jozef Lodewijk Marcel
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000612	A2	20010104	WO 2000-EP5675	20000620
WO 2001000612	A3	20010329		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
CA 2376676	AA	20010104	CA 2000-2376676	20000620
BR 2000012047	A	200020312	BR 2000-12047	20000620
EP 1196409	A2	200020417	EP 2000-943840	20000620
EP 1196409	B1	200040204		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103806	T2	20020621	TR 2001-200103806	20000620
JP 200303402	T2	20030128	JP 2001-507021	20000620
EE 200100688	A	20030415	EE 2001-688	20000620
EE 4591	B1	20060215		
NZ 515664	A	20040130	NZ 2000-515664	20000620
AT 258928	E	20040215	AT 2000-943840	20000620
PT 1196409	T	20040630	PT 2000-943840	20000620
ES 2215683	T3	20041016	ES 2000-943840	20000620
AU 778218	B2	20041125	AU 2000-58166	20000620
HR 2001000935	A1	20030630	HR 2001-935	20011219
ZA 2001010479	A	20030320	ZA 2001-10479	20011220
NO 2001006369	A	20020220	NO 2001-6369	20011227
US 6747028	B1	20040608	US 2001-19380	20011227
SG 106286	A	20021031	SG 2002-106286	20020108
PRIORITY APPL. INFO.:			EP 1999-202088	A 19990628
			WO 2000-EP5675	W 20000620


OTHER SOURCE(S): MARPAT 134:86249
 GI

L4 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Title compds. I; [a1:a2a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1, R2R4NCOAX1, specified (substituted) (hetero)cyclyl; A = (substituted) alkanediyl; X1 = imino,
 S, SO, SO2, O, CH2, CO, CH(OH), etc.; R1 = (substituted) monocyclic heterocyclyl, aryl; R2 = H, formyl, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, cycloalkyl, substituted alkyl; R4 = H, alkyl, aralkyl, were prepared Thus, 1-[ethoxy(2-pyridinyl)methyl]-N-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-2-amine was hydrogenated in MeOH over Pd/C to give
 1-[ethoxy(2-pyridinyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.00032-1.2589 µM.
 IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)
 RN 317384-54-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-3-ethanol, α-phenyl-2-(4-piperidinylmethyl)-, ethanedioate (1:2) (salt) (9C1) (CA INDEX NAME)
 CM 1
 CRN 317384-53-5
 CMF C20 H24 N4 O




CM 2
 CRN 144-62-7
 CMF C2 H2 O4

L4 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 317384-64-8 CAPLUS
CN 1-Imidazo[4,5-b]pyridine-3-ethanol, alpha-phenyl-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



IT 317384-96-6P 317384-97-7P 317385-02-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)

RN 317384-96-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(2-oxo-2-phenylethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 317384-97-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(2-hydroxy-2-phenylethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:12444 CAPLUS
DOCUMENT NUMBER: 134:86248
TITLE: Preparation of benzimidazoles as respiratory syncytial virus replication inhibitors.
INVENTOR(S): Janssens, Frans Eduard; Meersman, Kathleen Petrus Marie-Jose; Sommen, Francois Maria; Guillemont, Emile Georges; Lacrampe, Jean Fernand Armand;
Jerome, Koenraad Jozef Lodewijk Marcel
Andries, Janssens Pharmaceutica N.V., Belg.
PATENT ASSIGNEE(S): PCT Int. Appl., 119 pp.
SOURCE: CODEN: PJJXDX
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000611	A1	20010104	WO 2000-EP5676	20000620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2376781	AA	20010104	CA 2000-2376781	20000620
BR 2000012054	A	20020319	BR 2000-12054	20000620
EP 1196408	A1	20020417	EP 2000-943841	20000620
EP 1196408	B1	20040915		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200103804	T2	20020521	TR 2001-200103804	20000620
JP 2003503401	T2	20030128	JP 2001-507020	20000620
EE 200100692	A	20030217	EE 2001-692	20000620
EE 4590	B1	20060215		
NZ 515418	A	20031128	NZ 2000-515418	20000620
EP 1418175	A1	20040512	EP 2004-100543	20000620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, MK, CY, AL				
AT 276244	E	20040105	AT 2000-943841	20000620
AU 779516	B2	20050127	AU 2000-58167	20000620
PT 1196408	T	20050111	PT 2000-943841	20000620
ES 2228559	T3	20050416	ES 2000-943841	20000620
HR 2001000933	A1	20030630	HR 2001-933	20011219
ZA 2001010478	A	20030320	ZA 2001-10478	20011220
NO 2001006368	A	20020228	NO 2001-6368	20011227
US 6924287	B1	20050802	US 2001-30202	20011227
BG 106287	A	20021031	BG 2002-106287	20020108
US 2005234047	A1	20051020	US 2005-144103	20050603
US 2005239771	A1	20051027	US 2005-144126	20050603
PRIORITY APPL. INFO.:			EP 1999-202087	A 19990628
			EP 2000-200452	A 20000211

Habe

L4 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 317385-02-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(2-hydroxy-2-phenylethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


EP 2000-943841 A3 20000620
WO 2000-EP5676 W 20000620
US 2001-30202 A3 20011227
OTHER SOURCE(S): MARPAT 134:86248
GI




AB Use of title compds. [I; a1:a2a3:a4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:N:CH:CH, CH:CHN:CH, CH:CHCH:N; Q = R2R4NAX1, R2R4NCOAX1, specified (heterocyclic) ring, etc.; A = alkylene; R2 = H, CHO, alkylcarbonyl, pyrrolidinyl, piperidinyl, homopiperidinyl, aminocycloalkyl, etc.; R4 = H, alkyl, aralkyl; G = bond, alkanediyl; R1 = (substituted) piperidinyl, piperazinyl, pyridyl, pyrazinyl, pyridazinyl, pyrrolyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, etc.] for treatment of viral infection is claimed. Thus, 1,1-dimethylethyl 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate was refluxed 6 h in 10N HCl to give 4-[[1-[[3,5-dihydro-3,3-dimethyl-9-(phenylmethoxy)-1H-1,3-dioxepino[5,6-c]pyridin-2-yl]methyl]-1H-benzimidazol-2-yl]amino]piperidine. Tested I inhibited respiratory syncytial virus replication with IC50 = 0.00013-2.5119 µM.
IT 317846-02-9P 317846-40-5P 317847-09-9P 317847-24-8P 317847-25-9P 317847-34-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)
RN 317846-02-9 CAPLUS
CN 3-Pyridinol, 6-methyl-2-[[2-(4-piperidinylamino)-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 317846-40-5 CAPLUS
CN 1-Piperidineethanamine, 4-[[3-[(5-methoxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 317847-09-9 CAPLUS
CN 3-Pyridinol, 2-[[2-[[1-(2-amino-3-methylbutyl)-4-piperidinyl]amino]-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 317847-24-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(2,4-dimethyl-5-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 317847-84-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)
RN 317847-84-0 CAPLUS
CN 2-Furanmethanol, 5-[[2-[[1-(2-aminoethyl)-4-piperidinyl)methyl]-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)




IT 141567-59-1P 317847-44-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzimidazoles as respiratory syncytial virus replication inhibitors)
RN 141567-59-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(2,4-dimethyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 317847-25-9 CAPLUS
CN 1-Piperazineethanamine, 4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 317847-34-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 317847-44-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(3-hydroxy-6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:567449 CAPLUS
DOCUMENT NUMBER: 133:168392
TITLE: Composition and method for treating allergic diseases
INVENTOR(S): Aslanian, Robert G.; Piwinski, John J.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6103735	A	20000815	US 1999-412621	19991006

PRIORITY APPLN. INFO.: US 1999-412621 19991006

OTHER SOURCE(S): MARPAT 133:168392
AB The present invention is directed towards a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the composition comprises, in combination, a therapeutically effective amount of at least one neurokinin antagonist, a therapeutically effective amount of at least one H3 antagonist and a therapeutically effective amount of at least one H1 antagonist.
IT 110588-56-2, Noverastine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(antagonists of neurokinin receptors and histamine receptors for treating allergic diseases)
RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L4 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:259985 CAPLUS
DOCUMENT NUMBER: 132:284236
TITLE: Composition and method for treating allergic diseases
INVENTOR(S): Aslanian, Robert G.; Piwinski, John J.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021512	A2	20000420	WO 1999-US21437	19991006
WO 2000021512	A3	20000706		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, KZ, LC, LK, LR, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, T2, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2346227	A2	20000420	CA 1999-2346227	19991006
AU 9962526	A1	20000501	AU 1999-62526	19991006
EP 1117405	A2	20010725	EP 1999-949707	19991006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002527381	T2	20020827	JP 2000-575488	19991006
PRIORITY APPLN. INFO.:			US 1998-169608	A 19981009
			WO 1999-US21437	W 19991006

OTHER SOURCE(S): MARPAT 132:284236
AB The present invention is directed towards a pharmaceutical composition useful for the treatment of allergic rhinitis, asthma and related disorders. In one embodiment, the compns. comprise, in combination, a therapeutically effective amount of at least one neurokinin antagonist, a therapeutically effective amount of at least one H3 antagonist and a therapeutically effective amount of at least one H1 antagonist. The invention neurokinin antagonists include 3,5-dichloro-N-[3-(3,4-dichlorophenyl)-2-(methoxyimino)-5-(2-oxo[1,4'-bipiperidin]-1'-yl)pentyl]-N-methylbenzamide and deriva. thereof.
IT 110588-56-2, Noverastine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(pharmaceutical compns. containing neurokinin antagonists and antihistaminics for treatment of allergic diseases)
RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:574769 CAPLUS
 DOCUMENT NUMBER: 131:219171
 TITLE: Glycine transport inhibitors
 INVENTOR(S): Luyten, Walter Herman Maria Louis; Janssens, Frans
 Eduard; Kennis, Ludo Edmond Josephine
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944596	A2	19990910	WO 1999-EP1309	19990226
WO 9944596	A3	20000217		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
TM	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2322164	A1	19990910	CA 1999-2322164	19990226
AU 9934089	A1	19990920	AU 1999-34089	19990226
TR 200002567	T2	20001121	TR 2000-200002567	19990226
EP 1059922	A2	20001220	EP 1999-915541	19990226
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
BR 9907951	A	20010130	BR 1999-7951	19990226
EE 200000482	A	20020215	EE 2000-482	19990226
JP 2000505277	T2	20000219	JP 2000-534198	19990226
HR 2000000523	A1	20010228	HR 2000-523	20000802
BG 104685	A	20010430	BG 2000-104685	20000811
NO 2000004431	A	20001030	NO 2000-4431	20000905
PRIORITY APPLN. INFO.:			EP 1998-200701	A 19980306
			WO 1999-EP1309	W 19990226

OTHER SOURCE(S): MARPAT 131:219171
 AS The present invention is concerned with the use of glycine transport inhibiting [4,4-bis(4-fluorophenyl)butyl]-1-(piperazinyl and piperidinyl) derivs. for the preparation of medicaments for treating disorders of the central and peripheral nervous system, in particular psychoses, pain, epilepsy, neurodegenerative diseases (Alzheimer's disease), stroke, head trauma, multiple sclerosis and the like. E.g., 3-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-3,4-dihydro-2(1H)-quinazolinone was prepared as were a number of other derivs. The compds. were assayed for transport via GlyT1 transporters. Film-coated tablets were also prepared
 IT 242791-99-3P 242791-97-5P 242791-99-7P
 242792-01-4P 242792-04-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

L4 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 242791-99-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]methyl]-3-(phenylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
 CRN 242791-98-6
 CMF C34 H35 F2 N5




CM 2
 CRN 144-62-7
 CMF C2 H2 O4

Habte

L4 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (glycine transport inhibitors)
 RN 242791-95-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]methyl]-3-(2-pyridinylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
 CRN 242791-94-2
 CMF C33 H34 F2 N6



CM 2
 CRN 144-62-7
 CMF C2 H2 O4



RN 242791-97-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1
 CRN 242791-96-4
 CMF C34 H34 F3 N5

L4 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 242792-01-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]methyl]-3-(2-thienylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 242792-00-3
 CMF C32 H33 F2 N5 S



CM 2
 CRN 144-62-7
 CMF C2 H2 O4




RN 242792-04-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]methyl]-3-(2-furanylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
 CRN 242792-03-6
 CMF C32 H33 F2 N5 O

04/28/2006

L4 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4


L4 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:104511 CAPLUS
 DOCUMENT NUMBER: 130:163188
 TITLE: Treatment of upper airway allergic responses with H1- and H3-histamine receptor antagonists
 INVENTOR(S): Kreutner, William; Hey, John A.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: U.S., 5 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5869479	A	19990209	US 1997-909319	19970814
PRIORITY APPLN. INFO.:			US 1997-909319	19970814

AB Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H1 receptor antagonist; together with (b) a sufficient amount of a histamine H3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or sep. in the same or different dosage forms to maintain therapeutic systemic levels of both components.

IT 110588-56-2, Nohersastine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN (H1- and H3-histamine receptor antagonists for treatment of rhinitis)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L4 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:437072 CAPLUS
 DOCUMENT NUMBER: 129:156472
 TITLE: Structure-activity relationships of astemizole derivatives for inhibition of store-operated Ca2+ channels and exocytosis
 AUTHOR(S): Fischer, Marcel J. E.; Paulussen, Jeannette J. C.; Tollensere, Jan P.; De Mol, Nico J.; Janssen, Lambert H. M.
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Utrecht Institute for Pharmaceutical Sciences, Faculty of Pharmacy, Utrecht University, Utrecht, 3508 TB, Neth.
 SOURCE: European Journal of Pharmacology (1998), 350(2/3), 353-361
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The effects of a series of analogs of the antiallergic drug astemizole on the exocytosis of the enzyme β -hexosaminidase were studied in a mast cell model, the rat basophilic leukemia (RBL-2H3) cell. Besides differences in the effects on Fc ϵ R1 receptor-stimulated exocytosis, changes were also observed in Ca2+ influx and in the perturbation of the cell membrane. A strong correlation was found between the effects on antigen- and thapsigargin-stimulated 45Ca2+ influx. Furthermore, the inhibition of 45Ca2+ influx was correlated with the inhibition of β -hexosaminidase release and membrane stabilization. It is concluded that the astemizole analogs are capable of inhibiting mast cell β -hexosaminidase release through inhibition of Ca2+-store-operated Ca2+ channels (SOC). Compds. with high lipophilicity also released Ca2+ from intracellular stores. Lowering of the hydrophobicity by introduction of nitrogens or truncation at different sites in the astemizole structure decreased inhibitory activity on SOC channels. The inhibition of SOC channels cannot completely be ascribed to non-specific membrane effects. The piperidinyl-benzimidazole moiety was important for inhibition of SOC channels. The observed differences in activity possibly depend on the way


the compds. penetrate the membrane bilayer. Astemizole is an interesting new tool to study SOC channels and can be a lead for the design of mast cell-stabilizing antiallergic drugs.
 IT 73755-88-1 110588-56-2
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(structure-activity relationships of astemizole derivs. for inhibition of store-operated Ca2+ channels and exocytosis of β -hexosaminidase in mast cell model in relation to lipophilicity and effect on membrane stabilization)
 RN 73755-88-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




IT 75970-98-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationships of astemizole derive. for inhibition of store operated Ca^{2+} channels and exocytosis of β -hexosaminidase in mast cell model in relation to lipophilicity and effect on membrane stabilization)
RN 75970-98-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
10.2 loratadine and 10 mg/kg thioperamide in cats was 2.1 as compared with
H3 antagonist effective amt., lactose 100, 10% corn starch past 5, dried corn starch 25, and magnesium stearate 1.25 mg.
IT 110588-56-2, Noverastine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES (Uses) (treatment of upper airway allergic responses with combination of histamine receptor antagonists)
RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:124005 CAPLUS
DOCUMENT NUMBER: 128:208908
TITLE: Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
INVENTOR(S): Kreutner, William; Hey, John A.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806394	A1	19980219	WO 1997-US13903	19970813
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, DE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU				
RM: GH, KE, LS, MW, SD, SZ, UG, ZM, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9707263	A	19980216	ZA 1997-7263	19970813
CA 2263163	AA	19980219	CA 1997-2263163	19970813
AU 9739733	A1	19980306	AU 1997-39733	19970813
AU 722040	B2	20000720		
EP 920315	A1	19990609	EP 1997-937153	19970813
EP 920315	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO				
BR 9711149	A	19990817	BR 1997-11149	19970813
CN 1233179	CN	19991027	CN 1997-198713	19970813
JP 2000050594	T2	20000425	JP 1998-509859	19970813
JP 3638289	B2	20000413		
NZ 334063	A	20000929	NZ 1997-334063	19970813
JP 2003095979	A2	20030403	JP 2002-222138	19970813
TW 221768	B1	20041011	TW 1997-86111627	19970813
AT 314071	E	20060115	AT 1997-937153	19970813
KR 2000029975	A	20000525	KR 1999-701226	19990212
NO 9900706	A	19990215	NO 1999-706	19990215
PRIORITY APPL. INFO.:			US 1996-689951	A 19960816
			JP 1998-509859	A3 19970813
			WO 1997-US13903	W 19970813

AB Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H1 receptor antagonist; together with (b) a sufficient amount of a histamine H3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or sep. in the same or different dosage forms to maintain therapeutic systemic levels of both components. The nasal airways resistance following injection of 3 mg/kg




L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:516068 CAPLUS
DOCUMENT NUMBER: 127:135802
TITLE: N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl)piperidines as tachykinin antagonists
INVENTOR(S): Janssens, Frans Eduard; Sommen, Francois Maria; Surlerreaux, Dominique Louis Nestor Ghislaine
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724350	A1	19970710	WO 1996-EP5877	19961220
W: AL, AM, AU, BB, BG, BR, CA, CN, CU, CZ, DE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, RU, TJ, TM				
RM: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, ML, MR, TG, SN, TD, TN				
TW 429256	B	20010411	TW 1996-85115389	19961213
CA 2238816	AA	19970710	CA 1996-2238816	19961220
CA 2238816	C	20060321		
AU 9713080	A1	19970728	AU 1997-13080	19961220
AU 707116	B2	19990701		
EP 869955	A1	19981014	EP 1996-944686	19961220
EP 869955	B1	20011024		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI				
CN 1206414	A	19990127	CN 1996-199406	19961220
CN 1117090	B	20030806		
BR 9612326	A	19990713	BR 1996-12326	19961220
JP 2000052689	T2	20000307	JP 1997-524029	19961220
AT 207484	E	20011115	AT 1996-944686	19961220
PT 869955	T	20020429	PT 1996-944686	19961220
ES 2166915	T3	20020501	ES 1996-944686	19961220
IL 124642	A1	20020814	IL 1996-124642	19961220
PL 184489	B1	20021129	PL 1996-327440	19961220
SK 283533	B6	20030911	SK 1998-829	19961220
CZ 294199	B6	20041013	CZ 1998-1866	19961220
ZA 9610894	A	19980623	ZA 1996-10894	19961223
NO 9802406	A	19980824	NO 1998-2406	19980527
NO 313291	B1	20020909		
US 6110939	A	20000829	US 1998-102121	19980619
HK 1012187	A1	20020308	HK 1998-113363	19981215
PRIORITY APPL. INFO.:			EP 1995-203650	A 19951227
			EP 1995-203653	A 19951227
			EP 1995-203652	A 19951227
			WO 1996-EP5877	W 19961220

OTHER SOURCE(S): MARPAT 127:135802
GI

L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [n = 0-2; m = 1, 2; X = bond, O, S, NR3; X1, X2 = CH, N;
Q = O, NR3; R1 = aryl, aralkyl, diarylalkyl; R2 = aryl, aralkyl, heterocyclyl, heteroalkylalkyl; L = O1; R3 = H, alkyl; R4 = (un)substituted alkyl; R5 = H, halogen, OH, alkoxy; R6 = H, alkyl, aralkyl; p = 0-2] were prepared for use as substance P antagonists.

Thus, (2)-tert-Bu 7-benzyl-1,4-dioxo-8-azaspiro[4.5]decane-8-carboxylate was treated with 3,5-(F3C)2C6H3COCl, followed by 1-(2-ethoxyethyl)-2-(4-piperidinylamino)benzimidazole to give the title compound II. Cis-II gave 80.7% inhibition of substance P-induced relaxation of pig coronary artery at 3 X 10⁻⁸ M while trans-II gave 85.3 % inhibition.


IT 193199-83-6P 193199-85-8P 193199-88-1P
193199-91-6P 193200-26-9P 193200-28-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazolyl- and imidazopyridinylpiperidines as tachykinin antagonists)

RN 193199-83-6 CAPLUS

L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 193199-91-6 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 193200-26-9 CAPLUS
CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-[(3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-pyrrolidinyl]-2-(phenylmethyl)-, (2a,4a)-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN [1,4'-Bipiperidin]-4-amine, 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(2,4-dimethyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 193199-85-8 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(2,4-dimethyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 193199-88-1 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(5-

L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 193200-28-1 CAPLUS
CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-[(3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-pyrrolidinyl]-2-(phenylmethyl)-, (2a,4b)-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 193201-13-7P 193201-14-8P 193201-95-5P
193201-96-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzimidazolyl- and imidazopyridinylpiperidines as tachykinin antagonists)

RN 193201-13-7 CAPLUS
CN 4-Piperidinamine, 1-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-2-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 193201-14-8 CAPLUS
 CN 4-Piperidinamine, 1-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]-2-(phenylmethyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 193201-95-5 CAPLUS
 CN 1,4'-Bipiperidin]-4-amine,
 1'-[3,5-bis(trifluoromethyl)benzoyl]-N-[3-[(5-methyl-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]-2'-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1995:567916 CAPLUS
 DOCUMENT NUMBER: 123:659
 TITLE: Effects of acrivastine, azelastine, cetirizine and noberastine on rat peritoneal mast cells
 AUTHOR(S): Lau, H. Y. A.; Tsang, C. W.; Wong, P. P. P.
 CORPORATE SOURCE: Dep. of Pharmacology, Chinese Univ. of Hong Kong, Shatin, Hong Kong
 SOURCE: Inflammation Research (1995), 44(Suppl. 1), S30-S31
 CODEN: INREB; ISSN: 1023-3830
 PUBLISHER: Birkhaeuser
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB With better drug design, which increased the histamine H1 receptor binding specificity and reduces lipophilicity, the newly developed non-sedative antihistamines are less likely to modulate mast cell activities through nonspecific actions similar to those of the first generation counterparts.
 IT 110588-56-2, Noberastine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (H1 antihistamines effect on peritoneal mast cells)
 RN 110588-56-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanylmethyl)-N-4-piperidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 193201-96-6 CAPLUS
 CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[3-[(5-methyl-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 1994:402753 CAPLUS
 DOCUMENT NUMBER: 121:2753
 TITLE: Evaluation of the bovine corneal opacity-permeability assay as an in vitro alternative to the Draize eye irritation test
 AUTHOR(S): Vanparrys, P.; Deknadt, G.; Sysmans, M.; Teuns, G.; Coussment, W.; Van Cauteren, H.
 CORPORATE SOURCE: Dep. Toxicol., Janssen Pharm., Beerse, B-2340, Belg.
 SOURCE: Toxicology in Vitro (1993), 7(4), 471-6
 CODEN: TIVIEQ; ISSN: 0887-2333
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The bovine corneal opacity-permeability assay (BCO-P) was evaluated as an in vitro alternative test model for the Draize eye irritation test. Fifty pharmaceutical and com. available compds. were tested in the BCO-P assay. The compds. were selected on the basis of their in vivo irritancy potential as determined in previous Draize tests. Liqs. as well as solids were tested. Corneal opacity and permeability were measured to determine ocular irritation potential. When two irritancy classifications (non-irritant and irritant) were considered, 96% of the tested chems. were classified correctly. A 74% concordance was obtained when four irritancy classifications (non-irritant, mild, moderate and severe irritant) were considered. Furthermore, all compds. that were severe eye irritants in vivo were equally scored in vitro. The results of this study show that the BCO-P assay is a competent in vitro test system for the prediction of ocular irritation of chems. This test model can be used as a first screen to avoid in vivo testing of severe ocular irritants.
 IT 139751-07-8, R 83546
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (toxicity of, corneal opacity-permeability assay as in vitro alternative to Draize eye irritation test in relation to)
 RN 139751-07-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanylmethyl)-N-4-piperidinyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)
 CN 1
 CRN 110588-56-2
 CMF C17 H21 N5 O



CM 2

04/28/2006


L4 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CRN 77-92-9
 CMP C6 H8 O7



L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:54556 CAPLUS
 DOCUMENT NUMBER: 120:54556
 TITLE: Preparation of N-(arenoimidazol-2-ylalkyl)piperazines as antiallergics
 INVENTOR(S): Janssens, Frans Eduard; Leenaerts, Joseph Elisabeth; Diele, Gaston Stanislas Marcella; Sommen, Francois Maria
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9314088	A1	19930722	WO 1992-EP3000	19921229
M: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9332582	A1	19930803	AU 1993-32582	19921229
ZA 9300143	A	19940708	ZA 1993-143	19930108
PRIORITY APPLN. INFO.:				EP 1992-200042 A 19920109
				WO 1992-EP3000 A 19921229


OTHER SOURCE(S): MARPAT 120:54556
 GI




AB Title compds. [I; G = CH:CHCH:CH, N:CHCH:CH, etc.; R = H, (cyclo)alkyl, alkanoyl, alkoxy carbonyl, etc.; R1 = (hydroxyalkyl)furanyl, -oxazolyl, alkylloxazolyl; m = 1-4] were prepared. Thus, Et 1-piperazinecarboxylate was condensed with 2-chloromethyl-1H-benzimidazole and the product condensed with Et 5-chloromethyl-2-furancarboxylate to give, after reduction, title compound II. Selected I had ED50 of 0.02-0.08 mg/kg for protection of rats from compound 48/80-induced lethality (route of administration not given).

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 151856-07-4P 151856-08-5P 151856-09-6P
 151856-12-1P 151856-14-3P 151856-16-5P
 151856-19-8P 151856-20-1P 151856-21-2P
 151856-22-3P 151856-24-5P 152072-22-5P
 152072-26-9P 152072-28-1P 152072-30-5P
 152072-31-4P 152072-46-3P 152072-50-9P
 152072-52-1P 152072-54-3P 152072-56-5P
 152072-60-1P 152072-62-3P 152072-66-7P
 152072-67-8P 152072-69-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiallergic agent)
 RN 151856-07-4 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 151856-08-5 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[3-[[2-methyl-5-oxazolyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 151856-09-6 CAPLUS
 CN 2-Purenmethanol, 5-[[[2-(1-piperazinylmethyl)-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 151856-12-1 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 3-[[2-methyl-5-oxazolyl]methyl]-2-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)




RN 151856-14-3 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 2-[[4-[[2-(4-methoxyphenyl)ethyl]-1-piperazinyl]methyl]-3-[[2-methyl-5-oxazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 151856-16-5 CAPLUS
 CN 1-Piperazineacetoneitrile, 4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-26-9 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]-7-methyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 152072-25-8
CMF C26 H29 N7 O3 S

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Oxazolidinone, 3-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 152072-27-0
CMF C22 H28 N6 O4

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-30-5 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]-2-methyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 152072-29-2
CMF C28 H31 N7 O3

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-28-1 CAPLUS

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-31-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 2,3-dihydro-6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]-7-methyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 151856-22-3
CMF C26 H31 N7 O3 S


PAGE 1-A




L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 151856-19-8 CAPLUS
 CN 2-Furanmethanol, 5-[[2-[[4-(2-aminoethyl)-1-piperazinyl]methyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 151856-20-1 CAPLUS
 CN 2-Furanmethanol, 5-[[2-[[4-(2-((3-nitro-4-pyridinyl)amino)ethyl)-1-piperazinyl]methyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 151856-21-2 CAPLUS
 CN 3-Furancarboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 151856-24-5 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 7-methyl-6-[2-[4-[[3-[[2-methyl-5-oxazolyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 151856-22-3 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 2,3-dihydro-6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperazinyl]ethyl]-7-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 152072-22-5 CAPLUS
 CN 2-Furanmethanol, 5-[[2-[[4-(2-((1H-imidazo[4,5-c]pyridin-2-ylamino)ethyl)-1-piperazinyl]methyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-1-piperazinyl]ethyl]- (2E)-2-butenedioate (2:5) (salt) (9CI) (CA INDEX NAME)

CN 1


CRN 152072-21-4
 CNF C25 H29 N9 O2

PAGE 1-A



L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 152072-46-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 7-methyl-6-[2-[[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (2:5) (9CI) (CA INDEX NAME)


CM 1

CRN 151856-24-5
CMF C25 H28 N8 O2 S

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 152072-50-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[[2-methyl-5-oxazolyl)methyl]-2-[[[4-[(2-methyl-5-oxazolyl)methyl]-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 152072-49-6
CMF C21 H25 N7 O2

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 152072-52-1 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[[3-[[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperazinyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 152072-51-0
CMF C27 H30 F N5 O3

Habte

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 152072-54-3 CAPLUS
CN 2-Furanmethanol, 5-[[2-[[[4-[(2-methoxyphenyl)ethyl]-1-piperazinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 152072-53-2
CMF C26 H31 N5 O3

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-56-5 CAPLUS
CN 1-Piperazinepropanamide, 4-[[[3-[[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-(1-methylethyl)-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 152072-55-4
CMF C23 H32 N6 O3

04/28/2006


L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 152072-60-1 CAPLUS
CN Sulfamic acid, cyclohexyl-, compd. with 5-[[2-[(4-methyl-1-piperazinyl)methyl]-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-2-furanmethanol (2:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152072-59-8
CMF C18 H23 N5 O2

CM 2


CRN 100-88-9
CMF C6 H13 N O3 S

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-67-8 CAPLUS
CN 3-Furancarboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperazinyl]ethyl]-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 151856-21-2


Habe

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 152072-62-3 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 3-[(2-methyl-5-oxazolyl)methyl]-2-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152072-61-2
CMF C17 H22 N6 O

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 152072-66-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperazinyl]ethyl]-1-methyl-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 152072-65-6
CMF C29 H33 N7 O3

L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CMF C24 H28 N6 O4



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 152072-69-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperazinyl]ethyl]-1-methyl-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 152072-68-9
CMF C25 H31 N7 O3


CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

04/28/2006


L4 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:225162 CAPLUS
DOCUMENT NUMBER: 118:225162
TITLE: The time course of action of three differing doses of noberastine, a novel H1-receptor antagonist, on histamine-induced skin wheals and the relationship to plasma drug concentrations in normal human volunteers
AUTHOR(S): Wood-Baker, R.; Emanuel, M. B.; Hutchinson, K.; Howarth, P. H.
CORPORATE SOURCE: Dep. Med. 1, Southampton Gen. Hosp., Southampton, UK
SOURCE: British Journal of Clinical Pharmacology (1993), 35(2), 166-70
CODEN: BCPHEM; ISSN: 0306-5251
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The time course and magnitude of effect of the novel H1-receptor antagonist noberastine, structurally modified from astemizole to achieve
a more rapid onset while retaining a good duration of action, has been investigated using histamine-induced skin wheals in healthy volunteers. The pharmacokinetics and pharmacodynamics of three doses (10, 20 and 30 mg) have been studied in a double-blind, placebo controlled, randomized cross-over trial involving 12 healthy male volunteers. All doses of noberastine caused inhibition of histamine-induced skin wheals, which were significantly different from placebo when assessed as the area under the percent inhibition of the response vs time curves. Following single dose administration of 10, 20 and 30 mg noberastine significant inhibition of histamine-induced skin wheals occurred and this effect persisted beyond
24 h. At the higher (20 and 30 mg) doses studied significant inhibition of the histamine-induced skin wheal occurred by 1 h of dosing, whereas this did not occur until 2 h following the 10 mg dose. An increase in plasma concns. of noberastine was seen after administration of all doses, with mean concns. of 4.14, 8.38 and 12.66 mg ml⁻¹ 1 h following administration of 10, 20, and 30 mg resp. Visual analog scale measurements of drowsiness identified no sedative effects above those of placebo at any of the dose levels. We conclude that noberastine is an effective H1-receptor antagonist in the human as assessed by its effect on histamine-induced skin wheals.
IT 110588-56-2, Noberastine
RL: PROC (Process)
(antihistaminic activity and pharmacokinetics of, in humans)
RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:531195 CAPLUS
DOCUMENT NUMBER: 117:131195
TITLE: Preparation of substituted thiazoles and other heterocyclic derivatives
INVENTOR(S): Janssens, Frans Eduard; Sommen, Francois Maria; Diels, Gaston Stanislas Marcell
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201697	A1	19920206	WO 1991-EP1292	19910709
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU				
✓ RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9182093	A1	19920218	AU 1991-82093	19910709
AU 646280	B2	19940217		
EP 539420	A1	19930505	EP 1991-912667	19910709
EP 539420	B1	20000105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 64066	A2	19931129	HU 1993-96	19910709
JP 05508638	T2	19931202	JP 1991-511645	19910709
JP 3085707	B2	20000911		
RU 2067978	C1	19961020	RU 1992-16595	19910709
PL 170580	B1	19970131	PL 1991-297612	19910709
AT 188477	E	20000115	AT 1991-912667	19910709
ES 2142802	T3	20000501	ES 1991-912667	19910709
IL 98865	A1	19951127	IL 1991-98865	19910717
ZA 9105654	A	19930331	ZA 1991-5654	19910718
CZ 279903	B6	19950816	CZ 1991-2239	19910718
SK 280690	B6	20000612	SK 1991-2239	19910718
CN 1058216	A	19920129	CN 1991-104906	19910719
CN 1037770	B	19980318		
NO 9300139	A	19930115	NO 1993-139	19930115
NO 304791	B1	19990215		
FI 102753	B1	19990215	FI 1993-199	19930118
US 5360807	A	19941101	US 1994-197579	19940217
GR 3032999	T3	20000731	GR 2000-400699	20000321
PRIORITY APPLN. INFO.:			US 1990-554325	A 19900719
			US 1991-723878	B1 19910701
			WO 1991-EP1292	A 19910709
			US 1993-17363	B1 19930211
			US 1993-157845	B1 19931124

OTHER SOURCE(S): MARPAT 117:131195
GI

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I (A1:A2A3:A4 = CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHN:CH, CH:NCH:N wherein 1 or 2 H may each be replaced by halo, C1-6 alkyl, C1-6 alkoxy, HO, F3C; B = R1N, CH2, O, SO, SO2 wherein R1 = H, C1-4 alkyl; R = C1-6-alkyl-thiazolyl-C1-4 alkanediyl, -pyridyl-C1-4-alkanedyl; L = H, C1-12 alkyl, C3-6 cycloalkyl, etc.; n = 0-2), a salt or stereoisomer thereof, useful as antiallergics, are prepared

A mixture of I [L = H, B = NH, R = (2-methyl-4-thiazolyl)methyl, A1-A4 = CH:CHCH:CH, n = 1].3HCl (preparation given), polyoxymethylene, AcOK and MeOH

was hydrogenated at normal pressure and at 50° with Pd/C catalyst to give I [L = Me, B = NH, R = (2-methyl-4-thiazolyl)methyl, A1-A4 = CH:CHCH:CH, n = 1].ethanedioate (1:2) (II). II showed antiallergic and antihistaminic properties in rats with ED50 value of 0.04 mg/kg in the test "protection of rats from compound 48/80-induced lethality" (US

Patent 4,556,660).

IT 141840-95-1P 141840-96-2P 141840-97-3P

141840-98-4P 141840-99-5P 141841-00-1P

141841-01-2P 141841-02-3P 141841-03-4P


141841-04-5P 141841-05-6P 141841-13-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as antiallergic and antihistaminic)

RN 141840-95-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 141840-96-2 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[6-methyl-2-pyridinyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 141841-00-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[[1-[[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-3-[[6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 141841-01-2 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-methyl-3-[2-[[4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 141841-02-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[[1-[[2-aminoethyl]-4-piperidinyl]-3-[[6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 141840-97-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[[1-methyl-4-piperidinyl]-3-[[6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)



RN 141840-98-4 CAPLUS


CN 1-Piperidineethanol, 4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 141840-99-5 CAPLUS


CN Carbamic acid, [2-[[4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 141841-03-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[[1-[[2-[[4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 141841-04-5 CAPLUS

CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 2,3-dihydro-7-methyl-6-[2-[[4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 141841-05-6 CAPLUS

CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 7-methyl-6-[2-[[4-[[3-[[6-methyl-2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


04/28/2006

L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 141841-13-6 CAPLUS
 CH 5H-Thiazolo[3,2-a]pyrimidin-5-one, 2,3-dihydro-7-methyl-6-[2-[[4-[[3-[(2-methyl-4-thiazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:511638 CAPLUS
 DOCUMENT NUMBER: 117:111638
 TITLE: Preparation of piperidinyl benzimidazolyl ketones and related compounds as antihistaminics
 INVENTOR(S): Janssens, Frans Eduard; Diels, Gaston Stanislas Marcell; Sommen, Francois Maria
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9206086	A1	19920416	WO 1991-EP1782	19910917
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU, US				
RW: AT, BE, BF, BJ, CP, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9185067	A1	19920428	AU 1991-85067	19910917
PRIORITY APPLN. INFO.:			US 1990-590716	A 19901001
			WO 1991-EP1782	A 19910917

OTHER SOURCE(S): MARPAT 117:111638
 GI




AB The title compds. [I; A1:A2A3:A4 = (un)substituted CH:CHCH:CH, N:CHCH:CH, N:CHN:CH, etc.; m = 1-4; n = 0-2; R1 = aryl, DR2; D = O, S; R2 = (un)substituted C1-6 alkyl; L = H, C1-12 alkyl(carbonyl), C3-6 cycloalkyl, (aryl)C3-6 alkenyl, Alk-R3, Alk-YR4, etc.; R3 = cyano, aryl, heterocyclyl; R4 = H, aryl, heterocyclyl, (un)substituted C1-6 alkyl; Alk = C1-6 alkylene; Y = O, S, NR7; R7 = H, C1-6 alkyl(carbonyl) or their stereoisomers and pharmaceutically acceptable acid addition salts, effective antihistaminics (no data) useful in the treatment of, e.g., allergic

Habte


L4 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

rhinitis, conjunctivitis, asthma, and chronic urticaria, were prepd. A soln. of 2-MeO2CC6H4NCS in THF was added dropwise to a stirred mixt. of 1-(2-aminoethyl)-4-piperidinyl
 1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl ketone (prepn. given) and THF and the whole stirred for 2 h at the ambient temp. to give title compd. II.
 IT 142850-48-4P 142850-70-2P 142850-78-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of antihistaminics)
 RN 142850-48-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-2-methanol, 3-[(4-fluorophenyl)methyl]-α-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 142850-70-2 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]hydroxymethyl]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



RN 142850-78-0 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine-2-methanol, 3-(2-furanylmethyl)-α-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

PAGE 2-A



L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 142850-17-7 CAPLUS
 CN Methanone, [3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]-4-piperidinyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 142850-16-6
 CMF C19 H19 F N4 O



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 142850-19-9 CAPLUS
 CN Methanone, [3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]-4-piperidinyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142850-18-8
 CMF C17 H18 N4 O2

L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 142849-95-4P 142850-01-9P 142850-17-7P

142850-19-9P 142850-20-2P 142850-32-6P


142850-33-7P 142850-36-2P 142872-78-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as antihistaminic)

RN 142849-95-4 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[(3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]carbonyl]-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 142850-01-9 CAPLUS


CN Methanone, [3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl] [1-methyl-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142850-00-8
 CMF C20 H21 F N4 O



L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
 CMF C2 H2 O4



RN 142850-20-2 CAPLUS

CN Methanone, [3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl] [1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 142850-32-6 CAPLUS

CN Methanone, [3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl] [1-methyl-4-piperidinyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142850-31-5
 CMF C18 H20 N4 O2


L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 142850-33-7 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]carbonyl]-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 142850-38-2 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]carbonyl]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 142850-37-1
CMF C26 H28 N6 O3 S

L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
imidazo[4,5-b]pyridin-2-yl]carbonyl]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)



CM 1

CRN 142872-77-3
CMF C28 H29 F N6 O2 S

CM 2

CRN 144-62-7
CMF C2 H2 O4

IT 142850-97-3 142851-00-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antihistaminics)
RN 142850-97-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]hydroxymethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 142851-00-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-2-methanol, 3-[2-(furan-2-ylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Habe

L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 142872-78-4 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-

L4 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




04/28/2006

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1992:255611 CAPLUS
 DOCUMENT NUMBER: 116:255611
 TITLE: Preparation of oxazolyl derivatives
 INVENTOR(S): Janssens, Frans Eduard; Sommen, Francois Maria;
 Dierckx, Ann Christina Joannes; Coymans, Ludwig Paul
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201687	A1	19920206	WO 1991-EP1291	19910709
W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MC, MG, NO, PL, RO, RU				
US 5217980	A	19910608	US 1991-723862	19910701
AU 9182141	A1	19920218	AU 1991-82141	19910709
AU 644202	B2	19931202		
EP 539421	A1	19930505	EP 1991-912700	19910709
EP 539421	B1	19980923		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05508839	T2	19931209	JP 1991-511644	19910709
JP 3070951	B2	20000731		
HU 64340	A2	19931228	HU 1993-97	19910709
RU 2059636	C1	19960510	RU 1992-16607	19910709
PL 169361	B1	19960731	PL 1991-297611	19910709
RO 111768	B1	19970130	RO 1993-46	19910709
AT 171449	E	19981015	AT 1991-912700	19910709
ES 2121784	T3	19981216	ES 1991-912700	19910709
IL 98864	A1	19951208	IL 1991-98864	19910717
ZA 9105653	A	19930331	ZA 1991-5653	19910718
CZ 279244	B6	19950412	CZ 1991-2240	19910718
SK 278133	B6	19960207	SK 1991-2240	19910718
CN 1058215	A	19920129	CN 1991-104902	19910719
CN 1043640	B	19990616		
NO 9300156	A	19910118	NO 1993-156	19930118
NO 300459	B1	19970602		
US 5278165	A	19940111	US 1993-35854	19930323
PRIORITY APPLN. INFO.:			US 1990-554326	A 19900719
			US 1991-723862	A3 19910701
			WO 1991-EP1291	A 19910709


OTHER SOURCE(S): MARPAT 116:255611
 GI

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB Title compds. I (A1-A4 = CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N, N:CHN:CH, CH:NCH:N wherein 1 or 2 H may be replaced by halo, C1-6 alkyl, C1-6 alkoxy, HO, FIC; R = H, C1-4 alkyl; R1 = H, C1-4 alkyl, HO-C1-6-alkyl; D = C1-4 alkanediyl; B = R2N wherein R2 = H, C1-4 alkyl, H2C, O, S, SO, SO2; L = H, C1-12 alkyl, C3-6 cycloalkyl, (aryl) C3-6 alkenyl, C1-6 alkylcarbonyl, C1-6 alkoxy carbonyl, arylcarbonyl, etc.; m = 1,2; n = 0-2), stereoisomer or salt thereof, useful as antiallergic (no data), are prepared 5-(Bromomethyl)-2-methyloxazole, Et, 4-[(1H-benzimidazol-2-yl)amino]-1-piperidinecarboxylate, Na2CO3 and DMF were stirred for 18 h at 80° to give after work-up I [A1-A4 = CH:CHCH:CH, R = H, (R1)m = 2-Me, D = H2C, B = NH, L = EtO2C, n = 1].
 IT 141567-58-0P 141567-59-1P 141568-84-5P
 141568-85-6P 141568-86-7P 141568-87-8P
 141568-88-9P 141568-89-0P 141568-90-3P
 141568-96-9P 141568-97-0P 141568-99-2P
 141569-01-9P 141569-04-2P 141569-05-3P
 141569-08-6P 141569-10-0P 141569-11-1P
 141569-12-3P 141569-13-3P 141569-16-6P
 141591-89-1P 141591-91-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiallergic)
 RN 141567-58-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 141567-59-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(2,4-dimethyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 141568-84-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[2-methyl-5-oxazolyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 141568-85-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[2-methyl-5-oxazolyl)methyl]-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 141568-86-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(3-(4-fluorophenoxy)propyl)-4-piperidinyl]-3-[[2-methyl-5-oxazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 141568-87-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[2-methyl-5-oxazolyl)methyl]-N-(1-(2-propenyl)-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 141568-88-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]-3-[[2-methyl-5-oxazolyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 141568-89-0 CAPLUS
 CN 1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-7-(2-[[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl)-(9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl)-(9CI) (CA INDEX NAME)



RN 141568-99-2 CAPLUS
 CN 3-Purancarboxamide, N-[2-[[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl)-(9CI) (CA INDEX NAME)




RN 141569-01-9 CAPLUS
 CN 4(1H)-Pyrimidinone, 2-[[[2-[[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]amino]-, (2E)-2-butenedioate (2:5) (9CI) (CA INDEX NAME)

CM 1


CRN 141569-00-8
 CMF C22 H27 N9 O2

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 141568-90-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[[2-methyl-5-oxazolyl)methyl]-N-(1-[(2-pyridinyl)ethyl]-4-piperidinyl)-(9CI) (CA INDEX NAME)




RN 141568-96-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[[2-methyl-5-oxazolyl)methyl]-N-(1-[(2-thienyl)ethyl]-4-piperidinyl)-(9CI) (CA INDEX NAME)



RN 141568-97-0 CAPLUS
 CN 1H-Pyrrrole-2-carboxamide, 1-methyl-N-[2-[[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl)-(9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 141569-04-2 CAPLUS
 CN Pyrazinecarboxamide, 3-amino-N-[2-[[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl)-(9CI) (CA INDEX NAME)




RN 141569-05-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[[2-methyl-5-oxazolyl)methyl]-N-(1-[(2-pyrimidinylamino)ethyl]-4-piperidinyl)-(9CI) (CA INDEX NAME)

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 141569-08-6 CAPLUS
 CN 1-Piperidineethanol, 4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-α-(phenoxymethyl)- (9CI) (CA INDEX NAME)




RN 141569-10-0 CAPLUS
 CN 4(3H)-Pyrimidinone, 3,6-dimethyl-2-(methylamino)-5-[2-[4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-, (2E)-2-butenedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 141569-09-7
 CMF C25 H33 N9 O2


L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 141569-11-1 CAPLUS
 CN Phenol, 4-[2-[4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 141569-12-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(2-methyl-5-oxazolyl)methyl]-N-[1-[2-[(6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-3-yl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 141569-13-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-[(6-chloro-3-pyridazinyl)amino]ethyl]-4-piperidinyl]-3-[(2-methyl-5-oxazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 141569-16-6 CAPLUS
 CN Benzamide, 2-amino-N-[2-[4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 141591-89-1 CAPLUS
 CN [1,2,4]Triazolo[1,5-a]pyrimidin-7(1H)-one, 2,3-dihydro-1,3,5-trimethyl-6-[2-[4-[[3-[(2-methyl-5-oxazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-

Habte

L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PAGE 1-A



PAGE 2-A


RN 141591-91-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(2,5-dimethyl-4-oxazolyl)methyl]-N-[1-methyl-4-piperidinyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 141591-90-4
 CMF C18 H24 N6 O

04/28/2006


L4 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
CMP C4 H4 O4



Double bond geometry as shown.

L4 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 110588-56-2
CMP C17 H21 N5 O

CM 2

CRN 77-92-9
CMP C6 H8 O7IT 110588-56-2, Noberastine
RL: PROC (Process)
(salt formation of, with citric acid)RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:174145 CAPLUS
 DOCUMENT NUMBER: 116:174145
 TITLE: Preparation of noberastine citrate
 INVENTOR(S): De Knaep, Alfons Gaston Maria; Nelen, Tonny
 FRANCISCUS
 PATENT ASSIGNEE(S): Johanna; Janssens, Frans Eduard
 SOURCE: Janssen Pharmaceutica N. V., Belg.
 Eur. Pat. Appl., 6 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 464927	A2	19920108	EP 1991-201639	19910627
EP 464927	A3	19920408		
EP 464927	B1	19960904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2043564	AA	19920107	CA 1991-2043564	19910530
AT 142207	E	19960915	AT 1991-201639	19910627
ES 2091285	T3	19961101	ES 1991-201639	19910627
CZ 279435	B6	19950412	CZ 1991-1987	19910628
SK 278127	B6	19960207	SK 1991-1987	19910628
JP 04230382	A2	19920819	JP 1991-185901	19910701
AU 9180206	A1	19920109	AU 1991-80206	19910704
AU 632949	B2	19930114		
IL 98725	A1	19950731	IL 1991-98725	19910704
KR 165894	B1	19990115	KR 1991-11284	19910704
FI 9103281	A	19920107	FI 1991-3281	19910705
FI 94132	B	19950413		
NO 9102650	C	19950725		
NO 177854	A	19920107	NO 1991-2650	19910705
NO 177854	B	19950828		
NO 177854	C	19951206		
HU 58333	A2	19920228	HU 1991-2284	19910705
ZA 9105241	A	19930331	ZA 1991-5241	19910705
RU 2047615	C1	19951110	RU 1991-5001001	19910705
PL 168719	B1	19960329	PL 1991-290956	19910705
CN 1058020	A	19920122	CN 1991-104582	19910706
CN 1026790	B	19941130		

PRIORITY APPL. INFO.: US 1990-549350 A 19900706

AB Noberastine citrate (I) was prepared by salt formation of noberastine with citric acid. I is an antiallergic agent (no data) with superior light stability compared to noberastine and noberastine dimaleate.

Formulations
 of 1 were prepared

IT 139751-07-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as antiallergic agent)

RN 139751-07-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1991:608009 CAPLUS
 DOCUMENT NUMBER: 115:208009
 TITLE: Preparation of 2-aminopyrimidinones as antihistaminics



INVENTOR(S): and antisero-toninergics
 Janssens, Frans E.; Kennis, Ludo E. J.; Sommen, Francois M.; Dierckx, Ann C. J.
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 30 pp.
 CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 378254	A2	19900718	EP 1990-200004	19900103
EP 378254	A3	19910109		
EP 378254	B1	19940622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL				
US 5008268	A	19910416	US 1989-456391	19891226
ES 2058749	T3	19941101	ES 1990-200004	19900103
CA 2007198	AA	19900709	CA 1990-2007198	19900105
FI 9000084	A	19900710	FI 1990-84	19900108
FI 94526	B	19950615		
FI 94526	C	19950925		
NO 9000070	A	19900710	NO 1990-70	19900108
NO 172645	B	19930510		
NO 172645	C	19930818		
AU 9047780	A1	19900712	AU 1990-47780	19900108
AU 622509	B2	19920409		
HU 53364	A2	19901028	HU 1990-63	19900108
HU 206350	B	19921028		
ZA 9000120	A	19910925	ZA 1990-120	19900108
SU 1825364	A3	19930630	SU 1990-4742861	19900108
CN 1044099	A	19900725	CN 1990-100077	19900109
CN 1030452	B	19951206		
JP 02233678	A2	19900917	JP 1990-2414	19900109
PRIORITY APPL. INFO.: GB 1989-380				A 19890109

OTHER SOURCE(S): MARPAT 115:208009
 GI

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title compounds, I; [X1X2X3X4 = (substituted) CH:CH:CH, N:CH:CH; CH:
CH:NCH:CH, CH:CHN:CH, CH:CHXN:CH, N:CHN:CH, CH:CHN:CH; R1 = H, alkyl,
cycloalkyl, arylalkyl, etc.; R2, R3, R6 = H, alkyl; n = 0-2; R4 = H,
(substituted) alkyl; R5 = H, alkyl, allylaminocarbonyl, or
arylamino carbonyl;
R5R6 = (alkyl-substituted) CH2CH2, CH2CH2CH2, CH:CH, CH:N, N:CH, N:CH2;
2 - alkenylene; 21 = CH2, O, S, SO, SSO2, imino], were prepared Thus:
1. 2-chloropropene, 2-chlorobutane, 2-pentanol, 2-hexanol, 2-octanol, 2-dec-
anone, 2-methyl-2-pentanone, and NaOAc; were refluxed 42 h to give 51.2% title
compound II which had an EDSO of 0.005 mg/kg in rate for reduction of

```

11      triptamine-1-methylpiperenyl-
12      131263-46-2P 131263-48-4P 131263-56-4P
13      131263-58-6P 131263-62-2P 131263-64-4P
14      131263-65-5P 131263-77-9P 131263-80-4P
15      131263-81-5P 131263-83-7P 131263-85-9P
16      131263-91-7P 131263-96-2P 131264-01-2P
17      131264-04-5P 131264-08-9P 131264-14-7P
18      131264-16-9P 131264-18-1P 131264-19-2P
19      131264-20-5P 131264-23-8P 131264-28-3P
20      131264-29-4P 131264-30-7P 131264-31-8P
21      131264-34-1P 131264-35-2P 131283-59-5P
22      131283-65-3P 131283-68-6P
23      RL: SPN (Synthetic preparation); PREP (Preparation)
24      (preparation of, as antihistaminic and antiserotonergic)
25      CN 131263-46-2 CAPLUS
26      4 (3H)-Pyrimidinone,
27      3,6-dimethyl-2-(methylamino)-5-[2-[4-[[3-[[5-methyl-2-
28      furanyl-1-yl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-
29      [9CI] [CA INDEX NAME]

```


L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 131263-56-4 CAPLUS
CN 4(3H)-Pyrimidinone, 2-amino-3,6-dimethyl-5-[2-[4-[(3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinyl]ethyl]-(9CI) (CA INDEX NAME)



```


RN      131263-58-6  CAPLUS
CN
Urea,
N-[1, 6-dihydro-1,4-dimethyl-5-[2-(4-[[3-[(5-methyl-2-furanyl)methyl]-
3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinyl)ethyl]-6-oxo-2-
pyrimidinol]-N'-methyl- (9CI) (CA INDEX NAME)

```




RN 131263-62-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-amino-5-[2-{4-([3-{5-(hydroxymethyl)-2-furanyl)methyl}-3H-imidazo[4,5-b]pyridin-2-yl]amino}-1-piperidinyl)ethyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 131263-48-4 CAPLUS
CN 4(3H)-Pyrimidinone,
3,6-dimethyl-5-[2-{4-[[3-[[5-methyl-2-furanyl)methyl]-
3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinyl]ethyl]-2-
[(phenylmethyl)amino]-, ethanedicarboxylate (1:1) (9CI) (CA INDEX NAME)
CN 1




CM 2

CRN 144-62-7


CMF C2 H2 04




L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 131263-64-4 CAPLUS
CN 4(3H)-Pyrimidinone, 5-[2-{4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,6-dimethyl-2-(methylamino)- (9CI) (CA INDEX NAME)




RN 131263-65-5 CAPLUS
 CN 4 (3H)-Pyrimidinone,
 3,6-dimethyl-5-[2-{4-[[3-[(5-methyl-2-furanyl)methyl]-
 3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl}-2-{(2-
 pyridinylmethyl)amino}- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 131263-77-9 CAPLUS
 CN Urea,
 N-[[1,6-dihydro-1,4-dimethyl-5-[2-[4-[[3-[[5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-6-oxo-2-pyrimidinyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 131263-80-4 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-(ethylamino)-5-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)




RN 131263-81-5 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-[(2-ethoxyethyl)amino]-5-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 131263-85-9 CAPLUS
 CN 4(3H)-Pyrimidinone,
 3,6-dimethyl-5-[2-[4-[[3-[[5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-2-(propylamino)- (9CI) (CA INDEX NAME)




RN 131263-91-7 CAPLUS
 CN 4(3H)-Pyrimidinone, 5-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-3,6-dimethyl-2-[[5-methyl-2-furanyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 131263-96-2 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(1H)-one,
 1,2,7-trimethyl-6-[2-[4-[[3-[[5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 131263-83-7 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-(butylamino)-3,6-dimethyl-5-[2-[4-[[3-[[5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CH 1
 CRN 131263-82-6
 CMF C29 H40 N8 O2



CH 2
 CRN 144-62-7
 CMF C2 H2 O4




L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 131264-01-2 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(1H)-one, 1,7-dimethyl-6-[2-[4-[[3-[[5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CH 1
 CRN 131264-00-1
 CMF C27 H32 N8 O2




CH 2
 04/28/2006

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 144-62-7
CMP C2 H2 O4

RN 131264-04-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(1H)-one, 2,3-dihydro-1,7-dimethyl-6-[2-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 131264-08-9 CAPLUS
CN 6H-Pyrimido[2,1-c][1,2,4]triazin-6-one, 1,4-dihydro-1,3,8-trimethyl-7-[2-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 131264-18-1 CAPLUS
CN 6H-Pyrimido[2,1-c][1,2,4]triazin-6-one, 1,4-dihydro-7-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-1,3,8-trimethyl- (9CI) (CA INDEX NAME)




RN 131264-19-2 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 131264-14-7 CAPLUS
CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 1,3,7-trimethyl-6-[2-[4-[[3-[[5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 131264-16-9 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(1H)-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-1,7-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 131264-20-5 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(1H)-one, 2,3-dihydro-6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1,7-dimethyl- (9CI) (CA INDEX NAME)




RN 131264-23-8 CAPLUS
CN Imidazo[1,2-a]pyrimidin-5(1H)-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1,2,7-trimethyl- (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 131264-28-3 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one,
 6-[2-[[4-[(3-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)



RN 131264-29-4 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 1,3,7-trimethyl-6-[2-[[4-[(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 131264-34-1 CAPLUS
 CN Imidazo[1,2-a]pyrimidin-5(1H)-one, 6-[2-[[hexahydro-4-[[3-[(5-methyl-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-ylethyl]-1,2,7-trimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 131264-33-0
 CMP C29 H36 N8 O2




CM 2

CRN 110-17-8
 CMP C4 H4 O4


Double bond geometry as shown.

Habe

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 131264-30-7 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 6-[2-[[4-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]thio]-1-piperidinylethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)




RN 131264-31-8 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one, 6-[2-[[4-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]oxy]-1-piperidinylethyl]-1,3,7-trimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 131264-35-2 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one,
 6-[2-[[hexahydro-4-[[3-[(5-methyl-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-ylethyl]-1,2,7-trimethyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)




RN 131283-59-5 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-amino-5-[2-[[4-[[3-[(5-(hydroxymethyl)-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-3,6-dimethyl- (9CI) (CA INDEX NAME)



RN 131283-65-3 CAPLUS
 CN 6H-Pyrimido[2,1-c][1,2,4]triazin-6-one, 1,4-dihydro-7-[2-[[4-[[3-[(5-(hydroxymethyl)-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1,3,8-trimethyl- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 131283-68-6 CAPLUS
 CN 1,2,4-Triazolo[4,3-a]pyrimidin-5(1H)-one,
 1,3,7-trimethyl-6-[2-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 131283-67-5
 CMF C26 H31 N9 O2




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.

L4 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 33 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:220963 CAPLUS
 DOCUMENT NUMBER: 114:220963
 TITLE: A double-blind placebo controlled dose response study of noberastine on histamine induced weal and flare
 AUTHOR(S): Kamali, F.; Emanuel, M.; Rawlins, M. D.
 CORPORATE SOURCE: Dep. Pharmacol. Sci., Univ. Newcastle upon Tyne, Newcastle upon Tyne, NE1 7RU, UK
 SOURCE: European Journal of Clinical Pharmacology (1991), 40(1), 83-5
 CODEN: EJCPAS; ISSN: 0031-6970
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The antihistaminic effects of 7 days treatment with each of three doses of


nobersastine (10, 20 and 30 mg) were compared to placebo in healthy male volunteers. The antihistaminic activity was assessed from the inhibition of weal and flare formation after intradermal histamine injections. For both weal and flare there was a highly significant effect of treatment with each of the three doses of nobersastine, compared to placebo. The 30 mg daily dose produced the maximum inhibition of weal and flare. The mean values for the assessment of sedation by visual analog scales at 09.00 h, 15.00 h and 21.00 h showed no significant treatment, or order, effect for any of the three doses of nobersastine compared to placebo.

The mean steady-state plasma concns. of nobersastine were higher with increasing daily doses of nobersastine (through concns.: 1.0, 1.6 and 2.2 ng/mL; peak concns.: 3.5, 13.4 and 20.9 ng/mL for 10, 20 and 30 mg daily dose, resp.). The percentage weal inhibition correlated ($r = 0.77$) with steady-state nobersastine plasma trough levels. The percentage flare inhibition showed a weaker correlation ($r = 0.35$) with steady-state nobersastine plasma trough levels.

IT 110588-56-2 CAPLUS
 (Biological activity of nobersastine
 RL: BAC (Biological activity or effector, except adverse); BSU
 study, unclassified); THU (Therapeutic use); BIOL (Biological study);

USES
 (Uses)
 (antihistaminic activity of, on histamine-induced weal and flare formation in humans)

RN 110588-56-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:185500 CAPLUS
 DOCUMENT NUMBER: 114:185500
 TITLE: Preparation of [(hydroxyalkylfuryl)methyl]benzimidazides and -imidazopyridines as antihistamines
 INVENTOR(S): Janssens, Frans Eduard; Diels, Gaston Stanislas
 PATENT ASSIGNEE(S): Marcella; Leenserts, Joseph Elisabeth
 SOURCE: Janssen Pharmaceutica N. V., Belg.
 Eur. Pat. Appl., 48 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393738	A1	19901024	EP 1990-200720	19900327
EP 393738	B1	19941130		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ES 2067645	T3	19950401	ES 1990-200720	19900327
CA 2013892	AA	19901007	CA 1990-2013892	19900405
AU 9052951	A1	19901011	AU 1990-52951	19900405
AU 615612	B2	19911003		
ZA 9002664	A	19911224	ZA 1990-2664	19900405
IL 94008	A1	19970218	IL 1990-94008	19900405
NO 9001580	A	19901008	NO 1990-1580	19900406
NO 174851	B	19940411		
NO 174851	C	19940720		
JP 02290874	A2	19901130	JP 1990-90528	19900406
HU 58324	A2	19920228	HU 1990-2107	19900406
RU 2030415	C1	19950310	RU 1990-4743517	19900406
FI 95702	B	19951130	FI 1990-1755	19900406
FI 95702	C	19960311		
CN 1046161	A	19901017	CN 1990-101997	19900407
CN 1031403	B	19960327		
US 5272150	A	19931221	US 1992-842024	19920226
PRIORITY APPLN. INFO.:			US 1989-335022	A 19890407
			US 1990-488566	B1 19900305

OTHER SOURCE(S): MARPAT 114:185500
 GI

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I




II

AB The title compds. [I; A1A2A3A4 = (substituted) CH:CHCH:CH, N:CHCH:CH, CH:CHCH:CH, N:CHN:CH, etc.; D = C1-4 alkylene; R1 = H, alkyl, arylalkyl, alkylcarbonyl; R2, R3 = H, alkyl; n = 0-2; B = NR4, O, S, SO, CH2, R4 = H, alkyl, cycloalkyl, arylalkyl; L = H, alkyl, cycloalkyl, (aryl)alkenyl, alkylcarbonyl, alkoxy carbonyl, arylcarbonyl, arylalkoxy carbonyl, alkylsulfonyl, arylsulfonyl, heterocyclylalkyl, etc.], were prepared. Thus, a mixture of Et 4-(1H-benzimidazol-2-ylamino)-1-piperidinecarboxylate, Et 5-chloromethyl-2-furancarboxylate, Na2CO3, and DMF was stirred 2 nights at 70° to give 70.8% condensation product, which was refluxed with LiBH4 in THF followed by reflux with KOH in Me2CHOH to give title compound II. II had an ED50 of 0.04 mg/kg s.c. in rats for inhibition of compound 48/80-induced lethality. Several I are also

serotonin antagonists.
 IT 132551-40-7P 132551-41-8P 132551-42-9P
 132551-43-0P 132551-44-1P 132551-46-3P
 132551-47-4P 132551-48-5P 132551-49-6P
 132551-51-0P 132551-52-1P 132551-54-3P
 132551-55-4P 132551-56-5P 132551-58-7P
 132551-60-1P 132551-61-2P 132551-62-3P
 132551-63-4P 132551-64-5P 132551-65-6P
 132551-67-8P 132551-68-9P 132551-69-0P
 132551-70-3P 132551-72-5P 132551-73-6P
 132551-74-7P 132551-75-8P 132552-17-1P
 132552-31-9P 132552-46-6P 132552-48-8P
 132552-49-9P 132554-15-9P 132554-62-4P
 132554-63-5P 132559-59-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 132551-43-0 CAPLUS
 CN 2-Furanmethanol,
 5-[[2-[[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 132551-44-1 CAPLUS
 CN 2-Furanmethanol, 5-[[2-[[1-(2-ethoxyethyl)-4-piperidinyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of, as antihistaminic)

RN 132551-40-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 132551-41-8 CAPLUS

CN 2-Furanmethanol, 5-[[2-(4-piperidinylamino)-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)




RN 132551-42-9 CAPLUS

CN 2-Furanmethanol, 5-[[2-(4-piperidinylamino)-3H-imidazo[4,5-b]pyridin-3-yl]methyl]-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 132551-41-8
 CMF C17 H21 N5 O2

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 132551-46-3 CAPLUS

CN 1-Butanone, 1-(4-fluorophenyl)-4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 132551-45-2
 CMF C27 H30 F N5 O3



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 132551-47-4 CAPLUS


CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 132551-48-5 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 2,3-dihydro-6-[2-[4-[[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-7-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 132551-49-6 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-7-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 132551-51-0 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2-methyl-, (2E)-2-butenedioate (2:5) (salt) (9CI) (CA INDEX NAME)


CM 1
 CRN 132551-50-9
 CMP C28 H31 N7 O3

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 132551-52-1 CAPLUS
 CN 2-Furanmethanol, 5-[[2-[[[1-(phenylmethyl)-4-piperidinyl]methyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 132551-54-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[[[5-(methoxymethyl)-2-furanyl]methyl]-2-[[[1-(phenylmethyl)-4-piperidinyl]methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 132551-53-2
 CMP C26 H30 N4 O2


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 132551-55-4 CAPLUS
CN 2-Furanmethanol, 5-[[2-[(4-piperidinylmethyl)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 132551-56-5 CAPLUS
CN 2-Furanmethanol, 5-[[2-[(4-piperidinylmethyl)-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (2E)-2-butenedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 132551-55-4
CMF C18 H22 N4 O2


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



Me


PAGE 2-A



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 132551-60-1 CAPLUS
CN 1-Piperidinepropanamide, 4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-N-(1-methylethyl)-, ethanedioate (2:3) (salt) (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 132551-58-7 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 2,3-dihydro-6-[2-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-7-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 132551-57-6
CMF C27 H32 N6 O3 S

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 1

CRN 132551-59-8
CMF C23 H32 N6 O3

CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 132551-61-2 CAPLUS
CN 2-Furanmethanol, 5-[[2-[[1-methyl-4-piperidinyl]amino]-3H-imidazo[4,5-b]pyridin-3-yl)methyl]- (9CI) (CA INDEX NAME)




RN 132551-62-3 CAPLUS
CN 1-Piperidineethanol, α-[[4-(fluorophenoxy)methyl]-4-[[3-[[5-(hydroxymethyl)-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 132551-63-4 CAPLUS
 CN 2-Purancarboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 132551-64-5 CAPLUS
 CN 2-Purancarboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 132551-65-6 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-7-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 100-88-9
 CMF C6 H13 N O3 S



RN 132551-68-9 CAPLUS
 CN 7H-Isioxazolo[2,3-a]pyrimidin-7-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)


PAGE 1-A




Habte

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 132551-67-8 CAPLUS
 CN Sulfamic acid, cyclohexyl-, compd. with 1-(4-fluorophenyl)-4-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1-butanone (1:1) (9CI) (CA INDEX NAME)


CM 1
 CRN 132551-66-7
 CMF C28 H31 F N4 O3

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 132551-69-0 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 132551-70-3 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 3,4-dihydro-7-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-8-methyl- (9CI) (CA INDEX NAME)




RN 132551-72-5 CAPLUS
 CN 2-Purancarboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
imidazo[4,5-b]pyridin-3-yl)methyl]-, (2E)-2-butenedioate (2:3) (salt)
(9CI) (CA INDEX NAME)

CM 1


CRN 132551-71-4
CMP C25 H29 N5 O2



CM 2

CRN 110-17-8
CMP C4 H4 O4


Double bond geometry as shown.



```


RN      132551-73-6  CAPLUS
CN      2-Thiophenecarboxamide,
N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-
3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl) (9CI) (CA
INDEX NAME)

```



RN 132551-74-7 CAPLUS
CN Pyrazinecarboxamide, 3-amino-N-[2-{4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




```

RN      132552-31-9  CAPLUS
CN      2-Puramethanol, 5-[[2-[(hexahydro-1-methyl-1H-azepin-4-yl)amino]-3H-
        imidazo[4,5-b]pyridin-3-yl)methyl]-, (2E)-2-butenedioate (1:2) (salt)
        (9CI) (CA INDEX NAME)

```

CM 1

CRN 132552-30-8
CMF C19 H25 N5 O2




CM 2

CRN 110-17-B
CMP C4 H4 O4


Double bond geometry as shown.

Habte

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 132551-75-8 CAPLUS
CN Urea, N-ethyl-N'-[2-{4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl)- (9CI) (CA INDEX NAME)



```


RN      132552-17-1  CAPLUS
CN      2-Puramethanol, 5-[[2-[(hexahydro-1H-azepin-4-yl)amino]-3H-imidazo[4,5-
INDEX   b]pyridin-3-yl)methyl]-, (2E)-2-butenedioate (1:2) (salt) (9CI) (CA
        NAME)

```


CM 1

CRN 132552-16-0
CMP C18 H23 N5 O2


L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 132552-46-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 132552-48-8 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 132552-49-9 CAPLUS
CN 1H-Azepine-1-carboxylic acid, hexahydro-4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI)
(CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 132564-15-9 CAPLUS
 CN 7H-Isloxazolo[2,3-a]pyrimidin-7-one, 6-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 132929-59-0 CAPLUS
 CN 2-Puramethanol, 5-[[2-[[1-[(2-[9-methyl-9H-purin-6-yl]amino)ethyl]-4-piperidinyl]methyl]-3H-imidazo[4,5-b]pyridin-3-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 132584-62-4 CAPLUS
 CN 5H-Tetrazol-5-one, 1-ethyl-1,4-dihydro-4-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 132584-63-5 CAPLUS
 CN 1H-Indole-2-carboxamide, N-[2-[4-[[3-[[5-(hydroxymethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



IT 90518-52-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for antihistaminic)
 RN 90518-52-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 35 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1991:135873 CAPLUS
DOCUMENT NUMBER: 114:135873
TITLE: Comparative study of central and peripheral histamine-H1 receptor binding in vitro and ex vivo of non-sedating antihistamines and of noberastine, a new agent
AUTHOR(S): Leyssen, Josee E.; Gommeren, Walter; Janssen, Paul F. M.; Janssen, Paul A. J.
CORPORATE SOURCE: Dep. Biochem. Pharmacol., Janssen Res. Found., Beerse,
S-2340, Belg.
SOURCE: Drug Development Research (1991), 22(2), 165-78
CODEN: DDREDK; ISSN: 0272-4391
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new antihistamine, noberastine, and clin. used non-sedating antihistamines, astemizole, mequitazine, terfenadine, loratadine, and cetirizine were investigated for in vitro and ex vivo binding to histamine-H1 receptors in guinea-pig cerebellums and lungs. In vitro, all the drugs dissociated slowly from histamine-H1 receptors (half-times ≥ 100 min), $K_{i,app}$ -values decreased with longer incubation times and for potent lipophilic agents (astemizole, mequitazine, and terfenadine) $K_{i,app}$ -values were lower with more dilute tissue suspensions. Because of the slow dissociation, true binding equilibrium cannot be attained during limited incubation times and because of the apparently high tissue adsorption for some of the drugs, the actual free drug concentration in solution is unknown. Therefore, measured binding parameters are apparent; true equilibrium binding consts. cannot be estimated. Noberastine showed the lowest $K_{i,app}$ -value in various assay conditions (0.55-0.15 nM). In optimized assay conditions, astemizole and mequitazine were nearly as potent ($K_{i,app}$ -values 0.2 and 0.29 nM). Terfenadine, cetirizine, and loratadine bound with 30-, 80- and 100-times lower affinity. The in vitro receptor binding and neurotransmitter inhibition profile of these compds. revealed that they all primarily bound to histamine-H1 receptors. The occupation of lung and cerebellar histamine-H1 receptors was investigated after oral administration of different dosages of the drugs and at various times after drug administration using ex vivo binding techniques. Noberastine and astemizole were the most potent compds. and showed complete differentiation between lung and cerebellar receptor occupation (with 0.63 mg/kg: 70% lung receptor occupancy, <10% cerebellar receptor occupancy). With mequitazine and terfenadine, a 7-times higher dose was required to reach the same effect. Astemizole was extremely long acting and noberastine, mequitazine and terfenadine were short acting. Loratadine and cetirizine differentiated very poorly or not at all between lung and cerebellar receptor occupation (at 2.5 mg/kg: 70% and 60% lung receptor occupation, 50% and 70% cerebellar receptor occupation). The physicochem.

L4 ANSWER 35 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
properties of the drugs were considered in the discussion of the data.

IT appeared that penetration into the brain is not directly related to lipophilicity. The study allowed a quant. comparison of the receptor binding properties of the drugs. Noberastine, as a shorter acting agent, and astemizole, as a long acting agent, appeared to be the compds. of choice as non-sedating antihistamines.
IT 110588-56-2, Noberastine
RL: BIOL (Biological study)
(histamine-H1 receptors binding by, in brain cerebellum and lung)
RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:534153 CAPLUS
DOCUMENT NUMBER: 111:134153
TITLE: Preparation of (heterocyclylalkyl)imidazopyridines as antiallergy agents
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Jpn. Kokai Tokkyo Koho, 46 pp.
CODEN: JKOJAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01031782	A2	19890202	JP 1988-170051	19880709
US 4946843	A	19900807	US 1988-211652	19880627
EP 307014	A1	19890315	EP 1988-201387	19880704
EP 307014	B1	19921209		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 83147	E	19921215	AT 1988-201387	19880704
CA 1324131	A1	19931109	CA 1988-571030	19880704
ES 2042711	T3	19931216	ES 1988-201387	19880704
IL 87018	A1	19930221	IL 1988-87018	19880706
DK 8803823	A	19890111	DK 1988-3823	19880708
FI 8803282	A	19890111	FI 1988-3282	19880708
FI 89483	B	19930630		
FI 89483	C	19931011		
NO 8803069	A	19890111	NO 1988-3069	19880708
NO 167979	B	19910923		
NO 167979	C	19920102		
AU 8818853	A1	19890112	AU 1988-18853	19880708
AU 608336	B2	19910328		
HU 47573	A2	19890328	HU 1988-3598	19880708
HU 204827	B	19920228		
ZA 8804946	A	19900328	ZA 1988-4946	19880708
CN 1030587	A	19890125	CN 1988-104375	19880709
CN 1020906	B	19930526		
US 5011842	A	19910430	US 1990-561833	19900802
US 5086056	A	19920204	US 1991-652828	19910208
PRIORITY APPLN. INFO.:				GB 1987-16313 A 19870710
			US 1988-211652	A3 19880627
			EP 1988-201387	A 19880704
			US 1990-561833	A3 19900802

GI


L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; 1 of A1-A4 = N, the others = (un)substituted CH; L

H, C1-6 alkylcarbonyl, alkylsulfonyl, etc.; R = H, C1-6 alkyl; R1 = H, C1-10 alkyl, C3-6 cycloalkyl, etc.; n = 1-4; n = 1, 2), useful as antiallergy agents, were prepared. A mixture of N-[3-[(2-ethoxyethyl)amino]-4-pyridinyl]-4-(phenylmethyl)-1-piperazineacetamide, 4-MeC6H4SO3H, and xylene was refluxed 16 h to give 3-(2-ethoxyethyl)-2-[(4-(phenylmethyl)-1-piperazinyl)methyl]-3H-imidazo[4,5-c]pyridine. 2-[(4-Methyl-1-piperazinyl)methyl]-3-[2-(2-propynyloxy)ethyl]-3H-imidazo[4,5-b]pyridine exhibited an ED50 of 0.02 mg/kg against compound 48/80-induced allergy in rats.

IT 122659-71-6P 122659-79-4P 122659-86-3P
122659-94-3P 122659-95-4P 122660-00-8P
122660-04-2P 122681-89-4P 122681-91-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiallergic agent)
RN 122659-71-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 122659-79-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(3-methyl-2-furanyl)methyl]-2-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 122659-78-3

L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 122659-94-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[4-[[3-(2-ethoxyethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperazinyl)methyl]-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 122659-93-2
CMF C28 H34 N8 O2

PAGE 1-A




PAGE 2-A

CM 2

CRN 110-17-8


Hatte

L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C18 H23 N5 O

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 122659-86-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(5-methyl-2-furanyl)methyl]-2-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 122659-85-2
CMF C18 H23 N5 O


CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.


L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C4 H4 O4

Double bond geometry as shown.




RN 122659-95-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[(4-methyl-1-piperazinyl)methyl]-3-(2-piperazinylmethyl)- (9CI) (CA INDEX NAME)

CM 1

CRN 122659-99-8
CMF C17 H21 N5 O

RN 122660-00-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(5-methyl-2-furanyl)methyl]-2-(1-piperazinylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 122659-99-8
CMF C17 H21 N5 O

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 122660-04-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(3-methyl-2-furanyl)methyl]-2-(1-piperazinylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 1

CRN 122660-03-1
CMF C17 H21 N5 O


CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.


RN 122681-89-4 CAPLUS
CM 3H-imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-[(4-methyl-1-piperazinyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 122681-88-3
CMF C17 H21 N5 O

CM 2

L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 122681-91-8 CAPLUS

CM 3H-imidazo[4,5-b]pyridine, 2-[(4-methyl-1-piperazinyl)methyl]-3-(4-thiazolylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 122681-90-7
CMF C16 H20 N6 S

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 122659-71-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiallergic agent)

RN 122659-71-6 CAPLUS

CM 1-Piperazinecarboxylic acid, 4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1989:212855 CAPLUS

DOCUMENT NUMBER: 110:212855

TITLE: Preparation of [(bicyclic heterocyclyl)amino]hexahydro-

INVENTOR(S): 1H-azepines and -pyrrolidines as antihistamines
Janssens, Frans Eduard; Diele, Gaston Stanislas

PATENT ASSIGNEE(S): Marcella; Pille, Geert Marcel Ester

SOURCE: Janssen Pharmaceutica N. V., Belg.
Eur. Pat. Appl., 49 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 297661	A1	19890104	EP 1988-201291	19880623
EP 297661	B1	19920916		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 1317939	A1	19930518	CA 1988-568377	19880602
AT 80628	E	19921015	AT 1988-201291	19880623
ES 2052686	T3	19940716	ES 1988-201291	19880623
AU 8818353	A1	19890105	AU 1988-18353	19880624
AU 603684	B2	19901122		
JP 01034979	A2	19890206	JP 1988-161124	19880630
ZA 8804696	A	19900328	ZA 1988-4696	19880630
IL 86921	A1	19921115	IL 1988-86921	19880630
US 4988689	A	19910129	US 1989-338440	19890413
US 5071846	A	19911210	US 1990-609989	19910106
US 5151424	A	19920929	US 1991-756673	19910909
PRIORITY APPLN. INFO.:				US 1987-68515 A 19870701
				US 1988-198960 B1 19880526
				EP 1988-201291 A 19880623
				US 1989-338440 A3 19890413
				US 1990-609989 A3 19910106

OTHER SOURCE(S): MARPAT 110:212855

G1 For diagram(s), see printed CA Issue.

AB Title compds. I (R = H, C1-6 alkyl; R1 = H, C1-10 alkyl, C3-6 cycloalkyl, etc.; A1-A4 = CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N, N:CHN:CH, CH:NCH:N wherein 1 or 2 H may be replaced by halo, C1-6 alkyl, C1-6 alkoxy, F3C, HO; B = CH2, O, SO, SO2, R2N; R2 = H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 alkylcarbonyl, C1-6 alkoxy carbonyl, etc.; L = H, C1-6 alkylcarbonyl, C1-6 alkylsulfonyl, C1-6 alkoxy carbonyl, (un)substituted C2-6 alkenyl, etc.; n = 0, 2), a pharmaceutically acceptable salt, or stereochem. isomeric form thereof, are prepared MeNCO and N-[1-(2-aminoethyl)-3-pyrrolidinyl]-1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-amine were reacted in THF to give I (L = MeNHCONHCH2CH2; R = H, B = NH; R1 = 4-FC6H4CH2; A1-A4 = CH:CHCH:CH; n = 0) which had ED50

of

0.01 mg/kg for protection of rats from compound 48/80-induced lethality.

IT 120429-30-3P 120429-32-5P 120429-33-6P
120429-34-7P 120429-35-8P 120429-38-1P
120429-48-3P 120429-50-7P 120429-64-3P

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

120429-69-8P 120429-76-7P 120429-78-8P
 120429-82-5P 120429-84-7P 120429-86-9P
 120429-87-0P 120429-89-2P 120429-96-1P
 120430-02-6P 120430-04-8P 120430-10-6P
 120430-12-8P 120430-14-0P 120430-16-2P
 120430-17-3P 120430-23-1P 120430-27-5P
 120430-34-4P 120430-37-7P 120430-39-9P
 120430-44-6P 120430-46-8P 120430-48-0P
 120430-52-6P 120430-54-8P 120430-56-0P
 120430-58-2P 120430-60-4P 120430-62-8P
 120430-66-2P 120430-79-7P 120430-84-4P
 120430-89-9P 120430-92-4P 120430-95-7P
 120430-96-8P 120431-01-8P 120431-04-1P
 120431-05-2P 120431-07-4P 120431-13-2P
 120431-24-5P 120431-26-7P 120431-27-8P
 120431-30-3P 120431-32-5P 120431-34-7P
 120431-36-9P 120431-37-0P 120431-39-2P
 120431-46-1P 120431-49-4P 120431-51-8P
 120431-53-0P 120431-55-2P 120431-57-4P
 120431-65-4P 120431-70-1P 120431-72-3P
 120457-49-0P 120457-53-6P 120457-55-8P
 120457-57-0P 120457-59-2P 120457-61-6P
 120457-62-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as anti-allergic agent)

RN 120429-30-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3-[[3-(4-thiazolylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 120429-29-0

CMP C17 H20 N6 O2 S




CM 2

CRN 110-17-8


CMP C4 H4 O4

Double bond geometry as shown.

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

RN 120429-38-1 CAPLUS


CN 1H-Azepine-1-carboxylic acid, hexahydro-3-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]hexahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 120429-40-3 CAPLUS


CN 1H-Azepine-1-carboxylic acid, hexahydro-4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 120429-32-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 120429-33-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 120429-34-7 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[3-(2-furanyl-methyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 120429-35-8 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 120429-50-7 CAPLUS

CN 1H-Azepine-1-carboxylic acid, 4-[[3-(2-furanyl-methyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]hexahydro-, ethyl ester (9CI) (CA INDEX NAME)



RN 120429-64-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-3-pyrrolidinyl-3-(4-thiazolylmethyl)-, dihydrobromide (9CI) (CA INDEX NAME)



● 2 HBr


RN 120429-69-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-3-pyrrolidinyl-3-(4-thiazolylmethyl)-, dihydrobromide (9CI) (CA INDEX NAME)

04/28/2006


Habte

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
trihydrobromide (9CI) (CA INDEX NAME)



●3 HBr

RN 120429-76-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-(hexahydro-1H-azepin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 120429-78-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(hexahydro-1H-azepin-4-yl)-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 120429-77-8
CMF C18 H23 N5 O

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 120429-84-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-3-pyrrolidinyl-3-(2-thienylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 120429-86-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-3-pyrrolidinyl-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 120429-85-8
CMF C15 H17 N5 O



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 120429-87-0 CAPLUS

Habte


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 120429-82-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[(hexahydro-1H-azepin-4-yl)methyl]-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 120429-81-4
CMF C19 H24 N4 O




CM 2

CRN 110-17-8
CMF C4 H4 O4

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-3-pyrrolidinyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 120429-89-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-3-pyrrolidinyl-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120429-88-1
CMF C16 H19 N5 O



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 120429-96-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-3-pyrrolidinyl]-3-(2-pyridinylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120429-95-0

04/28/2006

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C25 H28 N6 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 120430-02-6 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, N-([2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl)-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 120430-01-5
CMF C25 H29 N5 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 120430-12-8 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, N-([2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl)-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-11-7
CMF C22 H31 N5 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4

Hahte


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120430-04-8 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, N-([2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl)-3-[(4-thiazolyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-03-7
CMF C23 H26 N6 O 5



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 120430-10-6 CAPLUS
CN 5H-Tetrazol-5-one, 1-ethyl-4-[2-[hexahydro-4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-yl]ethyl]-1,4-dihydro-, (2E)-2-butenedioate (3:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-09-3
CMF C23 H31 N9 O2


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120430-14-0 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, N-([hexahydro-1-[2-(2-thienyl)ethyl]-1H-azepin-4-yl]-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-13-9
CMF C24 H29 N5 O 5



CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 120430-16-2 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[hexahydro-4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-yl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-15-1
CMF C28 H32 F N5 O2

04/28/2006


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 120430-17-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-yl]ethyl-, 2,3-dihydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 120430-34-4 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-methyl-3-[2-[[3-[(2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 120430-37-7 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-methyl-3-[2-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (9CI) (CA INDEX NAME)




RN 120430-39-9 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-methyl-2-[2-[[3-[(4-thiazolyl)methyl]-

Habte

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 120430-23-1 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[2-[[3-[(2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, dinitrate (9CI) (CA INDEX NAME)

CM 1


CRN 120430-22-0
CMF C27 H26 N6 O2

CM 2

CRN 7697-37-2
CMF H N O3


RN 120430-27-5 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[2-[[3-[(4-thiazolyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-26-4
CMF C25 H24 N6 O2 S

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 120430-38-8
CMF C25 H26 N8 O S


CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 120430-44-6 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[2-[[3-[(2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (9CI) (CA INDEX NAME)




RN 120430-46-8 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[2-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 120430-45-7
CMF C27 H33 N7 O2


04/28/2006

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



RN 120430-48-0 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[(2-[3-[(4-thiazolylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinylethyl)-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1
CRN 120430-47-9
CMP C25 H30 N8 O 5



CM 2
CRN 110-17-8
CMP C4 H4 O4


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl)methyl]hexahydro-1H-azepin-4-yl]-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-53-7
CMP C27 H31 N5 O3




CM 2
CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.




RN 120430-56-0 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[(2-[4-[(3-(2-furanyl)methyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]hexahydro-1H-azepin-1-yl]ethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-55-9
CMP C28 H29 N5 O3




L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 120430-52-6 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[hexahydro-4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-yl]ethyl]-7-methyl-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-51-5
CMP C27 H31 N7 O2 5



CM 2
CRN 144-62-7
CMP C2 H2 O4



RN 120430-54-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[(2,3-dihydro-1,4-benzodioxin-2-


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2
CRN 144-62-7
CMP C2 H2 O4




RN 120430-58-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(4-methoxyphenyl)ethyl]-3-pyrrolidinyl]-3-(2-thienylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-57-1
CMP C24 H27 N5 O 5



CM 2
CRN 110-17-8
CMP C4 H4 O4


Double bond geometry as shown.



RN 120430-60-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanyl)methyl-N-[hexahydro-1-[2-(4-methoxyphenyl)ethyl]-1H-azepin-4-yl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-59-3
CMP C26 H31 N5 O2

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 144-62-7
CMF C2 H2 O4



RN 120430-62-8 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[2-[3-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinylethyl]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)


CM 1
CRN 120430-61-7
CMF C26 H25 N5 O3



CM 2
CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



RN 120430-84-4 CAPLUS
CN 1-Pyrrolidineacetonitrile, 3-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 120430-89-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-3-pyrrolidinyl]-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 120430-92-4 CAPLUS
CN Carboic acid, [2-[3-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinylethyl]-, ethyl ester, (2E)-2-butenedioate (1:1)


Habe

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 120430-66-2 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[3-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinylethyl]-2-methyl-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-65-1
CMF C26 H27 N7 O2



CM 2
CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 120430-79-7 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[2-[3-[[3-(5-methyl-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinylethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-78-6
CMF C27 H27 N5 O3

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 1

CRN 120430-91-3
CMF C20 H26 N6 O2 S




CM 2
CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 120430-95-7 CAPLUS
CN Carboic acid, [2-[3-[[3-(5-methyl-2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinylethyl]-, ethyl ester, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
CRN 120430-94-6
CMF C21 H28 N6 O3




CM 2
CRN 110-17-8
CMF C4 H4 O4


04/28/2006

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Double bond geometry as shown.




RN 120430-96-8 CAPLUS
 CN Carbamic acid, [2-[3-[[3-(4-thiazolylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 120431-01-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-3-pyrrolidinyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 120431-04-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-3-pyrrolidinyl]-3-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1


CRN 120431-12-1
 CMP C22 H25 N9



CM 2

CRN 110-17-8
 CMP C4 H4 O4


Double bond geometry as shown.



RN 120431-24-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(2-pyrimidinylamino)ethyl]-3-pyrrolidinyl]-3-(2-thienylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 120431-23-4
 CMP C21 H24 N8 S



CM 2


CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.

Habte

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 120431-05-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-3-pyrrolidinyl]-3-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 120431-07-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(2-pyrimidinylamino)ethyl]-3-pyrrolidinyl]-3-(4-thiazolylmethyl)-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1


CRN 120431-06-3
 CMP C20 H23 N9 S



CM 2


CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 120431-13-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-[2-(2-pyrimidinylamino)ethyl]-3-pyrrolidinyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 120431-26-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[hexahydro-1-[2-(2-pyrimidinylamino)ethyl]-1H-azepin-4-yl]-3-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 120431-27-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-isothiocyanatoethyl)-3-pyrrolidinyl]-3-[(5-methyl-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 120431-30-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-isothiocyanatoethyl)-3-pyrrolidinyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 120431-32-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-isothiocyanatoethyl)-3-pyrrolidinyl]-3-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120431-34-7 CAPLUS
 CN Thiourea, N-(4-amino-3-pyridinyl)-N'-[2-[3-[(3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 120431-36-9 CAPLUS
 CN Thiourea, N-(4-amino-3-pyridinyl)-N'-[2-[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 120431-37-0 CAPLUS
 CN Thiourea, N-(4-amino-3-pyridinyl)-N'-[2-[3-[(3-(4-thiazolylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
 CRN 144-62-7
 CMP C2 H2 O4




RN 120431-49-4 CAPLUS
 CN 3-Furancarboxamide, N-[2-[hexahydro-4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1H-azepin-1-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 120431-51-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-(1-methyl-3-pyrrolidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1
 CRN 120431-50-7
 CMP C17 H21 N5 O

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 120431-39-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-ylamino)ethyl]-3-pyrrolidinyl]-3-(4-thiazolylmethyl)-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1
 CRN 120431-38-1
 CMP C22 H24 N10 S



CM 2
 CRN 110-17-8
 CMP C4 H4 O4


Double bond geometry as shown.



RN 120431-46-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-ylamino)ethyl]-3-pyrrolidinyl]-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (2:5) (9CI) (CA INDEX NAME)


CM 1
 CRN 120431-45-0
 CMP C24 H27 N9 O

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.



RN 120431-53-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-methyl-3-pyrrolidinyl)-3-(2-pyridinylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
 CRN 120431-52-9
 CMP C17 H20 N6



CM 2
 CRN 144-62-7
 CMP C2 H2 O4




RN 120431-55-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-methyl-3-pyrrolidinyl)-3-(4-

04/28/2006

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
thiazolylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120431-54-1
CMP C15 H18 N6 S



CM 2


CRN 144-62-7
CMP C2 H2 O4



RN 120431-57-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-(hexahydro-1-methyl-1H-azepin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 120431-56-3
CMP C18 H23 N5 O



CM 2

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 120431-69-8
CMP C24 H33 N5 O



CM 2


CRN 144-62-7
CMP C2 H2 O4



RN 120431-72-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(hexahydro-1-methyl-1H-azepin-4-yl)-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120431-71-2
CMP C19 H25 N5 O



CM 2

CRN 144-62-7
CMP C2 H2 O4

Hahte


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 144-62-7
CMP C2 H2 O4



RN 120431-65-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(hexahydro-1-(1-methylethyl)-1H-azepin-4-yl)-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 120431-64-3
CMP C21 H29 N5 O



CM 2

CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



RN 120431-70-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-cyclohexylhexahydro-1H-azepin-4-yl)-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120457-49-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[hexahydro-1-[2-(4-methoxyphenyl)ethyl]-1H-azepin-4-yl]-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120457-48-9
CMP C27 H33 N5 O2



CM 2

CRN 144-62-7
CMP C2 H2 O4




RN 120457-53-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[2-{hexahydro-4-[(3-{(5-methyl-2-furanyl)methyl}-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1H-azepin-1-yl}ethyl)-1,3-dihydro-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 120457-52-5
CMP C28 H32 N6 O2

04/28/2006


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2



CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 120457-55-8 CAPLUS
CN 2H-1-Benzopyran-2-one, 3-[2-[3-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 120457-54-7
CMF C26 H25 N5 O2 SL4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C26 H31 N7 O2

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 120457-61-6 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[2-[3-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 120457-60-5
CMF C26 H31 N7 O S

CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



Habte


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 2CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 120457-57-0 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-methyl-3-[2-[3-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 120457-56-9
CMF C26 H27 N7 O S

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 120457-59-2 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[3-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 120457-58-1

L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 120457-62-7 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[3-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-pyrrolidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)


CM 1

CRN 120457-58-1
CMF C26 H31 N7 O2


CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




IT 120429-88-1P 120432-17-9P 120432-18-0P
120432-19-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate in preparation of antiallergic agents)
RN 120429-88-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanylmethyl)-N-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 120432-17-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-(hexahydro-1H-

04/28/2006


L4 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
azepin-4-yl)- (9CI) (CA INDEX NAME)



RN 120432-18-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-3-pyrrolidinyl-3-((2-chienylmethyl)- (9CI) (CA INDEX NAME)



RN 120432-19-1 CAPLUS
CN 1H-Azepine-1-ethanol, hexahydro-4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1989:173236 CAPLUS
DOCUMENT NUMBER: 110:173236
TITLE: Preparation of bicyclic condensed
N-(4-piperidinyl)-2-

INVENTOR(S): Janssens, Frans Eduard; Torreman, Joseph Leo
PATENT ASSIGNEE(S): Ghislenus, Diels, Gaston Stanislas Marcella
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXKDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 295742	A1	19881221	EP 1988-201172	19880608
EP 295742	B1	19920826		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4897401	A	19900130	US 1988-182814	19880418
CA 1324133	A1	19931109	CA 1988-565978	19880505
AT 79878	E	19920915	AT 1988-201172	19880608
ES 2045083	T3	19940116	ES 1988-201172	19880608
SU 1644717	A3	19910423	SU 1988-4355903	19880614
NO 8802641	A	19881220	NO 1988-2641	19880615
NO 167803	B	19910902		
NO 167803	C	19911211		
JP 01025776	A2	19890127	JP 1988-145933	19880615
DK 8803332	A	19881220	DK 1988-3332	19880617
DK 169761	B1	19950220		
FI 8802909	A	19881220	FI 1988-2909	19880617
FI 90233	B	19930930		
FI 90233	C	19940110		
AU 8818109	A1	19881222	AU 1988-18109	19880617
AU 600144	B2	19900802		
CN 88103784	A	19881228	CN 1988-103784	19880617
CN 1029964	B	19951011		
HU 48628	A2	19890628	HU 1988-3118	19880617
HU 201755	B	19901228		
ZA 8804346	A	19900228	ZA 1988-4346	19880617
IL 86788	A1	19920818	IL 1988-86788	19880617
KR 9701158	B1	19970129	KR 1988-7315	19880617
US 5006527	A	19910409	US 1989-445812	19891204
PRIORITY APPL. INFO.:				US 1987-63859 A 19870619
				US 1988-182814 A3 19880418
				EP 1988-201172 A 19880608

OTHER SOURCE(S): CASREACT 110:173236; MARPAT 110:173236
GI

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; A1:A2A3:A4 = CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, or CH:CHCH:CH optimally substituted by halo, C1-6 alkyl, C1-6 alkoxy, CF3 or OH; R = H, C1-6 alkyl; R1 = (C1-6 alkyl-substituted) furanyl or imidazolyl, pyrazinyl, thiazolyl; Z = C1-6 alkanediyl; R2 = H, C1-6 alkyl, C3-6 cycloalkyl, aryl-substituted C1-6 alkyl, C1-6 acyl; L = (aryl-substituted) C3-6 alkenyl, ZR3, ZOR4, ZNR5R6, ZZ1C(O)R7, CH2CH(OH)CH2OR9; R3 = H, arylthio, arylsulfonyl; (un)substituted 4,5-dihydro-5-oxo-1H-tetrazol-1-yl, etc.; R4 = C1-6 alkyl, aryl; R5 = (aryl-substituted) C1-6 alkyl; R6 = aryl, (aryl-substituted) C1-6 alkyl, etc.; R7 = C1-6 alkyl, (aryl-substituted) C1-6 alkyl or amino, 1-piperidinyl, 1-pyrrolidinyl, 4-morpholinyl, etc.; Z1 = O, NR8 where R8 =

H, (aryl-substituted) C1-6 alkyl; R9 = aryl; aryl = (substituted) Ph, naphthalenyl, (halo- or C1-6 alkyl-substituted) thienyl, (C1-6 alkyl-substituted) furanyl, etc.] were prepared as antihistaminic agents. A mixture of 1-(2-bromoethyl)-4-ethyl-1,4-dihydro-5H-tetrazol-5-one 3.32, 1-[(5-methyl-2-furanyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine, 4.65, Na2CO3 1.6 and AcOMe 45 parts was stirred overnight at 80° to give 55% benzimidazole derivative II. I protected rats against compound


48/80-induced lethal circulatory collapse with ED50 of 0.005-0.04 mg/kg p.o. or s.c.
IT 120072-91-5P 120072-93-7P 120072-95-9P
120072-97-1P 120072-99-3P 120073-01-0P
120073-02-1P 120073-03-2P 120073-05-4P
120073-11-2P 120073-13-4P 120073-17-8P
120073-29-2P 120073-32-7P 120073-34-9P
120073-35-0P 120073-36-1P 120073-37-2P
120073-39-4P 120073-40-7P 120073-41-8P
120073-43-0P 120073-45-2P 120073-47-4P
120073-50-9P 120073-52-1P 120073-58-7P
120073-59-8P 120073-60-1P 120073-63-4P
120073-66-7P 120073-67-8P 120073-69-0P
120073-70-2P 120073-72-5P 120073-73-6P
120073-76-8P 120073-78-9P 120073-78-1P
120073-81-6P 120073-82-7P 120116-03-2P

Hahte

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


120116-03-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as antihistaminic)

RN 120072-91-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 120072-93-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CN 1
CRN 120072-92-6
CMF C26 H31 N5 O2




CN 2
CRN 110-17-6
CMF C4 H4 O4

Double bond geometry as shown.

04/28/2006


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120072-95-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(1-methylethyl)-4-piperidinyl]-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 120072-94-8
 CMF C20 H27 N5 O



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 120072-97-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-ethyl-4-piperidinyl)-3-[(5-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 120072-96-0
 CMF C19 H25 N5 O

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 120073-01-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-ethoxyethyl)-4-piperidinyl]-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-00-9
 CMF C21 H29 N5 O2




CM 2

CRN 144-62-7
 CMF C2 H2 O4



RN 120073-02-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 120072-99-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-(2-propenyl)-4-piperidinyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 120072-98-2
 CMF C20 H25 N5 O




CM 2

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-03-2 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 120073-05-4 CAPLUS
 CN 5H-Tetrazol-5-one, 1-ethyl-1,4-dihydro-4-[2-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-04-3
 CMF C22 H29 N9 O2

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 120073-11-2 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, N-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-10-1
CMF C26 H29 N5 O3


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 120073-16-7
CMF C22 H29 N5 O2

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 120073-29-2 CAPLUS
CN 1-Piperidineethanol, 4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-α-(phenoxymethyl)- (9CI) (CA INDEX NAME)



RN 120073-32-7 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-ethyl-2-furanyl)methyl]-N-[1-(4-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)]


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 120073-13-4 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-(2-(2-thienyl)ethyl)-4-piperidinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-12-3
CMF C23 H27 N5 O 5


CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 120073-17-8 CAPLUS
CN 2-Pentanone, 5-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-34-9 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, N-[1-(2-ethoxyethyl)-4-piperidinyl]-3-[(5-ethyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 120073-33-8
CMF C22 H31 N5 O2

CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 120073-35-0 CAPLUS
CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-ethyl-2-furanyl)methyl]-N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-36-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-ethoxyethyl)-4-piperidinyl]-3-[(2-methyl-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 120073-37-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]-3-[(2-methyl-3-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 120073-39-4 CAPLUS
 CN Urea, N-methyl-N'-[2-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-40-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(2-methyl-3-furanyl)methyl]-N-(1-methyl-4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 120073-41-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 120073-43-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-hexyl-4-piperidinyl)-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-42-9
 CMF C23 H33 N5 O

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 120073-45-2 CAPLUS
 CN 2-Butanone, 4-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-44-1
 CMF C21 H27 N5 O2



CM 2

CRN 144-62-7
 CMF C2 H2 O4


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-47-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-(1-pentyl-4-piperidinyl)-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 120073-46-3
 CMP C22 H31 N5 O



CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 120073-50-9 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-{4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl}- (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-3-[(3-methyl-2-furanyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 120073-57-6
 CMP C26 H31 N5 O2



CM 2


CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.



RN 120073-59-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[[3-[(2-methyl-3-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-52-1 CAPLUS
 CN 2-Propanone, 1-[4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-51-0
 CMP C20 H25 N5 O2




CM 2

CRN 144-62-7
 CMP C2 H2 O4




RN 120073-58-7 CAPLUS

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-60-1 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[2-[4-[[3-[(5-ethyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 120073-63-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(3-methyl-2-furanyl)methyl]-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


04/28/2006

Habte

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-66-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]-3-[[5-(1-methylethyl)-2-furanyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 120073-67-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[[3-[[5-(1-methylethyl)-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CMP C4 H4 O4

Double bond geometry as shown.



RN 120073-70-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[4-methyl-2-furanyl]methyl]-N-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)




● 2 HCl

RN 120073-72-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[4-methyl-2-furanyl]methyl]-N-(1-methyl-4-piperidinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-71-4
 CMP C18 H23 N5 O




CM 2

CRN 110-17-8

Habte


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 120073-69-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-ethoxyethyl)-4-piperidinyl]-3-[[5-(1-methylethyl)-2-furanyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-68-9
 CMP C23 H33 N5 O2




CM 2


CRN 110-17-8

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CMP C4 H4 O4

Double bond geometry as shown.



RN 120073-73-6 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[[3-[[4-methyl-2-furanyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 120073-75-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]-3-[[4-methyl-2-furanyl]methyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-74-7
 CMP C26 H31 N5 O2

04/28/2006

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 120073-76-9 CAPLUS

CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 120073-78-1 CAPLUS

CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-[2-(phenylthio)ethyl]-4-piperidinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 120073-82-7 CAPLUS

CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-[2-(1-piperidinyl)ethyl]-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 120116-03-2 CAPLUS

CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-[3-phenyl-2-propenyl]-4-piperidinyl]-, (E)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

Hatte

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 120073-77-0

CMF C25 H29 N5 O S



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 120073-81-6 CAPLUS

CN 3H-imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-[1-[2-(phenylsulfonyl)ethyl]-4-piperidinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120073-80-5


CMF C25 H29 N5 O3 S

L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 120116-02-1

CMF C26 H29 N5 O

Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 120116-09-8 CAPLUS

CN 3H-imidazo[4,5-b]pyridin-2-amine, N-(1-butyl-4-piperidinyl)-3-[(5-methyl-2-furanyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 120116-08-7

CMF C31 H29 N5 O




CM 2

04/28/2006


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CRN 144-62-7
 CMP C2 H2 O4



IT 110588-56-2P 111921-84-7P 111921-97-2P
 120073-87-2P 120073-91-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for antihistaminics)
 RN 110588-56-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 111921-84-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(5-ethyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 111921-97-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(2-methyl-3-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1988:437821 CAPLUS
 DOCUMENT NUMBER: 109:37821
 TITLE: Preparation of 4-[(bicyclic heterocyclyl)methyl]piperidines and analogs as antihistaminics
 INVENTOR(S): Janssens, Frans E.; Kennis, Ludo E. J.; Hens, Jozef F.; Torremans, Joseph L. G.; Diels, Gaston S. M.
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: U.S., 59 pp. Cont.-in-part of U.S. Ser. No. 571,135, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4695575	A	19870922	US 1985-747754	19850624
ES 539281	A1	19870616	ES 1984-539281	19841231
AU 8537364	A1	19850912	AU 1985-37364	19850107
AU 573673	B2	19880616		
CA 1259609	A1	19890919	CA 1985-471589	19850107
DK 8500089	A	19850710	DK 1985-89	19850108
FI 8500079	A	19850710	FI 1985-79	19850108
FI 83867	B	19910531		
FI 83867	C	19910910		
NO 8500085	A	19850710	NO 1985-85	19850108
NO 160849	B	19890227		
NO 160849	C	19890607		
JP 60185777	A2	19850921	JP 1985-479	19850108
JP 07068240	B4	19850726		
HU 36471	A2	19850930	HU 1985-61	19850108
HU 200338	B	19900528		
ZA 8500187	A	19860827	ZA 1985-187	19850108
RO 90622	B3	19861210	RO 1985-117252	19850108
SU 1396964	A3	19880515	SU 1985-3836858	19850108
IL 74018	A1	19880831	IL 1985-74018	19850108
PL 145710	B1	19881031	PL 1985-251488	19850109
US 4838774	A	19890613	US 1987-94987	19870910
PRIORITY APPLN. INFO.:			US 1984-569369	A2 19840109
			US 1984-671135	A2 19841113
			US 1985-747754	A3 19850624

OTHER SOURCE(S): CASREACT 109:37821
 GI


L4 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 120073-87-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(5-methyl-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 120073-91-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-methyl-2-furanyl)methyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)




L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title compds. [I; 3 of A1-A4 = (un)substituted CH, the 4th = N, (un)substituted CH; B = CH2, O, SO, SO2; R = substituted C1-6 alkyl, alkoxy, alkylthio, amino, pyrrolidinyl, piperidinyl, hexahydroazepinyl, etc.; R1 = H, alkyl, cycloalkyl, (un)substituted aryl, heteroaryl, (hetero)aralkyl; R2 = H, alkyl] and their stereoisomers and acid salts were prepared as antihistaminics and serotonin antagonists.
 1-[(4-Fluorophenyl)methyl]-2-(4-piperidinylmethyl)-1H-benzimidazol-5-ol and PhSCH2CH2N were refluxed 2 h in Me2CHCH2COMe containing Na2CO3 to give 27.8% benzimidazole derivative (II). I inhibited compound 48/80-induced lethality in rats, caused by histamine release, with ED50 of 0.005-0.16 mg/kg s.c. or orally. I also inhibited gastric lesions caused by simultaneous release of serotonin.

IT 99960-07-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation of, with acetic anhydride)
 RN 99960-07-3 CAPLUS
 CN Benzamide, 2-amino-N-[2-(4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




IT 99964-21-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and N-alkylation of, by (bromoethyl)pyrimidothiazine derivative)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 99944-21-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




IT 99959-35-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and N-alkylation of, by (chloroethyl)thiazolopyrimidine derivative)
 RN 99959-35-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




IT 99959-90-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and N-arylation of, by bromothiazole)
 RN 99959-90-7 CAPLUS
 CN 1-Piperidineethanamine, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as antihistaminic)
 RN 99944-14-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(phenylmethyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 99944-22-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-(4-piperidinylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99944-21-5
 CMP C19 H21 F N4



CM 2
 CRN 110-17-8
 CMP C4 H4 O4


Double bond geometry as shown.



RN 99953-71-6 CAPLUS
 CN 2,4-(1H,3H)-Quinazolin-2-one, 3-[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


Hasbe

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 99944-14-6P 99944-22-6P 99953-71-6P
 99953-72-7P 99953-74-9P 99953-76-1P
 99953-80-7P 99953-84-1P 99953-94-3P
 99953-98-7P 99954-03-7P 99954-17-3P
 99956-67-3P 99956-69-7P 99956-74-6P
 99956-81-3P 99956-82-4P 99956-89-1P
 99959-00-9P 99959-01-0P 99959-07-6P
 99959-08-7P 99959-09-8P 99959-11-2P
 99959-26-9P 99959-27-0P 99959-33-8P
 99959-36-1P 99959-37-2P 99959-39-4P
 99959-54-3P 99959-55-4P 99959-56-5P
 99959-57-6P 99959-58-7P 99959-59-8P
 99959-61-2P 99959-62-3P 99959-64-5P
 99959-66-7P 99959-75-8P 99959-77-0P
 99959-85-0P 99959-87-4P 99960-29-9P
 99960-30-2P 99960-32-4P 99960-34-6P
 99960-47-1P 99960-52-8P 99960-62-0P
 99960-65-3P 99960-67-5P 99960-80-2P
 99960-81-3P 99960-87-9P 99960-91-5P
 99960-95-9P 99961-01-0P 99961-03-2P
 99961-05-4P 99961-13-4P 99961-14-5P
 99961-17-2P 99961-42-9P 99961-57-6P
 99961-59-8P 99961-61-2P 99961-65-6P
 99961-73-6P 99961-75-8P 99961-80-5P
 99961-82-7P 99961-84-9P 99961-89-4P
 99962-03-5P 99962-24-0P 99962-28-4P
 99962-35-3P 99962-39-7P 99962-58-0P
 99962-59-1P 99962-73-9P 99962-78-4P
 99962-80-8P 99962-85-1P 99962-88-6P
 99961-28-7P 99963-30-1P 99963-37-8P
 99963-39-0P 99963-41-4P 99963-45-8P
 99963-46-9P 99963-48-1P 99963-51-6P
 99963-55-0P 100015-33-6P 100015-35-8P
 100015-38-1P 100015-48-3P 100015-51-8P
 100015-53-0P 100015-54-1P 100015-59-6P
 100015-60-9P 100015-78-9P 100015-79-0P
 100015-84-7P 100015-86-9P 100015-88-1P
 100015-90-5P 100015-91-6P 100015-92-7P
 100015-94-9P 100016-07-7P 100016-08-8P
 100016-12-4P 100016-14-6P 100016-17-9P
 100016-19-1P 100016-20-4P 100365-76-2P
 115166-53-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylpropyl]- (9CI) (CA INDEX NAME)



RN 99953-72-7 CAPLUS
 CN 2,4-(1H,3H)-Quinazolin-2-one, 3-[2-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99953-74-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl)methyl]-3-(2-furanylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
 CRN 99953-73-8
 CMP C33 H34 F2 N4 O

04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99953-76-1 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 2-[[1-[[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]methyl]-3-(2-pyridinylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 99953-75-0
CMF C34 H35 F2 N5

CM 2

CRN 144-62-7
CMF C2 H2 O4

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99953-94-3 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 2-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]methyl]-3-(2-thienylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-93-2
CMF C26 H28 N4 O2 S

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99953-98-7 CAPLUS


Hatte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99953-80-7 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 2-[[1-[[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-79-4
CMF C35 H35 F2 N4

CM 2

CRN 144-62-7
CMF C2 H2 O4


RN 99953-84-1 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 2-[[1-[[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]methyl]-3-(phenylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-83-0
CMF C35 H36 F2 N4

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3H-imidazo[4,5-b]pyridine, 2-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]methyl]-3-(2-pyridinylmethyl)-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1


CRN 99953-97-6
CMF C27 H29 N5 O2

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99954-03-7 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99954-02-6
CMF C28 H31 F N6 O S

CM 2

04/28/2006


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 144-62-7
CMF C2 H2 O4



RN 99954-17-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]methyl]-3-(2-thienylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99954-16-2
CMF C33 H34 F2 N4 S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 99958-67-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(1-methylethyl)-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-66-4
CMF C22 H27 F N4


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99958-76-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(cyclohexyl-4-piperidinyl)methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-75-5
CMF C25 H31 F N4




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 99958-81-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(2-(2-pyridinyl)ethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 99958-82-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(2-(2-

Habte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 99958-69-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(1-methyl-4-piperidinyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-68-6
CMF C20 H23 F N4




CM 2

CRN 144-62-7
CMF C2 H2 O4

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
pyridinyl]ethyl]-4-piperidinyl]methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-81-3
CMF C26 H28 F N5




CM 2

CRN 144-62-7
CMF C2 H2 O4




RN 99958-97-1 CAPLUS
CN 1-Piperidineethanol, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 99959-00-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(2-(2-thienyl)ethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99959-01-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(2-thienylethyl)-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99959-07-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(4-morpholinylethyl)-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-06-5
 CMF C25 H32 F N5 O

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 99959-08-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(ethoxyethyl)-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 99959-09-8 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 99959-11-2 CAPLUS
 CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-(1-methylethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-10-1
 CMF C24 H30 F N5 O



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 99959-26-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(2-propenyl)-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

RN 99959-27-0 CAPLUS
 CN 1-Piperidinepropanamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-(1-methylethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)




RN 99959-33-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(phenylthio)ethyl]-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-32-7
 CMF C27 H29 F N4 S


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 144-62-7
CMP C2 H2 O4




RN 99959-36-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,7-dimethyl- (9CI) (CA INDEX NAME)



RN 99959-37-2 CAPLUS

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 144-62-7
CMP C2 H2 O4



RN 99959-54-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,7-dimethyl-, trihydrochloride (9CI) (CA INDEX NAME)




RN 99959-39-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[3-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]-1,3-dihydro-, ethanedioate (2:3) (9CI) (CA INDEX NAME)


CM 1
CRN 99959-38-3
CMP C27 H30 N6 O2

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




● 3 HCl

RN 99959-55-4 CAPLUS
CN 2,4-(1H,3H)-Quinazolin-2-one, 3-[3-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99959-56-5 CAPLUS
 CN 2,4-(1H,3H)-Quinoxalinedione,
 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99959-57-6 CAPLUS
 CN 2,4-(1H,3H)-Quinoxalinedione,
 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



RN 99959-58-7 CAPLUS
 CN 5H-Thiazolo[1,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

RN 99959-61-2 CAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-3,7-dihydro-1,3-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A




Habte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● 3 HCl

RN 99959-59-8 CAPLUS
 CN 2H-1-Benzopyran-2-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



● 2 HCl

RN 99959-62-3 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 99959-64-5 CAPLUS
 CN 2H,6H-Pyrimido[3,1-b][1,3]thiazin-6-one,
 7-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-3,4-dihydro-8-methyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-63-4
 CMF C27 H32 N6 O2 S




04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 99959-66-7 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2-methyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-65-6
CMF C28 H30 N6 O2

CM 2

CRN 144-62-7
CMF C2 H2 O4


RN 99959-75-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI)
(CA INDEX NAME)

CM 1


CRN 99959-74-7

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 99959-85-0 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 99959-97-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(2-isothiocyanatoethyl)-4-piperidinyl]methyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 99960-29-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 99960-30-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C26 H30 N4 O2

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99959-77-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-3-(phenylmethyl)-, (2E)-2-butenedioate (1:2) (9CI)
(CA INDEX NAME)


CM 1

CRN 99959-76-9
CMF C28 H32 N4 O


CM 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.




L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99960-32-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 99960-34-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-methoxyphenyl]methyl]-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 99960-47-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-methoxyphenyl]methyl]-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99960-52-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine,
 2-(4-(4-piperidinylmethyl)-3-(2-pyridinylmethyl)-,
 (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99960-51-7
 CMP C18 H21 N5



CM 2


CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.



RN 99960-62-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.



RN 99960-80-2 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,4-dihydro-8-methyl- (9CI) (CA INDEX NAME)




RN 99960-81-3 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,4-dihydro-8-methyl-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99960-80-2
 CMP C29 H33 F N6 O S


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99960-65-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-(4-piperidinylmethyl)-,
 (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99959-35-0
 CMP C17 H20 N4 O



CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 99960-67-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-(4-piperidinylmethyl)-3-(2-thienylmethyl)-,
 (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99960-66-4
 CMP C17 H20 N4 S

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
 CMP C2 H2 O4



RN 99960-87-9 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]-, ethanedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99960-86-8
 CMP C27 H30 N6 O S




L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 144-62-7
CMP C2 H2 O4

RN 99960-91-5 CAPLUS


CN 2,4-(1H,3H)-Quinazolin-2-one, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)



RN 99960-95-9 CAPLUS


CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99960-94-8
CMP C29 H30 F2 N4 O

CM 2

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMP C2 H2 O4

RN 99961-05-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)methyl]-3-(2-thienylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 99961-04-3
CMP C26 H30 N4 O S

CM 2

CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.




RN 99961-13-4 CAPLUS

Habte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 110-17-8
CMP C4 H4 O4


Double bond geometry as shown.



RN 99961-01-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)methyl]-3-(2-pyridinylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 99961-00-9
CMP C27 H31 N5 O

CM 2

CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



RN 99961-03-2 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-(4-fluorophenyl)methyl]-2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-02-1
CMP C28 H31 F N4 O


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-methyl-3-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 99961-14-5 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)



RN 99961-37-2 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 99961-42-9 CAPLUS


CN 1H-Benzimidazol-2-amine, N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99961-57-6 CAPLUS
 CN 2-Pyrimidinamine,
 N-[2-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99961-56-5
 CMP C23 H27 N7 O




CM 2
 CRN 144-62-7
 CMP C2 H2 O4




RN 99961-59-8 CAPLUS
 CN 2-Pyrimidinamine,
 N-[2-[[3-[(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, ethanedioate (2:7) (9CI) (CA INDEX NAME)
 CM 1

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99961-65-6 CAPLUS
 CN 2-Pyrimidinamine, N-[2-[[3-[(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99961-64-5
 CMP C25 H29 N7



CM 2
 CRN 144-62-7
 CMP C2 H2 O4




RN 99961-73-6 CAPLUS
 CN 1-Piperidineethanamine,
 4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-2-thiazolyl-, ethanedioate (1:3) (9CI) (CA INDEX NAME)



RN 99961-75-8 CAPLUS
 CN 1-Piperidineethanamine,
 4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-2-thiazolyl-, ethanedioate (1:3) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99961-73-6


Habte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CRN 99961-58-7
 CMP C24 H28 N8

CM 2
 CRN 144-62-7
 CMP C2 H2 O4




RN 99961-61-2 CAPLUS
 CN 2-Pyrimidinamine,
 N-[2-[[3-[(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99961-60-1
 CMP C23 H27 N7 S



CM 2
 CRN 110-17-8
 CMP C4 H4 O4


Double bond geometry as shown.

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CMP C22 H26 N6 O S

CM 2
 CRN 144-62-7
 CMP C2 H2 O4



RN 99961-80-5 CAPLUS
 CN 1-Piperidineethanamine, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-2-thiazolyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99961-79-2
 CMP C24 H27 F N6 S



CM 2
 CRN 144-62-7
 CMP C2 H2 O4

04/28/2006


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99961-82-7 CAPLUS
 CN 1-Piperidineethanamine, N-2-thiazolyl-4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-81-6
 CMF C22 H26 N6 S2



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 99961-84-9 CAPLUS
 CN 1-Piperidineethanamine, 4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-thiazolyl-, ethanedioate (2:7) (9CI) (CA INDEX NAME)

CM 1


CRN 99961-83-8
 CMF C24 H28 N6 S




L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 99962-24-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-((4-fluorophenyl)methyl)-2-[[1-(2-(2-pyridinylmethoxy)ethyl)-4-piperidinyl]methyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 99962-28-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99962-27-3
 CMF C25 H28 N8 O


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 99961-89-4 CAPLUS
 CN 1-Piperidineethanamine, 4-[[3-[(4-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-thiazolyl-, (9CI) (CA INDEX NAME)



RN 99962-03-5 CAPLUS
 CN 2-Pyrimidinamine, N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99962-02-4
 CMF C25 H28 F N7



CM 2

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



CM 2


CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 99962-35-3 CAPLUS
 CN Urea, N-ethyl-N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99962-39-7 CAPLUS
 CN 3-Furancarboxamide, N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 99962-58-0 CAPLUS
 CN Urea, N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99962-78-4 CAPLUS
 CN Benzamide, N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2-(methylamino)-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99962-77-3
 CMP C29 H33 F N6 O



CM 2

CRN 144-62-7
 CMP C2 H2 O4




RN 99962-80-8 CAPLUS
 CN Benzamide, 2-amino-N-[2-[4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99962-59-1 CAPLUS
 CN Urea, N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-N,N-dimethyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99962-58-0
 CMP C24 H31 F N6 O




CM 2

CRN 144-62-7
 CMP C2 H2 O4



RN 99962-73-9 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2,3-dihydro-2-thioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99962-85-3 CAPLUS
 CN 4(1H)-Quinazolinone, 2,3-dihydro-2,2-dimethyl-3-[2-[4-[[3-[(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99962-84-2
 CMP C30 H35 N7 O




CM 2

CRN 144-62-7
 CMP C2 H2 O4




RN 99962-88-6 CAPLUS
 CN 2,4-(1H,3H)-Quinazolinodione, 3-[4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]butyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99963-28-7 CAPLUS
 CN 1-Piperidineethanol,
 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99963-27-6
 CMP C20 H25 N5 O




CM 2
 CRN 110-17-8
 CMP C4 H4 O4
 Double bond geometry as shown.




RN 99963-30-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-[(1-naphthalenyloxy)methoxy]ethyl]-4-piperidinyl]methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99963-29-8
 CMP C32 H33 F N4 O2

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
 CRN 144-62-7
 CMP C2 H2 O4
 HO-C(=O)-C(=O)-OH
 RN 99963-39-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(1H-benzimidazol-2-ylmethyl)-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99963-38-9
 CMP C27 H27 F N6




CM 2
 CRN 144-62-7
 CMP C2 H2 O4




Hapte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
 CRN 110-17-8
 CMP C4 H4 O4
 Double bond geometry as shown.



RN 99963-37-8 CAPLUS
 CN 5H-Tetrazol-5-one, 1-ethyl-4-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-1,4-dihydro-, ethanedioate (1:2) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99963-36-7
 CMP C24 H29 F N8 O

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 99963-41-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99963-40-3
 CMP C28 H30 F2 N4 O



CM 2
 CRN 144-62-7
 CMP C2 H2 O4



RN 99963-45-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99963-44-7
 CMP C28 H29 F N4 O2




04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 144-62-7
CMF C2 H2 O4


RN 99963-46-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(1H-benzimidazol-2-yl)methyl]-1H-benzimidazol-2-yl)methyl]-4-piperidinylmethyl]-3-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 99963-48-1 CAPLUS
CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylpropyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99963-54-9
CMF C29 H32 N6 O

CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 100015-33-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(phenylsulfonyl)ethyl]-4-piperidinyl)methyl]-, ethanedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 100015-32-5
CMF C27 H29 F N4 O2 S

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99963-51-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[3-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylpropyl]-1,3-dihydro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 99963-50-5
CMF C29 H31 F N6 O

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 99963-55-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[[3-[(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylpropyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 100015-35-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[[3-[(2-pyridinylmethyl)-1H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylpropyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 100015-34-7
CMF C28 H31 N7 O


CM 2

CRN 144-62-7
CMF C2 H2 O4

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 100015-38-1 CAPLUS
CN 1-Piperidineacetic acid, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 100015-48-3 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[(4-methylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 100015-51-8 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[(2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
CMP C4 H4 O4


Double bond geometry as shown.



RN 100015-60-9 CAPLUS
CN 1-Piperidineethanamine, 4-[[3-[(2-thienyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 100015-78-9 CAPLUS
CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 100015-79-0 CAPLUS
CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-pyrimidinyl-, (2E)-2-butenedioate (1:2) (9CI)

Habe


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 100015-53-0 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 100015-54-1 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[(4-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)



RN 100015-59-6 CAPLUS
CN 1-Piperidineethanamine, 4-[[3-[(2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)


CM 1

CRN 99959-90-7
CMP C19 H25 N5 O

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1


CRN 100015-78-9
CMP C25 H26 F N7 O



CM 2

CRN 110-17-8
CMP C4 H4 O4


Double bond geometry as shown.



RN 100015-84-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[[3-[(2-pyridinyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-, ethanedioate (1:4) (9CI) (CA INDEX NAME)

CM 1

CRN 100015-83-6
CMP C26 H29 N9



CM 2

CRN 144-62-7
CMP C2 H2 O4

04/28/2006


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 100015-86-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1


CRN 100015-85-8
 CMF C25 H28 N8 S



PAGE 1-A

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 100015-88-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[4-[[3-[[4-methylphenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, ethanedioate (1:5) (9CI) (CA INDEX NAME)

CM 1

CRN 100015-87-0
 CMF C28 H32 N8



CM 2

CRN 144-62-7
 CMF C2 H2 O4


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 100015-90-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[4-[[3-[[4-fluorophenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 100015-89-2
 CMF C27 H29 F N8




CM 2

CRN 144-62-7
 CMF C2 H2 O4



RN 100015-91-6 CAPLUS
 CN 2-Pyridinemethanamine, N-[2-[4-[[3-[[4-fluorophenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




Hatte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 100015-92-7 CAPLUS
 CN 2-Pyridinemethanamine, N-[2-[4-[[3-[[4-fluorophenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 100015-91-6
 CMF C27 H31 F N6



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 100015-94-9 CAPLUS
 CN 3-Pyridinecarboxamide, N-[2-[4-[[3-[[4-fluorophenyl]methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 100015-93-8
 CMF C27 H29 F N6 O

04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 100016-07-7 CAPLUS
 CN Thieno[2,3-d]pyrimidin-4(1H)-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-6-methyl-2-thioxo- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 100016-12-4 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 100016-14-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 100016-13-5

CMF C28 H30 N6 O2



CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.


Habte

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 100016-08-8 CAPLUS
 CN Benzamide, N-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 100016-17-9 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-1-methyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 100016-19-1 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-1-methyl-2-thioxo- (9CI) (CA INDEX NAME)



RN 100016-20-4 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-2-thioxo- (9CI) (CA INDEX NAME)




RN 100165-76-2 CAPLUS
 CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-[[3-(2-furanylmethyl)-3H-


04/28/2006

L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl)ethyl]-6-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 115166-53-5 CAPLUS
CN Phenol, 4-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



```

IT 99959-86-1
   RL: RCT (Reactant); RACT (Reactant or reagent)
      (saponification-decarboxylation of)
RN 99959-86-1 CAPLUS
CN  Carboxylic acid, [2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-ylmethyl]-1-piperidinyl]thienyl], ethyl ester (9CI) (CA INDEX NAME)


```



```


IT 99958-80-2
   RL: RCT (Reactant); RACT (Reactant or reagent)
      (N-alkylation of)
RN 99958-80-2 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-(4-
   piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

```


 $\bullet_2 \text{ HCl}$

IT 99959-82-7

L4	ANSWER 39 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
	RL: RCT (Reactant); RACT (Reactant or reagent)
	(N-alkylation of, by chloroacetonitrile)
RN	99959-82-7 CAPLUS
CN	3H-Imidazo[4,5-b]pyridine, 3-[(4-methylphenyl)methyl]-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




IT 99960-00-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-carbamoylation and reductive N-alkylation reactions of)
RN 99960-00-6 CAPLUS
CN 1-Piperidineethanamine, 4--[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1988:21891 CAPLUS
DOCUMENT NUMBER: 108:21891
TITLE: Preparation of piperidinylaminobenzimidazoles and-
imidazole pyridines as allergy inhibitors
INVENTOR(S): Janssens, Frans E.; Nens, Jozef F.; Torremans, Joseph
L. G.; Heykants, Jozef J. P.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXDXW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 232937	A2	19870819	EP 1987-200128	19870128
EP 232937	A3	19880406		
EP 232937	B1	19920919		
US 4815161	RE, AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE	19860516		19870121
AT 79620	E	19920915	AT 1987-200128	19870128
CA 1127579	A1	19940308	CA 1987-528342	19870128
ES 2052544	T3	19940716	ES 1987-200128	19870128
DK 8700541	A	19870804	DK 1987-541	19870202
FI 8700448	A	19870804	FI 1987-448	19870202
NO 8700407	A	19870804	NO 1987-448	19870202
AO 8768218	A1	19870806	AO 1987-66218	19870202
AU 583706	B2	19890504		
JP 62215575	A2	19870922	JP 1987-20600	19870202
JP 07094393	B4	19951011		
HU 44544	A2	19860328	HU 1987-354	19870202
HU 201067	B	19900928		
IT 7400744	A	19861026	ZA 1987-744	19870202
IL 81448	A1	19900917	IL 1987-81448	19870202
CN 87100563	A	19870819	CN 1987-100563	19870203
CN 1018614	B	19921014		
JP 07179458	A2	19950718	JP 1994-260917	19941003
JP 08019126	B4	19960228		
PRIORITY APPLN. INFO.:			US 1986-825491	A 19860203
			EP 1987-200128	A 19870128

OTHER SOURCE(S) : CASREACT 108:21891
GI



AB The title compds. [I; R = H, alkyl; R1 = H, alkyl, cycloalkyl, (hetero)aryl, arylalkyl; R2 = H, alkyl, cycloalkyl, alkylcarbonyl,

04/28/2006


Habte

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
alkoxycarbonyl, (hetero)arylalkyl; R3 = H, alkoxycarbonyl, phenylmethoxycarbonyl; A1-A4 = (substituted) CH:CH-CH:CH, N:CH-CH:CH, CH:N-CH:CH] were prepd. as antihistaminics and serotonin antagonists. Et 4-amino-1-piperidinecarboxylate and 2-chloro-1-(4-fluorophenylmethyl)-1H-benzimidazole were heated at 120° with stirring for 43 h to give 40.5% Et 4-[[1-(4-fluorophenyl)methyl]-1H-benzimidazole-2-ylamino]-1-piperidinecarboxylate. The latter was treated with 48% HBr for 1 h to give 82% 1-[[4-(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazole-2-amine, 2HBr (II). The latter inhibited compd. 48/80-induced lethality in rate with an ED50 of 0.056 mg/kg.

IT 73733-99-0P 73734-02-8P 73734-21-1P
73734-27-7P 75978-98-2P 90518-52-8P
90518-56-2P 90518-66-4P 90518-75-5P
99139-10-3P 110588-56-2P 111921-82-5P
111921-83-6P 111921-84-7P 111921-91-6P
111921-92-7P 111921-93-8P 111921-94-9P
111921-95-0P 111921-97-2P 111921-98-3P
111922-01-1P 111922-03-3P 111922-04-4P
111922-05-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as allergy inhibitor)

RN 73733-99-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-ylamino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 73734-02-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 90518-52-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90518-56-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90518-66-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73734-21-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 73734-27-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-((4-fluorophenyl)methyl)-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 75978-98-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-ylamino]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 90518-75-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-pyridinylmethyl)-, trihydrobromide (9CI) (CA INDEX NAME)




● 3 HBr

RN 99139-10-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-thienylmethyl)-, trihydrobromide (9CI) (CA INDEX NAME)




RN 110588-56-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[5-methyl-2-furanylmethyl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 111921-82-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-((3-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 111921-83-6 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-((2-methyl-3-furanyl)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 111921-84-7 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-((5-ethyl-2-furanyl)methyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 110-16-7
 CMP C4 H4 O4

Double bond geometry as shown.



RN 111921-93-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 111921-94-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(2-methyl-3-furanyl)methyl]-N-4-piperidinyl-, (2R,3R)-2,3-dihydroxybutanedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 90518-66-4
 CMP C16 H19 N5 O




CM 2

CRN 87-69-4
 CMP C4 H6 O6

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 111921-91-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(3-furanylmethyl)-N-4-piperidinyl-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)



RN 111921-92-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 90518-66-4
 CMP C16 H19 N5 O




CM 2

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 111921-95-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(3-furanylmethyl)-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 111921-97-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(2-methyl-3-furanyl)methyl]-N-4-piperidinyl-, (9CI) (CA INDEX NAME)




RN 111921-98-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-ethyl-2-furanyl)methyl]-N-4-piperidinyl-, (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 111922-01-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(3-methyl-2-furanyl)methyl]-N-4-piperidinyl-, (9CI) (CA INDEX NAME)




RN 111922-03-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 111922-04-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl-, dinitrate (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Double bond geometry as shown.

L4 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 110588-56-2
 CMF C17 H21 N5 O




CM 2
 CRN 7697-37-2
 CMF H N O3



RN 111922-05-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(5-methyl-2-furanyl)methyl]-N-4-piperidinyl-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1
 CRN 110588-56-2
 CMF C17 H21 N5 O




CM 2
 CRN 110-16-7
 CMF C4 H4 O4

L4 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:564641 CAPLUS
 DOCUMENT NUMBER: 105:164641
 TITLE: Oral antiallergic activity in ascaris hypersensitive dogs: a study of known antihistamines and of the new compounds ramastine (R 57 959) and levocabastine (R 50 547)
 AUTHOR(S): Awouters, Frans; Vermeire, Jozef; Smeyers, Frans; Vermote, Patrick; Van Beek, Rene; Niemegeers, Carlos J. E.
 CORPORATE SOURCE: Dep. Pharmacol., Janssen Pharm. Res. Lab., Beerse, B-2340, Belg.
 SOURCE: Drug Development Research (1986), 8(1-4), 95-102
 CODEN: DDREDK; ISSN: 0272-4391
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The antiallergic effectiveness of 12 compds. was studied in ascaris hypersensitive dogs by measuring allergen-induced skin reactions before and 1, 4, 20, and 72 h after oral treatment. The specific serotonin S2-antagonist ritanserin [87051-43-2] at 2.5 mg/kg and the selective histamine H2-antagonist cimetidine [51481-61-9] at 10 mg/kg did not reduce the allergic wheals. Chlorpheniramine [113-92-8] and clemastine [15686-51-8] were inactive at 2.5 mg/kg. The remaining 8 compds. studied over a wide dose range produced peak activity at markedly different doses and time intervals. The lowest oral ED50 values in mg/kg were: levocabastine [79516-68-0]: 0.0035; R 57 959 [99156-66-8]: 0.048; astemizole [68844-77-9]: 0.13; ketotifen [34580-13-7]: 0.20; cyproheptadine [129-03-3]: 0.21; azatadine [3964-81-6]: 0.32; oxatomide [60607-34-3]: 1.26; and terfenadine [50679-08-8]: 1.26. The lowest oral ED50 values in dogs and in rats (compound 48/80 lethality test) were similar, the largest difference being a 4-fold potency gain of oxatomide in dogs. The short-acting compds. in rats (azatadine, cyproheptadine, ketotifen, and terfenadine) had also a duration of action of <12 h in dogs. Levocabastine, R 57 959, astemizole, and oxatomide acted for >16 h. Maximal inhibition of the allergic wheal vols. was highest with levocabastine (90%); it reached 80% with R 57 959, and ranged from 67 to 78% with the remaining compds. On the basis of their activity characteristics in dogs, levocabastine and R 57 959 are potentially very effective anti-allergic drugs.
 IT 99156-66-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiallergic activity of, in ascaris hypersensitive dogs)
 RN 99156-66-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[(3-(2-furanyl)methyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-2-methyl-, (9CI) (CA INDEX NAME)

L4 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:68861 CAPLUS
 DOCUMENT NUMBER: 104:68861
 TITLE: (Piperidinylmethyl)- and (piperidinylloxy)benzimidazole
 s and -imidazopyridines
 INVENTOR(S): Janssens, Frans Eduard; Kennis, Ludo Edmond
 Josephine;
 Hens, Jozef Francis; Torremans, Joseph Leo G.; Diels, Gaston Stanislas M.
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 140 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 151826	A1	19850821	EP 1984-201851	19841213
EP 151826	B1	19930331		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 87626	E	19930415	AT 1984-201851	19841213
ES 539281	A1	19870616	ES 1984-539281	19841231
AU 8537364	A1	19850912	AU 1985-37364	19850107
AU 573673	B2	19880616		
CA 1259609	A1	19890919	CA 1985-471589	19850107
DK 8500089	A	19850710	DK 1985-89	19850108
FI 8500079	A	19850710	FI 1985-79	19850108
FI 81867	B	19910531		
FI 81867	C	19910910		
NO 8500085	A	19850710	NO 1985-85	19850108
NO 160849	B	19890227		
NO 160849	C	19890607		
JP 60185777	A2	19850921	JP 1985-479	19850108
JP 07068240	B4	19950726		
HU 36471	A2	19850930	HU 1985-61	19850108
HU 200338	B	19900528		
ZA 8500187	A	19860827	ZA 1985-187	19850108
RO 90622	B3	19861210	RO 1985-117252	19850108
SU 1395964	A3	19880515	SU 1985-3836858	19850108
IL 74018	A1	19880831	IL 1985-74018	19850108
PL 145710	B1	19881031	PL 1985-251488	19850109
PRIORITY APPLN. INFO.:			US 1984-569369	A 19840109
			US 1984-671135	A 19841113
			EP 1984-201851	A 19841213


GI

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. I (Z-Z3 = CH, or one of Z-Z3 is N and the remainder are CH; Z4 = CH2, O, S, SO, SO2; R = alkyl, aryl, heteroaryl-, acyl-, hydroxy-, aryloxy, heteroaryloxy-, alkoxy-, arylthio-, carbonyl-, carboalkoxy-, cyano-, amino-, ureido-, thioureido-, or guanidinoalkyl, cycloalkyl, alkenyl, arylalkenyl; R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl, aryl- or heteroarylalkyl, which were prepared, exhibited antihistaminic activity. Thus, a mixture of 2-(4-MeC6H4CH2NH)C6H4NH2 and Et 1-benzyl-4-piperidineacetimidate hydrochloride in MeOH was refluxed and NH3 was added to give benzimidazole II.

IT 9959-97-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antihistaminic activity of)
 RN 9959-97-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(2-isothiocyanatoethyl)-4-piperidinyl]methyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




IT 99944-14-6P 99944-22-6P 99958-67-5P
 99958-69-7P 99958-76-6P 99958-81-3P
 99958-82-4P 99958-97-1P 99959-00-9P
 99959-01-0P 99959-07-6P 99959-08-7P
 99959-09-8P 99959-11-2P 99959-26-9P
 99959-27-0P 99959-33-8P 99959-36-1P
 99959-37-2P 99959-39-4P 99959-54-3P
 99959-55-4P 99959-56-5P 99959-57-6P

Habe

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

99959-58-7P 99959-59-8P 99959-61-2P
 99959-62-3P 99959-64-5P 99959-66-7P
 99959-75-8P 99959-77-0P 99960-80-2P
 99960-81-3P 99960-87-9P 99960-91-5P
 99960-93-9P 99961-01-0P 99961-03-2P
 99961-05-4P 99961-13-4P 99961-14-5P
 99961-37-2P 99961-42-9P 99961-57-6P
 99961-59-8P 99961-61-2P 99961-65-6P
 99961-73-6P 99961-75-8P 99961-80-5P
 99961-82-7P 99961-84-9P 99961-89-4P
 99962-03-5P 99962-24-0P 99962-28-4P
 99962-35-3P 99962-39-7P 99962-58-0P
 99962-59-1P 99962-73-9P 99962-78-4P
 99962-80-8P 99962-85-3P 99962-88-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and antihistaminic activity of)
 RN 99944-14-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 99944-22-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[(4-piperidinylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)
 CM 1
 CRN 99944-21-5
 CMF C19 H21 F N4

04/28/2006


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 99958-67-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[(1-methylethyl)-4-piperidinylmethyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 99958-66-4
CMF C22 H27 F N4

CM 2

CRN 144-62-7
CMF C2 H2 O4


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99958-81-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[(1-(2-(2-pyridinyl)ethyl)-4-piperidinyl)methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)



RN 99958-82-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[(1-(2-(2-pyridinyl)ethyl)-4-piperidinyl)methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99958-81-3
CMF C26 H28 F N5

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99958-69-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[(1-methyl-4-piperidinyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-68-6
CMF C20 H23 F N4

CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 99958-76-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[(1-cyclohexyl-4-piperidinyl)methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99958-75-5
CMF C25 H31 F N4


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 99958-97-1 CAPLUS
CN 1-Piperidineethanol, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 99959-00-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[(1-(2-(2-thienyl)ethyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99959-01-0 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(2-thienyl)ethyl]-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99959-07-6 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-06-5
 CMF C25 H32 F N5 O

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 99959-11-2 CAPLUS
 CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-(1-methylethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-10-1
 CMF C24 H30 F N5 O



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 99959-26-9 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(2-propenyl)ethyl]-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 99959-08-7 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 2-[[1-[2-(2-ethoxyethyl)-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 99959-09-8 CAPLUS
 CN 1-Butanone, 1-(4-(4-fluorophenyl)-4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

RN 99959-27-0 CAPLUS
 CN 1-Piperidinepropanamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 99959-33-8 CAPLUS
 CN 3H-imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[2-(phenylthio)ethyl]-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-32-7
 CMF C27 H29 F N4 S

04/28/2006


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 99959-36-1 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,7-dimethyl- (9CI) (CA INDEX NAME)



RN 99959-37-2 CAPLUS

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99959-54-3 CAPLUS
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,7-dimethyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 99959-39-4 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[3-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]-1,3-dihydro-, ethanediolate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99959-38-3
CMF C27 H30 N6 O2

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




● 3 HCl

RN 99959-55-4 CAPLUS
CN 2,4-[[1H,3H]-Quinazolin-2(1H)-one, 3-[3-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99959-56-5 CAPLUS
 CN 2,4-bis(2-furanylmethyl)-3H-imidazo[4,5-b]pyridine-1-piperidinylethyl-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99959-57-6 CAPLUS
 CN 2,4-bis(2-furanylmethyl)-3H-imidazo[4,5-b]pyridine-1-piperidinylethyl-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




RN 99959-58-7 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-7-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl


RN 99959-61-2 CAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-3,7-dihydro-1,3-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




● 3 HCl

RN 99959-59-8 CAPLUS
 CN 2H-1-Benzopyran-2-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-, dihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



● 2 HCl

RN 99959-62-3 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 99959-64-5 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-3,4-dihydro-8-methyl-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-63-4
 CMF C27 H32 N6 O2 S




L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 99959-66-7 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-2-methyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-65-6
CMF C28 H30 N6 O2

CM 2

CRN 144-62-7
CMF C2 H2 O4


RN 99959-75-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-74-7


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99960-80-2 CAPLUS
CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,4-dihydro-8-methyl-, ethanedioate (1:2) (9CI) (CA INDEX NAME)



RN 99960-81-3 CAPLUS
CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-3,4-dihydro-8-methyl-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 99960-80-2
CMF C29 H33 F N6 O 5

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99960-87-9 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]-, ethanedioate (2:3) (9CI) (CA INDEX NAME)

Hatte


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C26 H30 N4 O2

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99959-77-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]methyl]-3-(phenylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 99959-76-9
CMF C28 H32 N4 O

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 1

CRN 99960-86-8
CMF C27 H30 N6 O 5

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99960-91-5 CAPLUS
CN 2,4-(1H,3H)-Quinoxalinedione, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99960-95-9 CAPLUS

04/28/2006

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[[3-[[4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99960-94-8
 CMF C29 H30 F2 N4 O



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.




RN 99961-01-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)methyl]-3-(2-pyridinylmethyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-00-9
 CMF C27 H31 N5 O




L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 99961-04-3
 CMF C26 H30 N4 O S




CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 99961-13-4 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-methyl-3-[2-(4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 99961-14-5 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[2-(4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




Habte

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 99961-03-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-(4-fluorophenyl)methyl]-2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-02-1
 CMF C28 H31 F N4 O



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 99961-05-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl)methyl]-3-(2-thienylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99961-37-2 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 99961-42-9 CAPLUS
 CN 1H-Benzimidazol-2-amine, N-[2-[4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 99961-57-6 CAPLUS
 CN 2-Pyrimidinamine, N-[2-[4-[[3-(2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-56-5
 CMF C23 H27 N7 O



04/28/2006


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99961-59-8 CAPLUS
CN 2-Pyrimidinamine,
N-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-, ethanedioate (2:7) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-58-7
CMF C24 H28 N8

CM 2

CRN 144-62-7
CMF C2 H2 O4


RN 99961-61-2 CAPLUS
CN 2-Pyrimidinamine,
N-[2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-60-1


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99961-73-6 CAPLUS
CN 1-Piperidineethanamine,
4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 99961-75-8 CAPLUS
CN 1-Piperidineethanamine,
4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-thiazolyl-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-73-6
CMF C22 H26 N6 O S

CM 2


CRN 144-62-7
CMF C2 H2 O4

RN 99961-80-5 CAPLUS
CN 1-Piperidineethanamine, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-thiazolyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-79-2
CMF C24 H27 F N6 S


Habte

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C23 H27 N7 S

CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 99961-65-6 CAPLUS
CN 2-Pyrimidinamine, N-[2-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)


CM 1

CRN 99961-64-5
CMF C25 H29 N7

CM 2

CRN 144-62-7
CMF C2 H2 O4

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 99961-82-7 CAPLUS
CN 1-Piperidineethanamine, N-2-thiazolyl-4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-81-6
CMF C22 H26 N6 S2

CM 2


CRN 144-62-7
CMF C2 H2 O4

04/28/2006

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 99961-84-9 CAPLUS
 CN 1-Piperidineethanamine, 4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-2-thiazolyl-, ethanedioate (2:7) (9CI) (CA INDEX NAME)

CM 1

CRN 99961-83-8
 CMF C24 H28 N6 S




CM 2

CRN 144-62-7
 CMF C2 H2 O4



RN 99961-89-4 CAPLUS
 CN 1-Piperidineethanamine, 4-[[3-[(4-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-2-thiazolyl-, trihydrochloride (9CI) (CA INDEX NAME)




RN 99962-03-5 CAPLUS
 CN 2-Pyrimidinamine, N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 99962-02-4
 CMF C25 H28 F N7

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 99962-27-3
 CMF C25 H28 N8 O



PAGE 1-A




PAGE 2-A

CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 99962-35-3 CAPLUS
 CN Urea, N-ethyl-N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

Hahte


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 99962-24-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-(4-fluorophenyl)methyl]-2-[[1-[2-(2-pyridinylmethoxy)ethyl]-4-piperidinyl)methyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl


RN 99962-28-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99962-39-7 CAPLUS
 CN 3-Furancarboxamide, N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)



RN 99962-58-0 CAPLUS
 CN Urea, N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-N,N-dimethyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)



RN 99962-59-1 CAPLUS
 CN Urea, N'-[2-[4-[[3-[(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-N,N-dimethyl-, ethanedioate (2:5) (9CI)


04/28/2006

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)

CM 1

CRN 99962-58-0

CMF C24 H31 F N6 O




CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 99962-73-9 CAPLUS
CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-2-thioxo- (9CI)
(CA INDEX NAME)




RN 99962-78-4 CAPLUS

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
piperidinylethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99962-84-2

CMF C30 H35 N7 O




CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 99962-88-6 CAPLUS
CN 2,4-(1H,3H)-Quinazolinone, 3-[4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)



IT 99960-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation of, with acetic anhydride)


RN 99960-07-3 CAPLUS
CN Benzamide, 2-amino-N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzamide,
N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-(methylamino)-, ethanedioate (2:5) (9CI)
(CA INDEX NAME)

CM 1

CRN 99962-77-3

CMF C29 H33 F N6 O




CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 99962-80-8 CAPLUS
CN Benzamide,
2-amino-N-[2-[4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 99962-85-3 CAPLUS
CN 4(1H)-Quinazolinone, 2,3-dihydro-2,2-dimethyl-3-[2-[4-[[3-[(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 99944-21-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-alkylation of, by (bromoethyl)pyrimidothiazine derivative)

RN 99944-21-5 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 99959-35-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-alkylation of, by (chloroethyl)thiazolopyrimidine derivative)


RN 99959-35-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 99959-90-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-arylation of, by bromothiazole)

RN 99959-90-7 CAPLUS

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 1-Piperidineethanamine,
 CN 4-[[3-(5-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




IT 99953-71-6P 99953-72-7P 99953-74-9P
 99953-76-1P 99953-80-7P 99953-84-1P
 99953-94-3P 99953-98-7P 99954-03-7P
 99954-17-3P 99955-85-0P 99960-29-9P
 99960-30-2P 99960-32-4P 99960-34-6P
 99960-47-1P 99960-52-8P 99960-62-0P
 99960-65-3P 99960-67-5P 99963-28-7P
 99963-30-1P 99963-37-8P 99963-39-0P
 99963-41-4P 99963-45-8P 99963-46-9P
 99963-48-1P 99963-51-6P 99963-55-0P
 100015-33-6P 100015-35-8P 100015-38-1P
 100015-48-3P 100015-51-8P 100015-53-0P
 100015-54-1P 100015-59-6P 100015-60-9P
 100015-78-9P 100015-79-0P 100015-84-7P
 100015-86-9P 100015-88-1P 100015-90-5P
 100015-91-6P 100015-93-7P 100015-94-9P
 100016-07-7P 100016-08-8P 100016-12-4P
 100016-14-6P 100016-17-9P 100016-19-1P
 100016-20-4P 100165-76-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 99953-71-6 CAPLUS
 CN 2,4-(1H,3H)-Quinoxalinedione, 3-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99953-76-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl)methyl]-3-(2-pyridinylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-75-0
 CMF C34 H35 F2 N5



CM 2

CRN 144-62-7
 CMF C2 H2 O4




RN 99953-80-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl)methyl]-3-[[4-(4-fluorophenyl)methyl]-1-piperidinyl]ethyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-79-4
 CMF C35 H35 F3 N4

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 99953-72-7 CAPLUS
 CN 2,4-(1H,3H)-Quinoxalinedione, 3-[[2-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99953-74-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl)methyl]-3-(2-furanylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 99953-73-8
 CMF C33 H34 F2 N4 O



CM 2

CRN 144-62-7
 CMF C2 H2 O4

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
 CMF C2 H2 O4



RN 99953-84-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl)methyl]-3-(phenylmethyl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-83-0
 CMF C35 H36 F2 N4



CM 2

CRN 144-62-7
 CMF C2 H2 O4


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99953-94-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinylmethyl]-3-(2-thienylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-93-2
 C26 H28 N4 O2 S



CM 2

CRN 144-62-7
 C2 H2 O4



RN 99953-98-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinylmethyl]-3-(2-pyridinylmethyl)-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 99953-97-6
 C27 H29 N5 O2


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99954-17-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinylmethyl]-3-(2-thienylmethyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 99954-16-2
 C33 H34 F2 N4 S




CM 2

CRN 144-62-7
 C2 H2 O4




RN 99959-85-0 CAPLUS
 CN 1-Piperidineacetoneitrile, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 99960-29-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(phenylmethyl)-4-piperidinylmethyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 144-62-7
 C2 H2 O4



RN 99954-03-7 CAPLUS
 CN 5H-Thiazolo[3,2-e]pyrimidin-5-one, 6-[[2-[[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylmethyl]-2,3-dihydro-7-methyl-, ethanedioate (2:5) (9CI) (CA INDEX NAME)

CM 1


CRN 99954-02-6
 C28 H31 F N6 O S




CM 2

CRN 144-62-7
 C2 H2 O4


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99960-30-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-[[1-(phenylmethyl)-4-piperidinylmethyl]- (9CI) (CA INDEX NAME)




RN 99960-32-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-(phenylmethyl)-4-piperidinylmethyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 99960-34-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-methoxyphenyl)methyl]-2-[[1-(phenylmethyl)-4-piperidinylmethyl]- (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99960-47-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-methoxyphenyl)methyl]-2-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 99960-52-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-(4-piperidinylmethyl)-3-(2-pyridinylmethyl)-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99960-51-7
 CMF C18 H21 N5




L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99960-67-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-(4-piperidinylmethyl)-3-(2-thienylmethyl)-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99960-66-4
 CMF C17 H20 N4 S



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 99963-28-7 CAPLUS
 CN 1-Piperidineethanol, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, (2E)-2-butenedioate (2:3) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 99963-27-6
 CMF C20 H25 N5 O




Habte

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 99960-62-0 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 99960-65-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(2-furanylmethyl)-2-(4-piperidinylmethyl)-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-35-0
 CMF C17 H20 N4 O



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



RN 99963-30-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-fluorophenyl)methyl]-2-[[1-[(1-naphthalenyloxy)methoxy]ethyl]-4-piperidinylmethyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99963-29-8
 CMF C32 H33 F N4 O2



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 99963-37-8 CAPLUS
 CN 5H-Tetrazol-5-one, 1-ethyl-4-[2-[4-[[3-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-1,4-dihydro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 99963-36-7
CMF C24 H29 F N8 O



CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 99963-39-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(1H-benzimidazol-2-yl)methyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:3) (9CI)
(CA INDEX NAME)

CM 1

CRN 99963-38-9
CMF C27 H27 F N6



L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CRN 99963-44-7
CMF C28 H29 F N4 O2




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 99963-46-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[[1-[(1H-benzimidazol-2-yl)methyl]-1H-benzimidazol-2-yl]methyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)



RN 99963-48-1 CAPLUS
CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Habte

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 99963-41-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[[3-(4-fluorophenoxy)propyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI)
(CA INDEX NAME)

CM 1

CRN 99963-40-3
CMF C28 H30 F2 N4 O



CM 2


CRN 144-62-7
CMF C2 H2 O4



RN 99963-45-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 2-[[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]methyl]-3-[(4-fluorophenyl)methyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99963-51-6 CAPLUS
CN 2H-Benzimidazol-2-one, 1-[[3-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]-1,3-dihydro-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 99963-50-5
CMF C29 H31 F N6 O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 99963-55-0 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[3-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]propyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)

04/28/2006

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 99963-54-9
CMF C29 H32 N6 O

CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 100015-32-6 CAPLUS
CN 3H-imidazo[4,5-b]pyridine, 3-[[4-(4-fluorophenyl)methyl]-2-[[1-[2-(phenylsulfonyl)ethyl]-4-piperidinyl)methyl]-, ethanedioate (2:3) (9CI) (CA INDEX NAME)


CM 1

CRN 100015-32-5
CMF C27 H29 F N4 O2 S

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 100015-38-1 CAPLUS
CN 1-Piperidineacetic acid, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 100015-48-3 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[[4-(4-methylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 100015-51-8 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 100015-35-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[[3-[[4-(4-fluorophenyl)methyl]-1H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]propyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 100015-34-7
CMF C28 H31 N7 O


CM 2

CRN 144-62-7
CMF C2 H2 O4


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 100015-53-0 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 100015-54-1 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[3-[[4-(4-methoxyphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 100015-59-6 CAPLUS
CN 1-Piperidineethanamine, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 99959-90-7
CMF C19 H25 N5 O


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-B
CMP C4 H4 O4


Double bond geometry as shown.




RN 100015-60-9 CAPLUS
CN 1-Piperidineethanamine,
4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 100015-78-9 CAPLUS
CN 1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 100015-86-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-{4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl}ethyl]-, ethanediolate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 100015-85-8
CMP C25 H28 N8 S


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 100015-79-0 CAPLUS

1-Piperidineacetamide, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-N-2-pyrimidinyl-, (2E)-2-butenedioate (1:2) (9CI)
(CA INDEX NAME)

CM 1


CRN 100015-78-9
CMP C25 H26 F N7 O



CM 2

CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



RN 100015-84-7 CAPLUS


1H-Imidazo[4,5-c]pyridin-2-amine, N-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinyl]ethyl]-, ethanedioate (1:4) (9CI) (CA INDEX NAME)

CM 1


CRN 100015-83-6
CMF C26 H29 N9

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



CM 2



CRN 144-62-7
CMP C2 H2 O4



RN 100015-88-1 CAPLUS

N-2-[4-[[3-[(4-methylphenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinyl]ethanedioate
 (1:5) (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1
CRN 100015-87-0
CMF C28 H32 N8CM 2
CRN 144-62-7
CMF C2 H2 O4RN 100015-90-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridin-2-amine,
N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, ethanedioate (2:5) (9CI) (CA INDEX NAME)CM 1
CRN 100015-89-2
CMF C27 H29 F N8



L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 100015-94-9 CAPLUS
CN 3-Pyridinecarboxamide,
N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, ethanedioate (1:3) (9CI) (CA INDEX NAME)CM 1
CRN 100015-93-8
CMF C27 H29 F N6 OCM 2
CRN 144-62-7
CMF C2 H2 O4RN 100016-07-7 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-2,3-dihydro-6-methyl-2-thioxo- (9CI) (CA INDEX NAME)


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2
CRN 144-62-7
CMF C2 H2 O4RN 100015-91-6 CAPLUS
CN 2-Pyridinemethanamine,
N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)RN 100015-92-7 CAPLUS
CN 2-Pyridinemethanamine,
N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)CM 1
CRN 100015-91-6
CMF C27 H31 F N6



CM 2

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A


RN 100016-08-8 CAPLUS
CN Benzamide, N-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)methyl]-1-piperidinylethyl]-2-(methylamino)- (9CI) (CA INDEX NAME)

RN 100016-12-4 CAPLUS

04/28/2006

Habte


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4(3H)-Quinazolinone, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl]- (9CI) (CA INDEX NAME)



RN 100016-14-6 CAPLUS
 CN 4(3H)-Quinazolinone, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2-methyl]-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1


CRN 100016-13-5
 CMP C28 H30 N6 O2



CM 2


CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 100016-17-9 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-1-methyl-2-thioxo-


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (9CI) (CA INDEX NAME)



RN 100016-19-1 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-1-methyl-2-thioxo- (9CI) (CA INDEX NAME)




RN 100016-20-4 CAPLUS
 CN 4(1H)-Quinazolinone, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-2,3-dihydro-2-thioxo- (9CI) (CA INDEX NAME)




RN 100365-76-2 CAPLUS
 CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-6-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 99959-85-0
 RL: RCT (Reactant); RACT (Reactant or reagent) (reduction of)
 RN 99959-85-0 CAPLUS
 CN 1-Piperidineacetone, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 99959-86-1
 RL: RCT (Reactant); RACT (Reactant or reagent) (saponification-decarboxylation of)
 RN 99959-86-1 CAPLUS
 CN Carbamic acid, [2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]methyl]-1-piperidinylethyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 99958-80-2
 RL: RCT (Reactant); RACT (Reactant or reagent) (N-alkylation of)
 RN 99958-80-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-(4-fluorophenyl)methyl]-2-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

IT 99959-82-7
 RL: RCT (Reactant); RACT (Reactant or reagent) (N-alkylation of, by chloroacetonitrile)
 RN 99959-82-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[[4-(4-methylphenyl)methyl]-2-(4-

L4 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
piperidinylmethyl)- (9CI) (CA INDEX NAME)



IT 99960-00-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-carbamoylation and reductive N-alkylation reactions of)
RN 99960-00-6 CAPLUS
CN 1-Piperidineethanamine, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
EP 1984-201611 A 19841107
CA 1984-468587 A3 19841126
FI 1984-4708 A 19841129
US 1987-56200 A3 19870601
US 1989-447312 A3 19891207

OTHER SOURCE(S): CASREACT 104:68856

GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R = H, cycloalkyl, pyridinyl, pyrazinyl, alkyl-(un)substituted furanyl, thiazolyl, imidazolyl, halo-(un)substituted thienyl, (un)substituted alkyl, Ph; R1 = H, alkyl, cycloalkyl, alkanoyl, alkoxy-carbonyl, (un)substituted phenylalkyl; R2 = H, alkyl; R3 = alkyl, pyrrolidinyl, piperidinyl, homopiperonyl, each substituted by a group containing a bicyclic heterocyclic moiety; X = atoms required to complete an (un)substituted C6H6 or pyridine ring] (>150 in all) were prepared. Thus, 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine was alkylated by heating at 70° with 6-(2-bromoethyl)-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidin-5-one-HBr in DMP containing Na2CO3 to give 62.8% II.
II had antihistaminic activity in rats, counteracting the lethality of compound 48/80 with an ED50 of 0.31 mg/kg s.c. or orally, and inhibiting gastric lesions caused by the same agent with an ED50 of 0.63 mg/kg orally.


IT 99156-66-8P 99156-69-1P 99156-71-5P
99156-73-7P 99156-76-0P 99156-77-1P
99156-81-7P 99156-82-8P 99156-83-9P
99156-84-0P 99156-88-4P 99156-89-5P
99156-91-9P 99156-95-3P 99156-99-7P
99157-00-3P 99157-01-4P 99157-02-5P
99157-03-6P 99157-04-7P 99157-08-1P
99157-09-2P 99157-10-5P 99157-13-8P
99157-14-9P 99157-15-0P 99157-20-7P
99157-21-0P 99157-24-1P 99157-28-5P
99157-37-6P 99157-38-7P 99157-39-8P
99157-40-1P 99157-44-5P 99157-45-6P
99157-46-7P 99157-47-8P 99157-48-9P
99157-49-0P 99157-73-0P 99157-74-1P
99157-75-2P 99157-80-9P 99157-81-0P
99157-11-6P 99157-02-1P 99157-03-2P
99157-25-6P 99157-26-7P
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihistaminic activity of)
RN 99156-66-8 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-[(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1986:68856 CAPLUS
DOCUMENT NUMBER: 104:68856
TITLE: Bicyclic heterocyclic containing N-(bicyclic heterocyclic)-4-piperidinamines
INVENTOR(S): Janssens, Frans Eduard; Torremans, Joseph Leo; Ghislanus, Mens; Jozef Francis; Van Offenwert, Theophilus Theresia J. M.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 106 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 144101	A2	19850612	EP 1984-201611	19841107
EP 144101	A3	19850724		
EP 144101	B1	19910206		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4695569	A	19870922	US 1984-660608	19841012
AT 60769	E	19910215	AT 1984-201611	19841107
SU 1500162	A3	19890807	SU 1984-3814401	19841123
CA 1257258	A1	19890711	CA 1984-468587	19841126
CZ 281114	B6	19960612	CZ 1984-9128	19841128
SK 278443	B6	19970507	SK 1984-9128	19841128
DK 8405678	A	19850531	DK 1984-5678	19841129
FI 8404708	A	19850531	FI 1984-4708	19841129
FI 80446	B	19900228		
FI 80446	C	19900611		
NO 8404755	A	19850531	NO 1984-4755	19841129
NO 164171	B	19900528		
NO 164171	C	19900905		
AU 8436028	A1	19850606	AU 1984-36028	19841129
AU 579121	B2	19881117		
JP 60149583	A2	19850807	JP 1984-250660	19841129
JP 06092389	B4	19941116		
ZA 8409331	A	19860730	ZA 1984-9331	19841129
IL 73686	A1	19880531	IL 1984-73686	19841129
PL 146377	B1	19890131	PL 1984-250633	19841129
HU 35567	O	19850729	HU 1984-4444	19841130
HU 1990328	B			
RO 90414	B3	19861210	RO 1984-116474	19841130
US 4888426	A	19891219	US 1987-56200	19870601
SU 1694064	A3	19911123	SU 1987-4203318	19870917
CA 1330081	A1	19940607	CA 1988-564954	19880422
FI 8804037	A	19880901	FI 1988-4037	19880901
FI 84070	B	19910628		
FI 84070	C	19911010		
US 5025014	A	19910618	US 1989-447312	19891207
US 5126339	A	19920630	US 1991-671338	19910319
PRIORITY APPLN. INFO.:			US 1983-556742	A 19831130
			US 1984-660608	A 19841012

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 99156-69-1 CAPLUS
CN Thieno[2,3-b]pyridin-4(3aH)-one, 3,6-dimethyl-5-[2-[4-[[3-[(tetrahydro-2-furanyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 99156-71-5 CAPLUS
CN 1H-Purine-2,6-dione, 1-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl]-3,7-dihydro-3,7-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99156-73-7 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-3,4-dihydro-8-methyl- (9CI) (CA INDEX NAME)




RN 99156-76-0 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-3,4-dihydro-8-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 99156-83-9 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 99156-84-0 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 99156-88-4 CAPLUS
 CN 2,4-(1H,3H)-Quinoxalinedione, 3-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-2-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Habe

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99156-77-1 CAPLUS
 CN 2H,6H-Pyrimido[2,1-b][1,3]thiazin-6-one, 7-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-3,4-dihydro-8-methyl-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 99156-81-7 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-2,7-dimethyl- (9CI) (CA INDEX NAME)




RN 99156-82-8 CAPLUS

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)



RN 99156-89-5 CAPLUS
 CN 2,4-(1H,3H)-Quinoxalinedione, 3-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]- (9CI) (CA INDEX NAME)




RN 99156-91-9 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[(3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl)amino]-1-piperidinylethyl]-6,7-dihydro-7-methyl- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 99156-95-3 CAPLUS
 CN 2,4-(1H,3H)-Quinazolinodione, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl-, (9CI) (CA INDEX NAME)


PAGE 2-A




L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99156-99-7 CAPLUS
 CN 2,4-(1H,3H)-Quinazolinodione, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]hexahydro-1-methyl-, (9CI) (CA INDEX NAME)




RN 99157-00-3 CAPLUS
 CN 2,4-(1H,3H)-Quinazolinodione, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl-, (9CI) (CA INDEX NAME)




L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99157-01-4 CAPLUS
 CN 2,4-(1H,3H)-Quinazolinodione, 3-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1-methyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 99157-02-5 CAPLUS
 CN 2,4-(1H,3H)-Quinazolinodione, 3-[3-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)



RN 99157-03-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(7-methyl-5H-thiazolo[3,2-a]pyrimidin-6-yl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 99157-04-7 CAPLUS

Hatte


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99157-05-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(7-methyl-5H-thiazolo[3,2-a]pyrimidin-6-yl)ethyl]-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 99157-08-1 CAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl-, (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 99157-09-2 CAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl- (9CI) (CA INDEX NAME)




RN 99157-10-5 CAPLUS
 CN 1H-Purine-2,6-dione, 7-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-3,7-dihydro-1,3-dimethyl-, dihydrobromide (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 99157-15-0 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




Habte

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HBr


RN 99157-13-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




RN 99157-14-9 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A



RN 99157-20-7 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 99157-21-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99157-24-1 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2,7-dimethyl- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99157-28-5 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2,6,8-trimethyl- (9CI) (CA INDEX NAME)




RN 99157-37-6 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2,8-dimethyl- (9CI) (CA INDEX NAME)




RN 99157-38-7 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2,6,8-trimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99157-44-5 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2-methyl-3-[2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99157-45-6 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 99157-46-7 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2-methyl-3-[2-[4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 99157-39-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 99157-40-1 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-2,6,8-trimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99157-47-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 6,7,8,9-tetrahydro-2-methyl-3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99157-48-9 CAPLUS
 CN 2,4-(1H,3H)-Quinazolin-2(1H)-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99157-49-0 CAPLUS
 CN 2,4-(1H,3H)-Quinazolin-2(1H)-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99157-73-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-yl)ethyl]-4-piperidinyl]-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 99157-74-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-yl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 99157-75-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-yl)ethyl]-4-piperidinyl]-, ethanedioate (1:4) (9CI) (CA INDEX NAME)

CM 1

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CRN 99157-74-1
 CMP C26 H27 F N8



CM 2


CRN 144-62-7
 CMP C2 H2 O4




RN 99157-80-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-yl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 99157-81-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-[1-[2-(1H-imidazo[4,5-c]pyridin-2-yl)ethyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 99157-80-9
 CMP C24 H26 N8 O

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 99195-11-6 CAPLUS
 CN 5H-Thiazolo[3,2-a]pyrimidin-5-one, 6-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]aminol]-1-piperidinyl]ethyl]-3,7-dimethyl- (9CI) (CA INDEX NAME)


Habte

04/28/2006


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99228-02-1 CAPLUS
 CN 2H-Pyrido[1,2-a]pyrimidine-2,4(3H)-dione,
 3-[2-{4-[[3-(2-pyridinylmethyl)-
 3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl}- (9CI) (CA INDEX NAME)




RN 99228-03-2 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2,3-dihydro-2-methyl-3-[2-{4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl}- (9CI) (CA INDEX NAME)




RN 99436-25-6 CAPLUS


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 90518-56-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 90518-86-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 90518-86-8 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




IT 90519-11-2P 90519-13-4P 99158-33-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and N-acylation and N-alkylation of)
 RN 90519-11-2 CAPLUS
 CN 3H-imidazo[4,5-b]pyridin-2-amine,
 N-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Hahte

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 2,4(1H,3H)-Quinazolinodione,
 3-[2-{4-[[3-(3-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl}- (9CI) (CA INDEX NAME)




RN 99436-26-7 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-{4-[[3-(3-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl}-6,7,8,9-tetrahydro-2-methyl- (9CI) (CA INDEX NAME)




IT 90518-52-8P 90518-56-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and decarboxylation of)

RN 90518-52-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 90519-13-4 CAPLUS
 CN 3H-imidazo[4,5-b]pyridin-2-amine,
 N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 99158-33-5 CAPLUS
 CN 3H-imidazo[4,5-b]pyridin-2-amine,
 N-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-furanylmethyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 90519-20-3
 CMF C18 H24 N6 O




CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.

04/28/2006


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 90518-66-4P 90518-75-5P 99158-32-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and N-alkylation of)
 RN 90518-66-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 90518-75-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-pyridinylmethyl)-, trihydrobromide (9CI) (CA INDEX NAME)



● 3 HBr

RN 99158-32-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1986:50874 CAPLUS
 DOCUMENT NUMBER: 104:50874
 TITLE: N-(4-Piperidinyl) bicyclic condensed 2-imidazolamine derivatives
 INVENTOR(S): Janssens, Frans Eduard; Torremans, Joseph Leo Ghislainus; Hens, Jozef Francis; Van Offenwert, Theophilus Theresia Joannes
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
 SOURCE: Eur. Pat. Appl., 68 pp.
 CODEN: EPXKDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 151824	A2	19850821	EP 1984-201812	19841206
EP 151824	A3	19851009		
EP 151824	B1	19900404		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4588722	A	19860513	US 1984-660670	19841015
CA 1246070	A1	19881206	CA 1984-469245	19841204
AT 51421	E	19900415	AT 1984-201812	19841206
ES 539266	A1	19860116	ES 1984-539266	19841231
AU 8537363	A1	19850801	AU 1985-37363	19850107
AU 575612	B2	19880804		
JP 60174778	A2	19850909	JP 1985-251	19850107
RO 91075	B3	19870227	RO 1985-117231	19850107
PL 144514	B1	19880630	PL 1985-251476	19850107
DK 8500088	A	19850710	DK 1985-88	19850108
FI 8500078	A	19850710	FI 1985-78	19850108
FI 83781	B	19910515		
FI 83781	C	19910826		
NO 8500084	A	19850710	NO 1985-84	19850108
HU 37780	A2	19860228	HU 1985-62	19850108
HU 196389	B	19881128		
ZA 8500186	A	19860827	ZA 1985-186	19850108
IL 74017	A1	19880331	IL 1985-74017	19850108
SU 1400509	A3	19880530	SU 1985-3838812	19851008
NO 8902563	A	19850710	NO 1989-2563	19890621
PRIORITY APPLN. INFO.:				
			US 1984-660670	A 19841015
			EP 1984-201812	A 19841206
			NO 1985-84	A1 19850108

OTHER SOURCE(S): CASREACT 104:50874


G1 For diagram(s), see printed CA Issue.
 AB The title compds. [I; A = (un)substituted C6H6 or pyridine ring; R = H, alkyl; R1 = H, alkyl, cycloalkyl, aralkyl, (alkyl)furanyl, (alkyl)imidazolyl, (halo)thienyl, pyridinyl, pyrazinyl, thiazolyl, (un)substituted Ph; R2 = H, alkyl, cycloalkyl, aralkyl, alkanoyl, alkoxy-carbonyl; R3 = R4Z, (un)substituted saturated heterocyclyl; R4 = acyl, acylamino, acyloxy, acylthio, (un)substituted Ph, aryl, etc.; Z = alkylene] were prepared Thus 3-chloro-2-nitropyridine was aminolyzed with

Habr


L4 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 90518-90-4P 90518-91-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, reduction, and conversion of, to isothiocyanate)
 RN 90518-90-4 CAPLUS
 CN 1-Piperidineacetoneitrile, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 90518-91-5 CAPLUS
 CN 1-Piperidineacetoneitrile, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

4-FC6H4CH2NH2 and the product hydrogenated to give N3-[[4-(fluorophenyl)methyl]-2,3-pyridinediamine. This was condensed with Et 4-isothiocyanatopiperidinecarboxylate to give pyridinylthiourea deriv. II which was cyclized by heating in EtOH with HgO and S to give imidazopyridinamine III (R5 = CO2Et). The latter was decarboxylated by heating in 48% aq. HBr to give III.2HBr (R5 = H) which was alkylated with a p-methoxyphenethyl halide to give III (R5 = 4-MeOC6H4CH2CH2) (IV). I are antihistaminics. In mice IV inhibited compd. 48/80-induced lethality with an ED50 of 0.08 mg/kg s.c. or orally.
 IT 90518-66-4P 90518-75-5P 90518-13-4P
 99139-10-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and condensation reactions of)
 RN 90518-66-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 90518-75-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-pyridinylmethyl)-, trihydrobromide (9CI) (CA INDEX NAME)




● 3 HBr

RN 90519-13-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[[1-(2-aminoethyl)-4-piperidinyl]-3-[[4-(fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99139-10-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(4-(2-(thienylmethyl))-1-piperidinyl)- (9CI) (CA INDEX NAME)




IT 90518-52-8P 90518-56-2P 99780-66-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deethoxycarbonylation of)
 RN 90518-52-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 90518-56-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as antihistaminic)
 RN 99780-03-7 CAPLUS
 CN 2H-1-Benzopyran-2-one, 3-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 99780-10-6 CAPLUS
 CN 2H-1-Benzopyran-2-one, 3-[2-[4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 99780-11-7 CAPLUS
 CN 2H-1-Benzopyran-2-one, 3-[2-[4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




Habte


L4 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 99780-66-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 90518-86-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrogenation of)
 RN 90518-86-8 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




IT 99780-03-7P 99780-10-6P 99780-11-7P
 99780-59-3P 99796-67-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological)

L4 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 99780-59-3 CAPLUS
 CN 2H-1-Benzopyran-2-one, 3-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 99796-67-5 CAPLUS
 CN Carbamidothioic acid, N-cyano-N'-[2-[4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



04/28/2006

L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1985:615287 CAPLUS
 DOCUMENT NUMBER: 103:215287
 TITLE: Five membered heterocyclic ring containing
 N-(bicyclic

INVENTOR(S): heterocyclyl)-4-piperidinamines
 Janssens, Frans Eduard; Torremans, Joseph Leo
 Ghislaenus; Hens, Jozef Francis; Van Offenwert,
 Theophilus Theresia
 Janssen Pharmaceutica N. V., Belg.
 Eur. Pat. Appl., 76 pp.
 CODEN: EPXXDW

PATENT ASSIGNEE(S):
 SOURCE: Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 145037	A2	19850619	EP 1984-201326	19840914
EP 145037	A3	19850710		
EP 145037	B1	19890118		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4634704	A	19870106	US 1984-625343	19840627
CA 1247614	A1	19881227	CA 1984-462540	19840906
AT 40130	E	19890215	AT 1984-201326	19840914
IL 73118	A1	19880331	IL 1984-73118	19840930
RO 90457	B3	19861210	RO 1984-115894	19841004
DK 8404784	A	19850407	DK 1984-4784	19841005
DK 163239	B	19920210		
DK 163239	C	19920629		
FI 8402934	A	19850407	FI 1984-3934	19841005
FI 81797	B	19900831		
FI 81797	C	19901210		
NO 8404009	A	19850409	NO 1984-4009	19841005
NO 160441	B	19890109		
NO 160441	C	19890419		
AU 8433872	A1	19850418	AU 1984-33872	19841005
AU 565884	B2	19871001		
ES 536590	A1	19851116	ES 1984-536590	19841005
JP 61010577	A2	19860118	JP 1984-208394	19841005
JP 07098818	B4	19951025		
ZA 8407847	A	19860528	ZA 1984-7847	19841005
HU 38629	A2	19860630	HU 1984-3771	19841005
HU 207514	B	19930428		
SU 1440346	A3	19881123	SU 1984-3796140	19841005
PL 146228	B1	19890131	PL 1984-249916	19841005
PRIORITY APPLN. INFO.:			US 1983-539597	A 19831006
			US 1984-625343	A 19840627
			EP 1984-201326	A 19840914

OTHER SOURCE(S): CASREACT 103:215287
 GI For diagram(s), see printed CA Issue.
 AB The title compds. [I; R = H, alkyl; R1 = H, alkyl, thienyl, halothienyl,

L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 pyrazinyl, thiazolyl, alkylthiazolyl, imidazolyl, alkylimidazolyl,
 (un)substituted Ph, alkyl substituted by 1 or 2 of these arom. groups; R2
 = H, alkyl, cycloalkyl, alkanoyl, alkoxy carbonyl, (un)substituted Ph; R3

R4(CH2)nZZ1, R4(CH2)nZZ2(X1)ZZ1, Q; R4 = 5-membered heterocyclyl contg.
 21 N atoms, optionally fused to a C6H6 ring; X = (un)substituted
 CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N; X1 = O, S, O2NCH,
 RSH; R5 = H, alkyl, cyano, NO2, acyl; Z = O, S, R6 N, bond; R6 = H,
 alkyl


amino, acyl; Z1 = alkylene; Z2 = O, S, R7N, bond; R7 = H, alkyl; n = 0-6;
 m = 0-2) were prepd. Thus, N-(2-nitrophenyl)-2-furanmethanamine was
 hydrogenated and the diamine condensed with Et 4-isothiocyanato-1-
 piperidinecarboxylate to give thiourea deriv. II. This was cyclized to a
 benzimidazole deriv. by heating with HgO and S in EtOH, decarboxylated by
 heating in aq. HBr, and N-alkylated with 4-(chloromethyl)-5-methyl-1H-
 imidazole-HCl to give benzimidazolamine III. The antihistaminic
 properties of I were demonstrated in rats, where I inhibited the

lethality
 of compd. 48/80 with ED50 0.005-1.25 mg/kg s.c. or orally, and inhibit
 gastric lesions in rats caused by the same agent with ED50 0.04-1.25
 mg/kg
 s.c.

IT 99137-55-0P 99138-07-5P 99138-14-6P
 99138-13-5P 99138-16-6P 99138-17-7P
 99138-21-3P 99151-06-1P 99151-32-3P
 RL BAC (Biological activity or effector, except adverse); BSU


(Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and antihistaminic activity of)

RN 99137-55-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[3-(2-
 thiazolylamino)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 99138-07-5 CAPLUS
 CN 1,3,4-Thiadiazole-2,5-diamine, N-[2-{4-[(3-(2-pyridinylmethyl)-3H-
 imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl}ethyl]- (9CI) (CA INDEX
 NAME)

L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 99138-14-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-[2-(2-
 thiazolylamino)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 99138-15-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-[1-[2-(2-
 thiazolylamino)ethyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:2) (9CI)
 (CA INDEX NAME)

CM 1

CRN 99138-14-4
 CMF C21 H25 N7 O S




CM 2


CRN 110-17-8
 CMF C4 H4 O4

Hahte

L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 Double bond geometry as shown.




RN 99138-16-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-[2-(2-
 thiazolylamino)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 99138-17-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-[2-(2-
 thiazolylamino)ethyl]-4-piperidinyl]-, (2E)-2-butenedioate (1:3) (9CI)
 (CA INDEX NAME)

CM 1


CRN 99138-16-6
 CMF C22 H26 N8 S



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.




RN 99138-21-3 CAPLUS

04/28/2006


L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(2-thiazolylamino)ethyl)-4-piperidinyl]-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)



RN 99151-06-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-[(1-methyl-4-nitro-1H-imidazol-5-yl)amino]ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 99151-32-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-chlorophenyl)methyl]-N-[1-(2-(2-thiazolyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




IT 90518-66-4 90518-75-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and cyanoalkylation of)
 RN 90518-66-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 90518-86-8 90518-90-4 90518-91-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and lithium aluminum hydride reduction of)
 RN 90518-86-8 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 90518-90-4 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 90518-91-5 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 90518-75-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-pyridinylmethyl)-, trihydrobromide (9CI) (CA INDEX NAME)




● 3 HBr

IT 99139-10-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyanoalkylation of)
 RN 99139-10-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




IT 90518-52-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and decarboxylation of)
 RN 90518-52-8 CAPLUS


L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 99139-18-1P 99139-19-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and lithium aluminum hydride reduction of)
 RN 99139-18-1 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-(2-thienylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 99139-19-2 CAPLUS
 CN 1-Piperidinepropanenitrile, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




IT 90518-52-8 90518-53-1 90518-56-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation and N-alkylation and decarboxylation of)
 RN 90518-52-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 90518-55-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 90518-56-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




RN 99151-09-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(3-aminopropyl)-4-piperidinyl]-3-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 90519-11-2P 90519-13-4P 90519-21-4P
 99151-09-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and N-alkylation of)
 RN 90519-11-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 90519-13-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 90519-21-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(2-furanylmethyl)-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1

CRN 90519-20-3
 CMP C18 H24 N6 O


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1985:596032 CAPLUS
 DOCUMENT NUMBER: 103:196032
 TITLE: New antihistaminic N-heterocyclic 4-piperidinamines. 3. Synthesis and antihistaminic activity of N-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amine
 AUTHOR(S): Janssens, Frans; Torremans, Joseph; Janssen, Marcel; Stokbroekx, Raymond A.; Luyckx, Marcel; Janssen, Paul A. J.
 CORPORATE SOURCE: Res. Lab., N. V. Janssen Pharm., Beerse, B-2340, Belg.
 SOURCE: Journal of Medicinal Chemistry (1985), 28(12), 1943-7
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 103:196032
 GI




AB To study the bioisosteric replacement of a 2-pyridyl ring for a Ph nucleus in astemizole, a series of N-(4-piperidinyl)-3H-imidazo[4,5-b]pyridin-2-amines I [R = H, F; R1 = (un)substituted alkyl] was synthesized and evaluated. The title compds. were obtained starting from either I (R1 = H) by 4 synthetic methods. The in vivo antihistamine activity was evaluated by the compound 48/80-induced lethality test in rats and the histamine-induced lethality test in guinea pigs after oral and/or s.c. administration. Compound I (R = F, R1 = p-MeOC6H4CH2CH2), the isostere of astemizole, showed the most potent antihistaminic properties in the rat. However, astemizole is superior to I (R = F, R1 = p-MeOC6H4CH2CH2) as to duration of action and total potency.
 IT 73734-21-1P 73734-27-7P 75979-00-9P
 76031-50-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and alkylation of)
 RN 73734-21-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 73734-27-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 75979-00-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 76031-50-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-(4-piperidinyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(3-phenyl-2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-00-9 CAPLUS
 CN 5H-Tetrazol-5-one, 1-ethyl-4-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1,4-dihydro- (9CI) (CA INDEX NAME)



RN 73735-12-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-phenylethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-17-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-butyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-18-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-phenoxyethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

Habe


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 73734-48-2P 73734-60-8P 73734-78-8P
 73735-00-9P 73735-12-3P 73735-17-8P
 73735-18-9P 73735-19-0P 73735-21-4P
 73735-22-5P 73735-24-7P 73735-25-8P
 73735-26-9P 73735-27-0P 73735-33-8P
 73735-68-9P 73735-72-5P 73735-74-7P
 73735-94-1P 73735-95-2P 73735-99-6P
 73736-00-2P 73735-85-8P 73735-86-9P
 73735-88-1P 75970-98-8P 75971-13-0P
 98331-30-7P 98331-31-8P 98331-32-9P
 98331-33-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (Preparation and antihistaminic activity of)

RN 73734-48-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-phenylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73734-60-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73734-78-8 CAPLUS


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-19-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(3,3-diphenylpropyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-21-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-22-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-[1-(2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-24-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-morpholinyl)ethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




04/28/2006

L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 73735-25-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-[1-(3-phenyl-2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 73735-26-9 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-27-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-hexyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-33-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[3-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-94-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 73735-95-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-methyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-99-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-cyclohexyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73736-00-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(1-methylethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 73735-68-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-(2-thienyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-72-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-pyridinyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-74-7 CAPLUS
 CN Benzamide, 4-fluoro-N-[2-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73755-85-8 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 73755-86-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73755-88-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 75970-98-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 75971-13-0 CAPLUS
CN 1-Piperidineethanol, alpha-(phenoxyethyl)-4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 98331-30-7 CAPLUS
CN 1-Piperidinebutanamide, N,N-dimethyl-alpha,alpha-diphenyl-4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 98331-31-8 CAPLUS
CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-{4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinylethyl}- (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 98331-32-9 CAPLUS
CN 1-Piperidineacetamide, N-(2,6-dimethylphenyl)-4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 98331-33-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-{4,4-bis(4-fluorophenyl)butyl}-4-piperidinyl]-3-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 73733-99-OP 73734-02-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 73733-99-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 73734-02-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN




ACCESSION NUMBER: 1984:423473 CAPLUS
DOCUMENT NUMBER: 101:23473
TITLE: N-(Bicyclic heterocyclyl)-4-piperidinamines
INVENTOR(S): Janssens, Frans Eduard; Torremans, Joseph Leo
Ghislanus, Hens, Jozef Francis; Van Offenwert, Theophilus Theresia J. M.
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 87 pp.
DOCUMENT TYPE: CODEN: EPXXDW
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English
PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 99139	A2	19840125	EP 1983-200832	19830608
EP 99139	A3	19840222		
EP 99139	B1	19870211		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4556660	A	19851203	US 1983-487774	19830422
IN 156065	A	19850504	IN 1983-CA599	19830512
CA 1266267	A1	19900227	CA 1983-429869	19830607
AT 25459	E	19870215	AT 1983-200832	19830608
SU 1297728	A3	19870315	SU 1983-360869	19830627
DK 8303185	A	19840113	DK 1983-3185	19830711
FI 8302521	A	19840113	FI 1983-2521	19830711
FI 78480	B	19890428		
FI 78480	C	19890810		
NO 8302524	A	19840113	NO 1983-2524	19830711
NO 160850	B	19890227		
NO 160850	C	19890607		
JP 59021680	A2	19840203	JP 1983-124900	19830711
HU 32108	O	19840628	HU 1983-2471	19830711
HU 203550	B	19910828		
AU 8316728	A1	19850117	AU 1983-16728	19830711
AU 563363	B2	19870709		
ZA 8305044	A	19850227	ZA 1983-5044	19830711
RO 87533	B3	19851031	RO 1983-111600	19830711
ES 534029	A1	19851116	ES 1983-524029	19830711
IL 69198	A1	19870130	IL 1983-69198	19830711
PL 147092	B1	19890429	PL 1983-242970	19830712
US 4760074	A	19880726	US 1985-800587	19851121
US 4820822	A	19890411	US 1987-115272	19871102
US 33833	E	19920225	US 1990-619558	19901129
PRIORITY APPLN. INFO.:			US 1982-397626	A 19820712
			US 1983-487774	A 19830422
			EP 1983-200832	A 19830608
			US 1985-800587	A1 19851121
			US 1987-115272	A5 19871102

OTHER SOURCE(S):
G1

CASREACT 101:23473

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB About 100 antihistaminic title compds. I [R = substituted piperidinyl, substituted alkyl; R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, acyl, aralkyl; R3 = H, (un)substituted alkyl, cycloalkyl, aryl; X = CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N] were prepared. Thus N-piperidinylbenzimidazolamine II (R4 = 2-pyrimidinyl) (III) was prepared from 2-chloropyrimidine and II (R4 = H), which was prepared from N-piperidinylbenzimidazolamine IV. III had an ED50 of 0.63 mg/kg s.c. against stomach lesions induced by vasoactive amines in rats.


IT 90517-24-1P 90517-27-4P 90517-28-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antihistamine activity of)

RN 90517-24-1 CAPLUS


CN 3-Pyridinecarboxamide, 2-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 90517-27-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-(2-(2-pyrimidinylamino)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 90517-28-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-(2-(2-pyrimidinylamino)ethyl)-4-piperidinyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 90517-27-4

CMF C23 H27 N9




CM 2

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 90517-29-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-[1-(2-(2-pyrimidinylamino)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 90517-47-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-[(3-chloro-2-pyridinyl)amino]ethyl)-4-piperidinyl]-3-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




IT 90518-52-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deethoxycarbonylation of)

RN 90518-52-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 90518-90-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 90518-90-4 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)



IT 90517-23-0P 90517-28-5P 90518-12-0P

90518-13-1P 90518-55-1P 90518-56-2P

90518-66-4P 90518-75-5P 90518-86-8P


90518-91-5P 90519-11-2P 90519-13-4P

90519-21-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 90517-23-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-(2-pyridinylamino)ethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 90517-28-5 CAPLUS

04/28/2006

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-pyridinylmethyl)-N-[1-[2-(2-pyrimidinylamino)ethyl]-4-piperidinyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1


CRN 90517-27-4
 CHF C23 H27 N9




CM 2

CRN 110-17-8
 CHF C4 H4 O4

Double bond geometry as shown.




RN 90518-12-0 CAPLUS
 CN Thiourea, N-(4-amino-3-pyridinyl)-N'-[2-[4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 90518-13-1 CAPLUS
 CN Thiourea, N-(4-amino-3-pyridinyl)-N'-[2-[4-[[3-(4-fluorophenyl)methyl]-3H-


L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 90518-66-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-furanylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 90518-75-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-4-piperidinyl-3-(2-pyridinylmethyl)-, trihydrobromide (9CI) (CA INDEX NAME)




● 3 HBr

RN 90518-86-8 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 90518-55-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 90518-56-2 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[3-(2-pyridinylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 90518-91-5 CAPLUS
 CN 1-Piperidineacetonitrile, 4-[[3-(2-furanylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 90519-11-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 90519-13-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-aminoethyl)-4-piperidinyl]-3-[[4-(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 90519-21-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine,
 N-[1-(2-aminoethyl)-4-piperidinyl]-3-[(2-
 furanylmethyl)-, (2E)-2-butenedioate (1:3) (9CI) (CA INDEX NAME)

CM 1


CRN 90519-20-3
 CMP C18 H24 N6 O



CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.




IT 90519-52-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with pyrrolidinone)
 RN 90519-52-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-
 isothiocyanatoethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1981:30579 CAPLUS
 DOCUMENT NUMBER: 94:30579
 TITLE: N-Heterocyclol-4-piperidinamines
 INVENTOR(S): Janssens, Frans; Luyckx, Marcel; Stokbroekx, Raymond;
 Torremans, Joseph
 Janssen Pharmaceutica N. V., Belg.
 U.S., 27 pp. Cont.-in-part of U.S. Ser. No. 892,534,
 abandoned
 CODEN: USXQAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4219559	A	19800826	US 1979-2276	19790110
CA 1140119	A1	19830125	CA 1979-323763	19790319
AU 7945296	A1	19791018	AU 1979-45296	19790321
AU 523352	B2	19820722		
DK 7901298	A	19791004	DK 1979-1298	19790329
DK 169325	B1	19941010		
EP 5318	A1	19791114	EP 1979-300525	19790330
EP 5318	B1	19820106		
R: BE, CH, DE, FR, GB, IT, LU, NL, SE				
RO 79320	P	19820817	RO 1979-97082	19790330
FI 7901084	A	19791004	FI 1979-1084	19790402
FI 64801	B	19830930		
FI 64801	C	19840110		
NO 7901097	A	19791004	NO 1979-1097	19790402
NO 154058	B	19860401		
NO 154058	C	19860709		
JP 54151982	A2	19791129	JP 1979-38447	19790402
JP 01001477	B4	19890111		
ES 479206	A1	19791216	ES 1979-479206	19790402
ZA 7901557	A	19801126	ZA 1979-1557	19790402
IL 56992	A1	19830331	IL 1979-56992	19790402
AT 7902425	A	19830715	AT 1979-2425	19790402
AT 373887	B	19840227		
CS 256358	B2	19880415	CS 1979-2227	19790402
CS 256380	B4	19880415	CS 1984-3451	19790402
PL 123380	B1	19821030	PL 1979-214648	19790403
HU 25906	O	19830829	HU 1979-JA841	19790403
HU 182965	B	19840328		
SU 1056902	A3	19831123	SU 1979-2747000	19790403
AT 8204538	A	19830715	AT 1982-4538	19821214
AT 373888	B	19840227		
DK 8300831	A	19830224	DK 1983-831	19830224
DK 171841	B1	19970630		
ES 524224	A3	19841216	ES 1983-524224	19830719
NO 8402563	A	19791004	NO 1984-2563	19840625
NO 154090	B	19860407		
NO 154090	C	19860716		
ES 542804	A3	19851216	ES 1985-542804	19850503
JP 01117880	A2	19890510	JP 1988-144898	19880614
JP 02040666	B4	19900912		
PRIORITY APPLN. INFO.:			US 1978-892534	A2 19780403
			US 1979-2276	A 19790110

Habte

L4 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 US 1979-2279 A 19790110
 DK 1979-1298 A 19790329
 AT 1979-2425 A 19790402
 OTHER SOURCE(S): CASREACT 94:30579
 GI




AB 1-(4-Piperidinyl)-3-(2-aminophenyl)thioureas and heteroarom. analogs
 underwent cyclocondensation to give title compds. I [R = alkyl, halo-,
 hydroxy-, cyano-, isothiocyanato-, alkoxy-, aryl-, heteroaryl-, aryloxy-,
 (heteroaryl)oxy-, arylthio-, (heteroaryl)thio-, arylsulfonyl-,
 (heteroaryl)sulfonyl-, or aminoalkyl, alkenyl, aryl- or
 (heteroaryl)alkenyl, cycloalkyl, cyanocycloalkyl, aryl- or
 (heteroaryl)cycloalkyl, a 1H-benzimidazol-2-yl group, R5CmH2m [m = 1-6;
 RS = a 4,5-dihydro-5-oxo-1H-tetrazol-1-yl group,
 2,3-dihydro-1,4-benzodioxin-
 6-yl, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl, 2,3-dihydro-3-oxo-4H-1,4-
 benzoxazin-4-yl, (10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-
 ylidene)methyl, 4-morpholinyl, 1-piperidinyl, 1-pyrrolidinyl, mono- or
 disubstituted aminol; R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, aryl- or
 (heteroaryl)alkyl, alkanoyl; R3 = H, alkyl, aryl- or
 (heteroaryl)cycloalkyl, aryl- or (heteroaryl)alkyl, diaryl- or
 bis(heteroaryl)alkyl; Z = CH, N; n = 0, 1, 2; R4 = halo, alkyl, alkoxy,
 CF3], useful as antihistaminics (no data). A mixture of thiourea II and
 MeI
 in EtOH was refluxed 8 h to yield I (R = CO2Et, Z = CH, n = 0, R1 = R2 =
 R3 = H), the latter was converted to the resp. I (R = H), and the product
 was N-alkylated to give I (R = PhCH2CH2, Z = CH, n = 0, R1 = R2 = R3 =
 H).
 IT 73734-02-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and decarboxylation of)
 RN 73734-02-8 CAPLUS
 CN 1-Piperidinecarboxylic acid,
 4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-
 2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT	73733-99-0P
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and decarboxylation of, and N-alkylation of product from)
RN	73733-99-0 CAPLUS
CN	1-Piperidinecarboxylic acid, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5- b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 75978-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
CN 75978-98-2 CAPLUS
RN 1-Piperidinecarboxylic acid,
4-[[3-[[4-(4-fluorophenyl)methyl]-3H-imidazo[4,5-
b]pyridin-2-yl]amino]-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 73734-21-1P 73734-27-7P 75979-00-9P

L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


73735-22-5P 73735-23-6P 73735-24-7P
73735-25-8P 73735-26-9P 73735-27-0P
73735-33-8P 73735-35-0P 73735-68-9P
73735-72-5P 73735-94-1P 73735-95-2P
73735-99-6P 73736-00-2P 73755-85-8P
73755-86-9P 73755-88-1P 75970-90-0P
75970-98-8P 75971-13-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 73734-48-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 73734-60-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(3-phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73734-78-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(3-phenyl-2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 73735-00-9 CAPLUS
CN 5H-Tetrazol-5-one, 1-ethyl-4-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1,4-dihydro- (9CI)
(CA INDEX NAME)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. and N-alkylation of)

RN 73734-21-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-4-piperidinyl-,
dihydrochloride (9CI) (CA INDEX NAME)




●₂ HCl

RN 73734-27-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-4-piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)


 $\bullet_2 \text{HCl}$

RN 75979-00-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-((4-fluorophenyl)methyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)




IT 73734-48-2P 73734-60-8P 73734-78-8P
73735-00-9P 73735-12-3P 73735-17-8P
73735-18-9P 73735-19-0P 73735-21-4P


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-12-3 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-(2-phenylethyl)-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-17-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-butyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-18-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-phenoxyethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-19-0 CAPLUS
CN 3H-Imidazo(4,5-b)pyridin-2-amine,
N-[1-(3,3-diphenylpropyl)-4-piperidinyl]-
3-(phenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-21-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-22-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-[1-(2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-23-6 CAPLUS
 CN Ethanone, 1-(2,6-dimethylphenyl)-2-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-24-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(4-morpholinyl)ethyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-25-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-[1-(3-phenyl-2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 73735-26-9 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-27-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-hexyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-33-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[3-[[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 73735-35-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[3-[[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 73735-68-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[4-(fluorophenyl)methyl]-N-[1-[2-(2-thienyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-72-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[4-(fluorophenyl)methyl]-N-[1-[2-(2-pyridinyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-94-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[[4-(fluorophenyl)methyl]-N-[1-methyl-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 73735-95-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-methyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-99-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-cyclohexyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73736-00-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(1-methylethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73755-85-8 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl- (9CI) (CA INDEX NAME)



RN 73755-86-9 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73755-88-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 75970-90-0 CAPLUS
CN 1-Piperidinebutanenitrile, 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-α,α-diphenyl-, dihydrochloride (9CI)


L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl


RN 75970-98-8 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 75971-13-0 CAPLUS
CN 1-Piperidineethanol, α-(phenoxymethyl)-4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




IT 76031-50-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(N-alkylation of)
RN 76031-50-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-4-piperidinyl- (9CI) (CA INDEX NAME)



L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:215439 CAPLUS
DOCUMENT NUMBER: 92:215439
TITLE: N-Heterocycl-4-piperidinamines and pharmaceutical compositions comprising them
INVENTOR(S): Janssens, Frans; Stokbroekx, Raymond; Torremans, Joseph; Luyckx, Marcel
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: Eur. Pat. Appl., 100 pp.
CODEN: EPXDXW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 5318	A1	19791114	EP 1979-300525	19790330
EP 5318	B1	19820106		
R: BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4219559	A	19800826	US 1979-2276	19790110
CS 256358	B2	19880415	CS 1979-2227	19790402
CS 256380	B4	19880415	CS 1984-3451	19790402
PRIORITY APPLN. INFO.:			US 1978-892534	19780403
			US 1979-2276	19790110
			US 1979-2279	A 19790110

GI




AB Antihistaminic (no data) piperidinylaminoimidazoles I (X = CH, N; R = optionally substituted alkyl, alkenyl, aralkyl, 1-aralkyl-2-benzimidazolyl;
R1 = H, alkyl; R2 = H, alkyl, cycloalkyl, aralkyl, alkanoyl; R3 = H, alkyl, aryl, cycloalkyl, aralkyl; R4 = halogen, alkyl, alkoxy, CF3) were prepared. Thus, II (R5 = CH2CH2OPh) was obtained in 70% yield by treating I (R5 = H) with BrCH2CH2OPh.
IT 73733-99-0P 73734-02-8P 73734-21-1P
73734-27-7P 73734-48-2P 73734-60-6P
73734-78-8P 73735-00-9P 73735-12-3P
73735-17-8P 73735-18-9P 73735-19-0P
73735-21-4P 73735-22-5P 73735-23-6P
73735-24-7P 73735-25-8P 73735-26-9P
73735-27-0P 73735-33-8P 73735-35-0P
73735-48-9P 73735-72-3P 73735-73-4P
73735-74-7P 73735-85-0P 73735-84-1P
73735-95-2P 73735-99-6P 73736-00-2P
73755-85-8P 73755-86-9P 73755-88-1P
RL: SPN (Synthetic preparation); PREP (Preparation)


L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of)
 RN 73733-99-0 CAPLUS
 CN 1-Piperidinecarboxylic acid,
 4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-
 b]pyridin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 73734-02-8 CAPLUS
 CN 1-Piperidinecarboxylic acid,
 4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-
 2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 73734-21-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-4-piperidinyl-,
 dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 73734-27-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-4-
 piperidinyl-, dihydrochloride (9CI) (CA INDEX NAME)


L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-00-9 CAPLUS
 CN 5H-Tetrazol-5-one, 1-ethyl-4-[2-[[3-[(4-fluorophenyl)methyl]-3H-
 imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]-1,4-dihydro- (9CI)
 (CA INDEX NAME)



RN 73735-12-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-phenylethyl)-4-piperidinyl]-3-
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-17-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-butyl-4-piperidinyl)-3-
 (phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-18-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(2-phenoxyethyl)-4-piperidinyl]-3-
 (phenylmethyl)- (9CI) (CA INDEX NAME)


Hahte

L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● 2 HCl

RN 73734-48-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(2-
 phenylethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73734-60-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(3-
 phenoxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73734-78-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-(3-
 phenyl-2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73735-19-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine,
 N-[1-(3,3-diphenylpropyl)-4-piperidinyl]-
 3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-21-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[(2,3-dihydro-1,4-benzodioxin-2-
 yl)methyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-22-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-[1-(2-propenyl)-4-
 piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-23-6 CAPLUS
 CN Ethanone, 1-(2,6-dimethylphenyl)-2-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-
 b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-24-7 CAPLUS

04/28/2006


L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-[2-(4-morpholinylethyl)-4-piperidinyl]-3-(phenylmethyl)]- (9CI) (CA INDEX NAME)




RN 73735-25-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(phenylmethyl)-N-[1-(3-phenyl-2-propenyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 73735-26-9 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-27-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-hexyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73735-33-8 CAPLUS
 CN 2H-Benzimidazol-2-one, 1-[3-[4-[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]propyl]-1,3-dihydro- (9CI) (CA INDEX NAME)


L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 73735-72-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(2-pyridinyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 73735-73-6 CAPLUS
 CN Benzamide, 4-fluoro-N-[2-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 73735-74-7 CAPLUS
 CN Benzamide, 4-fluoro-N-[2-[4-[[3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 73735-85-0 CAPLUS
 CN 1-Piperidineethanol, β-(phenoxymethyl)-4-[1-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 73735-35-0 CAPLUS
 CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[3-[4-[(3-(phenylmethyl)-3H-imidazo[4,5-b]pyridin-2-yl]amino)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)




RN 73735-68-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(2-thienyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 73735-94-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-[(4-fluorophenyl)methyl]-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 73735-95-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-methyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73735-99-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-(1-cyclohexyl-4-piperidinyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73736-00-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, N-[1-(1-methylethyl)-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 73755-85-8 CAPLUS
 CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-[[3-[(4-fluorophenyl)methyl]-3H-imidazo[4,5-b]pyridin-2-yl]amino]-1-piperidinyl]- (9CI) (CA INDEX NAME)

04/28/2006


L4 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 73755-86-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-2-amine, N-[1-[3-(4-fluorophenoxy)propyl]-4-piperidinyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 73755-88-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine-2-amine, 3-[(4-fluorophenyl)methyl]-N-[1-[2-(4-methoxyphenyl)ethyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 26925-25-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 26925-28-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 27112-67-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1972:99669 CAPLUS
 DOCUMENT NUMBER: 76:99669
 TITLE: Pharmacologically active 3H-imidazo[4,5-b]pyridine derivatives
 INVENTOR(S): Hoffmann, Charles; Dordilly, Andree
 PATENT ASSIGNEE(S): Hexachimie S. A.
 SOURCE: Brit., 6 pp.
 CODEN: BRXGAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1260857	A	19720119	GB 1968-32987	19680710
BE 735418	A	19691201	BE 1969-735418	19690630
CH 507265	A	19710515	CH 1969-507265	19690630
DE 1934966	A	19700326	DE 1969-1934966	19690710
PRIORITY APPLN. INFO.:			GB 1968-32987	A 19680710

GI For diagram(s), see printed CA Issue.

AB The title comds. (I) showing antihistaminic activities, were prepared
 Thus, pyrrolidine was refluxed with I (R = Cl, R1 = H) 12 hr to give 73%

I (R = 1-pyrrolidinyl, R1 = H). Similarly prepared were 59-93% I (R, R1 given): piperidino, H; [HO(CH2)2]2N, H; 1-pyrrolidinyl, Cl. ED50 and LD50 in guinea pigs were given.


IT 26925-23-5P 26925-24-6P 26925-25-7P

26925-28-0P 27112-67-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 26925-23-5 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 26925-24-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1971:463689 CAPLUS
 DOCUMENT NUMBER: 75:63689
 TITLE: Derivatives of imidazo[4,5-b]- and of imidazo[4,5-c]pyridines
 AUTHOR(S): Cleve, Gerhard; Gibian, Heinz; Hoyer, Georg A.; Rahtz, Dieter; Schroeder, Eberhard; Schulz, Gerhard
 CORPORATE SOURCE: Exp. Forsch. Pharma, Schering A.-G., Berlin, Fed. Rep.
 SOURCE: Ger. Justus Liebig's Annalen der Chemie (1971), 747, 158-71
 CODEN: JLABCF; ISSN: 0075-4617
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 75:63689

AB Condensation of 2,3-diamino- and of 3,4-diaminopyridine with ClCH₂CN in polyphosphoric acid yielded 3-(chloromethyl)imidazo[4,5-b]- and -[4,5-c]pyridine, resp. By reaction with cyclic amines, i.e. pyrrolidine, piperidine, and 1-alkylpiperazines, the corresponding amino deriva. were obtained. The Na salts of these compds. reacted with PhCH₂Cl to give different products, the structures of which were elucidated by NMR and uv spectroscopy and by Hueckel MO calcns. Benzoylation occurred in imidazo[4,5-b]pyridines preferentially at N-3 and, to a smaller extent,

at N-1, in imidazo[4,5-c]pyridines at N-1 and N-5 and in one case at N-3. The obtained compds. were more toxic and less antiinflammatory than aspirin.


IT 26925-25-7P 26925-28-0P 33232-57-4P
 33232-60-9P 33232-61-0P 33232-62-1P
 33232-63-2P 33232-64-3P 33232-65-4P
 33232-66-5P 33232-68-7P 33232-69-8P
 33250-34-9P
 RL: 6PM (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 26925-25-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 26925-28-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● HCl


RN 33232-57-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-fluorobenzyl)-2-(1-pyrrolidinylmethyl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 33232-60-9 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-methoxybenzyl)-2-(piperidinomethyl)-, monohydrochloride (8CI) (CA INDEX NAME)

L4 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 33232-61-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-chlorobenzyl)-2-(piperidinomethyl)-, monohydrochloride (8CI) (CA INDEX NAME)




● HCl

RN 33232-62-1 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-chlorobenzyl)-2-(piperidinomethyl)- (8CI) (CA INDEX NAME)




RN 33232-63-2 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-fluorobenzyl)-2-(piperidinomethyl)-, monohydrochloride (8CI) (CA INDEX NAME)

L4 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 33232-64-3 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-benzyl-2-[(4-methyl-1-piperazinyl)methyl]- (8CI) (CA INDEX NAME)




RN 33232-65-4 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-chlorobenzyl)-2-[(4-methyl-1-piperazinyl)methyl]- (8CI) (CA INDEX NAME)





RN 33232-66-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-benzyl-6-bromo-2-(piperidinomethyl)- (8CI) (CA INDEX NAME)

L4 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)





RN 33232-68-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-methoxybenzyl)-2-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

RN 33232-69-8 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 2-[(4-ethyl-1-piperazinyl)methyl]-3-(p-methoxybenzyl)- (8CI) (CA INDEX NAME)




RN 33250-34-9 CAPLUS

L4 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1970:121538 CAPLUS
 DOCUMENT NUMBER: 72:121538
 TITLE: 2-Methyl-3-benzyl-3H-imidazo[4,5-b]pyridines
 INVENTOR(S): Hoffmann, Charles; Dordilly, Andree
 PATENT ASSIGNEE(S): Hexachimie S. A.
 SOURCE: Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1934966	A	19700326	DE 1969-1934966	19690710
GB 1260857	A	19720119	GB 1968-32987	19680710
PRIORITY APPLN. INFO.:			GB 1968-32987	A 19680710

GI For diagram(s), see printed CA Issue.
 AB The title compds. (I), which have sedative, analgesic, anesthetic, antihistaminic, antispasmodic, antitussive, antiinflammatory, and antisecretory properties, were prepared by heating a mixture of 2-(chloromethyl)-3-benzyl-3H-[4,5-b]imidazopyridine and an amine in an anhydrous solvent 1-24 hr at 30-80°. Described are I (R, NR1R2, 4 yield, m.p., and m.p. HCl salt given): H, 1-pyrrolidinyl, 73.5, 86°, 208-15°; H, piperidino, 84, 111.5°, -; H, N(CH2CH2OH)2, 93, 90°, 140-1.5°; 4-Cl, 1-pyrrolidinyl, 59, 76-7°, 230-1° (decomposition).
 IT 26925-23-5P 26925-24-6P 26925-25-7P
 26925-28-0P 27112-67-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 26925-23-5 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 26925-24-6 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3H-Imidazo[4,5-b]pyridine, 3-(p-chlorobenzyl)-2-[(4-ethyl-1-piperazinyl)methyl]-, dihydrochloride (8CI) (CA INDEX NAME)




● 2 HCl

L4 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● HCl

RN 26925-25-7 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-(phenylmethyl)-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 26925-28-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 27112-67-0 CAPLUS
 CN 3H-Imidazo[4,5-b]pyridine, 3-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

